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Summary 
Since the post-genomics era, our understanding of intracellular and intercellular processes, and 
interaction mechanisms has increased, this has led to the discovery of new biological targets for 
drug discovery. Generally modern medicinal chemistry and pharmacognosy research seek to 
identify new small molecules which can selectively modulate the functions of these biological 
targets. Natural products (such as substances extracted from plants or animals) are a vast 
reservoir of complex and highly structurally diverse chemical compounds. As a result they 
remain to play a vital role in the discovery of novel bioactive molecules (lead compounds) which 
could have therapeutic benefit in medicinal chemistry, and/or structures that could be used as 
chemical probes for understanding certain unknown biological processes. Especially following 
technological advances on instruments that are used for characterisation of natural products as 
well as in extraction and screening methods, the field of natural products is growing fast and 
making significant contributions in areas of biochemistry and drug discovery. Given the facts 
discussed so far, natural products need to be continually tested on emerging biological targets, 
via processing them and analysing their results with modern technologies such as HPLC-UV-MS-
ELSD and microprobe NMR. 
Based on aforementioned background, the main aims of this study are: (a) to test the activity of 
various plant and fungal extracts on four emerging biological targets (assays), and (b) to 
characterise the active extracts and to distinguish the molecules which are possibly responsible 
for observed biological activities on each of the four biological targets (assays). These four 
emerging biological targets (assays) and their purposes are: (1) inhibition of complex formation 
between CUGn-RNA and MBNL1; which was identified as an important target for the treatment 
of Myotonic Dystrophy type 1 (DM1); (2) inhibition of the expression of a protein named 
coronin-1, since expression of coronin-1 is essential for the survival of pathogenic 
Mycobacterium tuberculosis in the human host, thus inhibiting this expression is identified as 
an important target for the treatment of Tuberculosis (TB); (3) promotion of Lymphatic 
Endothelial Cell (LEC) growth, which was identified to be an important testing platform for 
pinpointing bioactive molecules which could possibly be used for the treatment of lymphedema 
or chronic skin inflammation; and (4) inhibiting thrombin-induced [Ca2+] influx, since the 
underlying mechanism through which Crataegus WS 1442 extracts treat Chronic Heart Failure 
(CHF) was found to be via inhibiting thrombin-induced [Ca2+] influx which leads to a reduction in 
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endothelial hyperpermeability. Thus this assay was identified to be an important testing 
platform for pinpointing bioactive molecules which could possibly be used for the treatment of 
CHF. Based on the respective biological targets given above, this study was divided into four 
projects, namely: DM1-project, TB-project, Lymphatic-project, and CHF-project. Three of these 
projects (DM1, TB, and Lymphatic) started with an extract library screening; whereas the last 
project (CHF) was initiated due to the use of Crataegus WS 1442 extracts as an adjuvant 
therapy. Moreover, in each of these projects, to track activity and characterise selected natural 
products that exhibit an interaction with the biological targets, the approach known as HPLC-
based activity profiling is utilised. The main findings and concluding remarks of these four 
projects are summarised as follows: 
[1] DM1-project: based on the screening results, harmine (from Peganum harmala) as 
well as 1,2-dihydrotanshinquinone I and methylenetanshinquinone (from Salvia 
miltiorrhiza) were identified as the most active compounds in inhibiting CUGn-RNA and 
MBNL1 complex formation. Also subsequent to the identification of active scaffold of 
harmine; planar-nitrogen-based compounds (such as protoberberine alkaloids) were 
projected to possess higher activity. Thus an alkaloid library was tested and berberine 
was found to be another main active compound. These bioactive alkaloids (i.e., harmine 
and berberine) are able to ameliorate certain aspects of the DM1 pathology, whereas 
the compounds from Salvia species (i.e., S. miltiorrhiza) exhibit some activities with 
certain degrees of toxicity, thereby these compounds need further investigation. 
Notably, the findings of this study exhibited that compounds with planar scaffolds which 
contain mostly nitrogen were more active in inhibiting CUGn-RNA–MBNL1 complex 
formation and restoring MBNL1 function. It was projected that the mechanism through 
which these active molecules restore MBNL1 function is due to these bioactive 
molecules-induced reversible intercalation into the RNA hairpin loop via electrostatic 
interactions, thereby blocking the binding of MBNL1 and allowing it to carry out its 
normal function. Overall the hit compounds found in this study may have the potential 
for drug discovery in RNA-mediated diseases. 
[2] TB-project: following the feedback from extract library screening, HPLC-based 
activity profiling (bioactivity tracking) was carried out on prioritised extracts. This led to 
the identification of active constituents (class of compounds) that are feasibly 
responsible for inhibition of coronin-1 expression, namely: alkaloids (from Pancratium 
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littorale MeOH extract) and furanocoumarins (from Dorstenia contrajerva EtOAc 
extract). Furthermore, a compound named ‘dorstenin’ was isolated from D. contrajerva 
EtOAc extract and it was found that the compound is active only at a much higher 
concentration; this implied that dorstenin was not the major contributor for activity 
observed from D. contrajerva extract. On the other hand, 15 alkaloids were isolated 
from P. littorale MeOH extract. Subsequently their activities were tested using Green 
Fluorescence Protein (GFP) as a readout for coronin-1 inhibition as well as their 
toxicities were tested using Red Fluorescence Protein (RFP). Activity/toxicity correlated 
structural analysis of these pure alkaloids showed that molecules with secondary 
nitrogen and methylenedioxy groups are higher in toxicity, whereas molecules which 
contain a hemiacetal ring and acetylation of some hydroxy functions are active. 
Moreover further examination using western blotting illustrates that alkaloid 
compounds which showed highest activity in GFP assay were inactive in inhibiting 
coronin-1 expression at the protein level. Because of these contrasting GFP assay and 
western blotting activity outcomes, this study recommends that (a) after GFP testing, it 
is crucial to confirm coronin-1 expression on a genetic level while identifying lead 
compounds, such as via RT-PCR tests; and (b) it is important to re-evaluate the 
utilisation of GFP assay for testing coronin-1 inhibition, which may include the need of 
conducting further investigation on understanding the interaction mechanism of 
compounds with GFP and its responses. This is also important to provide insights into 
the use of natural products as chemical probes in cell biology. 
[3] Lymphatic-project: based on the extract library screening, DCM extract of Daphne 
giraldii was identified as an active extract in inducing LEC growth. Afterwards this 
extract underwent a series of fractionation and assaying. The results of this profiling 
showed that activities are localised in lipophilic regions of the D. giraldii DCM extract. 
Also, each active micro-fraction contains trace amounts of potent bioactive 
constituents; as a result this study was unable to isolate the active compounds that are 
responsible for observed activities. However, through various correlative analysis 
techniques (such as using minimum effective concentration as a reference, clustering 
script and NMR), this study projected that daphnetoxin could be (at least one of) the 
main contributing factors for observed activities. In addition to this, fatty acid signals 
were identified in the active micro-fractions, these fatty acids might also play a role in 
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overall observed activity. To certainly identify this and other constituents of D. giraldii 
active micro-fractions, this study recommends the need of working with large amounts 
of optimally prepared extracts; which will allow bioassay-guided refined separations to 
end up with suitable amounts of pure compounds for identification. 
[4] CHF-project: Crataegus WS 1442 extract was separated into 9 fractions and their 
activities were tested via calcium imaging assay. The results exhibited that only 2 
fractions were active in inhibiting thrombin-induced [Ca2+] influx which leads to a 
reduction in endothelial hyperpermeability. Further fractionation of the two active 
fractions (via semi-preparative HPLC-UV chromatography) and analysis on the resulting 
active sub-fractions showed that all of them contain fatty acids and triterpenes. 
Moreover selective analysis on one of the active sub-fractions showed that it 
constituted 40% fatty acids (stearic acid and palmitic acid) and 50% of a triterpene 
(hyptatic acid A). These constituents which comprise almost 90% of this active sub-
fraction were tested in their pure form and were found to be inactive in inhibiting 
thrombin-induced calcium influx. This implies that minor compounds which comprise 
maximum 10% of the active sub-fraction constituents were responsible for observed 
activities. Based on the results given so far, this study deduced that the activities of 
Crataegus WS 1442 extracts were possibly induced by: (a) a minor constituent with 
potent activity; or (b) minor constituents with moderate activity which act 
synergistically. This study thus recommends further research on large amounts of 
optimally prepared Crataegus extracts to be able to certainly identify the molecule(s) 
responsible for observed activity and to assess their biological interactions. 
Overall each of the studies presented in this thesis were one of the first to employ natural 
products in assessing their interactions or abilities to interact with the four emerging biological 
targets which are summarised above. The final remark of this study is that there are very few or 
no known drugs on the market to treat these specific diseases that are associated with the 
aforementioned four projects. In this context, this study makes significant contributions, via 
providing: (a) new hit compounds; (b) possible constituents of potently active fractions; (c) 
activity correlated structural analysis and extract characterisation; as well as (d) by identifying 
challenges and providing possible recommendations. Lastly, besides presenting the findings of 
this study on different conferences, parts of the results presented in this thesis have been 
published. 
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Zusammenfassung 
Seit der postgenomischen Ära hat sich unser Verständnis von intrazellulären und interzellulären 
Prozessen und Interaktionsmechanismen verbessert, was zur Entdeckung neuer biologischer 
Targets geführt hat. Im Allgemeinen versucht die moderne medizinische Chemie- und 
Pharmakognosieforschung, neue Kleinmoleküle zu identifizieren, die die Funktionen dieser 
biologischen Ziele selektiv modulieren können. Dafür ist die Gesamtheit der Naturstoffe (wie z. 
B. Moleküle aus Pflanzen und Tieren) ein riesiges Reservoir an komplexen und stark strukturell 
verschiedenen chemischen Verbindungen. Daher spielen sie eine wichtige Rolle bei der 
Entdeckung neuartiger bioaktiver Moleküle (Leitstrukturen) mit therapeutischem Nutzen in der 
medizinischen Chemie. Andererseits können solche Strukturen als chemische Sonden zum 
Verständnis bestimmter unbekannter biologischer Prozesse verwendet werden. Die 
technologischen Fortschritte von modernen Instrumenten, die zur Charakterisierung von 
Naturstoffen sowie für Extraktions- und Screening-Methoden eingesetzt werden, sind im 
Bereich der Naturstoffe substanziell und leisten einen wichtigen Beitrag in der Biochemie und 
der Wirkstoffforschung. Angesichts dessen, müssen Naturstoffe kontinuierlich auf neu 
entdeckten biologischen Zielen getestet werden. Dabei helfen moderne Technologien wie 
HPLC-UV-MS-ELSD und Mikrosonden-NMR, um möglichst viele Informationen zu bekommen 
und auszuwerten. 
Vor diesem Hintergrund sind die Hauptziele dieser Arbeit: (a) die Aktivität verschiedener 
Pflanzen- und Pilz-Extrakte auf vier neuen biologischen Targets (Assays) zu testen und (b) die 
aktiven Extrakte zu charakterisieren und die Moleküle zu identifizieren, die möglicherweise für 
die beobachteten biologischen Aktivitäten verantwortlich sind. Diese vier neuen biologischen 
Ziele (Assays) und ihre Anwendungen sind: (1) Hemmung der Komplexbildung zwischen CUGn-
RNA und MBNL1, was als wichtiges Ziel für die Behandlung der Myotonischen Dystrophie Typ 1 
(DM1) identifiziert wurde; (2) Hemmung der Expression des Proteins Coronin-1, da Coronin-1 
für das Überleben von pathogenen Mycobacterium tuberculosis-Bakterien im menschlichen 
Wirt essentiell ist, sodass die Expressionshemmung als wichtiges Ziel für die Behandlung von 
Tuberkulose (TB) gesehen wird; (3) Förderung des Lymphatischen Endothelzell (LEC) -
Wachstums, das als eine wichtige Testplattform für die Lokalisierung von bioaktiven Molekülen 
identifiziert wurde, die möglicherweise für die Behandlung von Lymphödemen verwendet 
werden könnten; Und (4) Hemmung des Thrombin-induzierten [Ca2+] -Einstroms, was der 
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zugrundeliegende Mechanismus ist, durch den Crataegus WS 1442 Extrakte chronische 
Herzversagen (CHF) behandeln. Dabei wurde eine Hemmung des Thrombin-induzierten [Ca2+] - 
Zustroms gefunden, was zu einer Reduktion der Hyperpermeabilität des Endothels führt. Damit 
wurde dieser Assay als eine wichtige Testplattform für die Lokalisierung von bioaktiven 
Molekülen identifiziert, die für die Behandlung von CHF verwendet werden könnten. Auf 
Grundlage der oben genannten biologischen Ziele wurde diese Studie in vier Projekte unterteilt: 
DM1-Projekt, TB-Projekt, Lymphatic-projekt und CHF-Projekt. Drei dieser Projekte (DM1, TB 
und Lymphatic) begannen mit einem Extrakt-Bibliotheks-Screening, während das letzte Projekt 
(CHF) aufgrund der Verwendung von Crataegus WS 1442-Extrakten als adjuvante Therapie 
initiiert wurde. Darüber hinaus wird in jedem dieser Projekte, um die Aktivität zu verfolgen und 
ausgewählte Naturstoffe zu charakterisieren, die eine Wechselwirkung mit den biologischen 
Targets aufweisen, der Ansatz, der als HPLC-basierte Aktivitätsprofilierung bekannt ist, 
verwendet. Die wichtigsten Erkenntnisse und Schlussbemerkungen dieser vier Projekte sind wie 
folgt zusammengefasst: 
[1] DM1-Projekt: Basierend auf den Screening-Ergebnissen wurden Harmin (aus 
Peganum harmala) sowie 1,2-Dihydrotanshinchinon I und Methylentanshinchinon (aus 
Salvia miltiorrhiza) als die aktivsten Verbindungen bei der Inhibierung von CUGn-RNA 
und MBNL1-Komplexbildung identifiziert. Nach der Identifizierung des aktiven Gerüstes 
von Harmin wurde eine höhere Aktivität bei planaren Stickstoffverbindungen (wie 
Protoberberin-Alkaloiden) vermutet. Daher wurde eine Alkaloidbibliothek getestet und 
Berberin als ein weiterer Hauptwirkstoff gefunden. Diese bioaktiven Alkaloide (d.h. 
Harmin und Berberin) sind in der Lage, bestimmte Aspekte der DM1-Pathologie zu 
lindern während die Verbindungen aus Salvia-Spezies (d.h. S. miltiorrhiza) Aktivität 
verbunden mit einer gewissen Toxizität aufweisen, so dass diese Verbindungen weiter 
genauer werden müssen. Bemerkenswerterweise zeigten die Ergebnisse dieser Studie, 
dass Verbindungen mit planaren Gerüsten, die meistens Stickstoff enthalten, bei der 
Hemmung der CUGN-RNA und MBNL1-Komplexbildung und der Wiederherstellung der 
MBNL1-Funktion aktiver waren. Es wurde prognostiziert, dass der Mechanismus, durch 
den diese aktiven Moleküle die MBNL1-Funktion wiederherstellen, auf der Interkalation 
in die RNA-Haarnadelschleife über elektrostatische Wechselwirkungen beruht. Dadurch 
wird die Bindung von MBNL1 blockiert und ihm ermöglicht wird, seine normale Funktion 
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auszuführen. Insgesamt können die in dieser Studie gefundenen Hit-strukturen das 
Potenzial für die Wirkstoffforschung bei RNA-vermittelten Erkrankungen haben. 
[2] TB-Projekt: Nach den Ergebnissen aus dem Extrakt-Bibliotheks-Screening wurde ein 
HPLC-basiertes Aktivitätsprofiling (Bioaktivitätsverfolgung) auf priorisierten Extrakten 
durchgeführt. Dies führte zur Identifizierung von aktiven Bestandteilen (Klasse von 
Verbindungen), die für die Hemmung der Coronin-1-Expression verantwortlich sind, 
nämlich: Alkaloide (aus Pancratium littorale MeOH-Extrakt) und Furanocumarinen (aus 
Dorstenia contrajerva EtOAc-Extrakt). Weiterhin wurde eine Verbindung namens 
'Dorstenin' aus D. contrajerva EtOAc-Extrakt isoliert und es wurde gefunden, dass die 
Verbindung nur in hohen Konzentrationen aktiv ist. Dies bedeutet, dass Dorstenin nicht 
den Hauptbeitrag zur Aktivität leistet, die im D. contrajerva-Extrakt beobachtet wurde. 
Auf der anderen Seite wurden 15 Alkaloide aus P. littorale MeOH-Extrakt isoliert. 
Anschließend wurden die Aktivitäten mit Green Fluorescence Protein (GFP) getestet und 
ihre Toxizitäten wurden mit Red Fluorescence Protein (RFP) getestet. Aktivität / Toxizität 
korrelierte Strukturanalyse dieser reinen Alkaloide zeigte, dass Moleküle mit 
sekundären Stickstoff- und Methylendioxygruppen eine höhere Toxizität aufweisen 
während Moleküle, die einen Hemiacetalring und eine Acetylierung von einigen 
Hydroxyfunktionen enthalten, aktiver sind. Darüber hinaus zeigt die weitere 
Untersuchung mit Western-Blotting, dass Alkaloidverbindungen, die die höchste 
Aktivität im GFP-Assay zeigten, bei der Inhibierung der Coronin-1-Expression auf 
Proteinebene inaktiv waren. Aufgrund dieser kontrastierenden GFP-Assay- und 
Western-Blotting-Aktivitätsergebnisse empfiehlt diese Studie, dass (a) nach dem GFP-
Testen entscheidend ist, die Coronin-1-Expression auf genetischer Ebene etwa mit RT-
PCR-Tests zu bestätigen, um Leitstrukturen zu identifizieren; Und (b) es ist wichtig, die 
Verwendung des GFP-Tests zur Prüfung der Coronin-1-Hemmung neu zu bewerten, was 
die Notwendigkeit einer weiteren Untersuchung des Verständnisses des 
Interaktionsmechanismus von Verbindungen mit GFP und deren Reaktionen 
einschließen kann. Dies ist auch wichtig, um Einblicke in die Verwendung von 
Naturstoffen als chemische Sonden in der Zellbiologie zu bekommen. 
[3] Lymphatic-projekt: Auf der Basis des Extraktbibliotheks-Screenings wurde der DCM-
Extrakt von Daphne giraldii als aktiver Extrakt bei der Induktion des LEC-Wachstums 
identifiziert. Danach wurde dieser Auszug einer Reihe von Fraktionierungen und 
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Untersuchungen unterzogen. Die Ergebnisse dieses Profilings zeigen, dass die Aktivität 
in den lipophilen Regionen des D. giraldii DCM-Extrakts lokalisiert ist. Auch enthält jede 
aktive Mikrofraktion Spurenmengen von stark bioaktiven Bestandteilen; Infolgedessen 
war diese Studie nicht in der Lage, die Wirkstoffe zu isolieren, die für beobachteten 
Aktivitäten verantwortlich sind. Allerdings prognostiziert diese Studie durch 
verschiedene Korrelatanalysetechniken (z. B. die Verwendung von minimaler effektiver 
Konzentration als Referenz, Clustering-Skript und NMR), dass Daphnetoxin einer der 
wichtigsten Faktoren für die beobachtete Aktivität sein könnte. Darüber hinaus wurden 
in den aktiven Mikrofraktionen Fettsäure-Signale identifiziert, die auch bei der 
Gesamtaktivität eine Rolle spielen könnten. Um diese und andere Bestandteile von D. 
giraldii aktiven Mikrofraktionen sicher zu identifizieren, empfiehlt diese Studie, mit 
größeren Mengen optimierten Extrakten zu arbeiten, die es ermöglichen, Bioassay-
geführte verbesserte Trennungen mit geeigneten Mengen an reinen Verbindungen zur 
Identifizierung zu beenden. 
[4] CHF-Projekt: Crataegus WS 1442-Extrakt wurde in 9 Fraktionen aufgetrennt und die 
Aktivität wurde mittels Calcium-Imaging-Assay getestet. Die Ergebnisse zeigten 2 aktive 
Fraktionen, die den Thrombin-induzierten [Ca2+] - Einstrom hemmen, der zu einer 
Verringerung der endothelialen Hyperpermeabilität führt. Eine weitere Fraktionierung 
der beiden aktiven Fraktionen (über semi-präparative HPLC-UV-Chromatographie) und 
die Analyse der resultierenden aktiven Teilfraktionen zeigte, dass alle Fettsäuren und 
Triterpene enthalten. Darüber hinaus zeigte die selektive Analyse an einer der aktiven 
Teilfraktionen, dass sie aus 40% Fettsäuren (Stearinsäure und Palmitinsäure) und 50% 
Triterpen (hyptatische Säure A) besteht. Diese Bestandteile, die fast 90% dieser aktiven 
Teilfraktion ausmachten, wurden in ihrer reinen Form getestet und es wurde 
festgestellt, dass sie bei der Inhibierung des Thrombin-induzierten Calcium-Zustroms 
inaktiv waren. Dies bedeutet, dass für beobachtete Aktivitäten andere Verbindungen, 
die maximal 10% der aktiven Teilfraktionsbestandteile enthalten, verantwortlich sind. 
Auf der Grundlage der bisherigen Ergebnisse ergab diese Studie, dass die Aktivitäten von 
Crataegus WS 1442-Extrakten möglicherweise durch: (a) einen Bestandteil, der in 
geringfügigen Mengen vorliegt aber eine hohe Aktivität aufweist, induziert wurden; 
Oder (b) geringfügig vorliegende Bestandteile mit mäßiger Aktivität, die synergistisch 
wirken. Diese Studie empfiehlt daher, weitere Mengen an optimal vorbereiteten 
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Crataegus-Extrakten zu untersuchen, um das für die beobachtete Aktivität 
verantwortliche(n) Molekül(e) sicher zu identifizieren und ihre biologischen 
Wechselwirkungen zu beurteilen. 
Insgesamt war jede der in dieser Arbeit vorgestellten Studien eine der ersten, die die 
Interaktion von Naturstoffen mit den vier oben beschriebenen biologischen Targets 
untersuchen. Das Fazit dieser Studie ist, dass es nur wenige oder keine bekannten 
Medikamente auf dem Markt gibt, um diese spezifischen Krankheiten zu behandeln, die mit 
den vorgenannten vier Projekten verbunden sind. In diesem Zusammenhang leistet diese Studie 
erhebliche Beiträge, indem sie: (a) neue Hit-strukturen identifiziert hat, (b) mögliche 
Bestandteile von stark aktiven Fraktionen gefunden hat, (c) Aktivitätskorrelierte Strukturanalyse 
und Extraktcharakterisierung durchgeführt hat sowie (d) Hindernisse identifiziert und mögliche 
Lösungsstrategien genannt hat. Schließlich wurden neben der Präsentation der Erkenntnisse 
auf verschiedenen Plattformen auch Teile der in dieser Arbeit vorgestellten Studien 
veröffentlicht. 
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Chapter 1 
1. Introduction 
1.1 Drug Discovery and Development 
Medicine is considered as one of the most important necessity to all of us. It is derived from the 
Latin words ‘ars medicina’ meaning "the art of healing". It’s a branch of the health sciences and 
is the sector of public life concerned with maintaining or restoring human health through the 
study, diagnosis, treatment and possible prevention of disease, injury and other damage to our 
body or mind1. This area encompasses an understanding of the body system, its diseases, and 
treatment by drugs, diet, exercise and other nonsurgical means, which is used to maintain our 
health. An agent such as a drug is employed to treat a disease or injury1. A drug can be defined 
as a chemical that interacts with a biological system and produces a biological response2. Drug 
discovery and development is a complex process where chemistry, preclinical, and clinical 
pharmacology have a prevalent role but it is also supported by the knowledge of several other 
life science disciplines such as genetics, physiology, pathology, microbiology, and molecular 
biology2. Generally, drug discovery and development is a time- and financially- consuming 
process and can be divided into three main stages (see Fig. 1.2): drug discovery, drug 
development, and registration; which are briefly discussed below3. 
The process of drug discovery starts because there is a continuous unmet need for new 
medicine to combat diseases or clinical conditions with insufficient medical products available. 
This is the underlying motivation that drives drug discovery efforts4. Generally, discovery of the 
biological target and validation, hit identification, as well as lead optimisation are the main 
steps in the drug discovery process. During these processes chemistry is involved in various 
fundamental forms such as synthesis or extraction, drug analysis, formulation and 
pharmaceutical technologies2. Historically, the first medicinal drugs came from natural sources 
and existed in the form of herbs, plants, roots, vines and fungi5. Medicinal value of these 
natural sources were discovered through traditional means or by serendipitous discovery5.  
The initial research of drug discovery involves two main approaches as depicted in Fig. 1.1: 
classical pharmacology6, and reverse pharmacology7. In the classical approach (also known as 
phenotypic drug discovery8), synthetic molecules or natural extracts are screened in intact cells 
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or whole organisms for biological activity without knowledge of the biological target. Only after 
an active substance was identified to have a desirable therapeutic effect is an effort made to 
identify the target. This approach is quick but often leads to various time consuming mode of 
action studies and challenging lead optimisation9. An additional challenge is effectively 
incorporating new screening technologies to address the limitation of considerably lower 
throughput than target-based assays7. The second approach, reverse pharmacology (also 
known as target-based drug discovery10), is the most frequently used approach today7. This 
approach first identifies a target (such as a protein or pathway) which is hypothesised that upon 
its inhibition or activation, a therapeutic effect will be observed in the disease state4. Cloning of 
the human genome made possible the screening of large libraries of compounds against 
specific targets thought to be linked to specific diseases. The advantage of this approach is that 
once a lead is found the mode of action is already known, therefore easier medicinal chemistry 
and lead optimisation9. Also, since the protein target is already known the hits can immediately 
be tested in further cell or animal models7. The strengths of the target-based approach include 
the ability to apply molecular and chemical knowledge to investigate specific molecular 
hypotheses7. However, many potential leads may be lost because they act on different targets, 
and protein expression and assay development can be challenging9. Additionally, the solution 
to the specific molecular hypotheses may not be relevant to the disease pathogenesis or 
provide a significant therapeutic index7. During drug discovery, ADMET (Absorption, 
Distribution, Metabolism, Elimination, and Toxicity) properties are also assessed11. Based on 
these data, lead structures are optimised, before they enter the drug development phase. 
 
Figure 1.1: Phenotype- versus target- based drug discovery. In the phenotype-based approach, 
lead molecules are first obtained, followed by target deconvolution to identify the molecular 
targets that underlie the observed phenotypic effects. Conversely, in the target-based 
approach, molecular targets are identified and validated before lead discovery starts (adapted 
from10). 
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Generally, the origin of lead compounds can be from natural or synthetic sources. Natural 
products and their derivatives have been recognised for many years as a source of therapeutic 
agents and structural diversity12. In addition to their structural diversity and bioactivity, the 
development of new technologies has revolutionised the screening of natural products for the 
discovery of new drugs. Applying these technologies compensates for the inherent limitations 
of natural products and offers a unique opportunity to re-establish natural products as a major 
source of lead compounds for drug discovery. Accordingly, natural products are an enormous 
source of effective drug compounds that is unsurpassed by synthetic libraries12. The 
development and formulation of various novel drugs from natural sources, as an alternative to 
conventional synthetic products, increases the scientific community’s interest in medicinal 
plants13. Further discussion on natural products and technologies which improve the use of 
natural products in drug discovery is provided in section 1.2 and 1.3, respectively. Overall, once 
these lead compounds are identified, they are evaluated for their potential to be developed 
into pharmaceutical drugs for a particular disease. This is an important initial step which links 
drug discovery and drug development. The drug development process is divided into three 
main stages: preclinical testing in animals, phase I (first in man studies), and full clinical trials 
(phase II and III); before the compound finally enters the registration phase. Prior to market 
launch, new drugs undergo a long and complicated series of steps, including an evaluation of 
efficacy and safety, application for approval, and investigation and approval of drug 
applications by regulatory authorities. A new active principle that has received marketing 
authorisation is usually protected by a patent and can be marketed only by the company 
owning the patent or by licensed companies. However, when the patent expires, generic drugs 
can be developed and, under some given rules, can be produced and marketed by any other 
company2. 
 
Figure 1.2: Simplified process of drug discovery and development with an estimate of the time 
required for the three main stages (adapted from14,15). 
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1.2 Natural Products in Drug Discovery 
1.2.1 The Importance of Natural Products 
Since ancient times, man has relied on nature to sustain his basic needs, and for curing or 
relieving various maladies or symptoms. Natural products include a large and diverse group of 
secondary metabolites from a variety of sources, such as marine organisms, bacteria, fungi, and 
plants. Not only do natural products provide sustenance or medicine but also possess a 
plethora of novel molecular scaffolds and interrogate a different and wider chemical space with 
structural and chemical diversity that is unsurpassed by synthetic derivatives16–20. Many natural 
products have gone onto become current drug candidates20. 
The history of natural products in drug discovery is full of noteworthy accounts on how the 
discovery of a natural compound impacted advances in biology and therapies. Isolation of the 
well-known drug, morphine, from Papaver somniferum (the opium poppy) in 1817 spurred 
interest in identifying the active principles of plant-based medicines21. Following this 
breakthrough many alkaloids were discovered from plant sources, such as emetine from 
Carapichea ipecacuanha in 1817, which is nowadays used for its emetic properties22. Coniine, 
first isolated in 1826 from Conium maculatum23 (poison hemlock), is still a candidate today for 
current drug discovery, this time being a model for induction of apoptosis in trypanosomal 
infections24. Commercialisation of the antibiotic penicillin in the 1940s was a significant 
milestone in drug discovery research, and spurred an enormous amount of effort in this field25. 
The structures of the above discussed compounds can be found in Fig. 1.3. 
Many interesting biologically active secondary metabolites are alkaloids. However, not all drugs 
derived from natural products are nitrogen based. One natural product, salvinorin A (see Fig. 
1.3), first isolated in 1982 from Salvia divinorum, a trans-neoclerodane diterpene26, is a 
hallucinogenic molecule that acts as a κ-opiod selective agonist, making it the first known 
compound acting on this receptor that is not an alkaloid27. Additionally, salvinorin A has no 
action at the 5-HT2A serotonin receptor, which is the principal molecular target responsible for 
the action of classical hallucinogens such as LSD or mescaline27. The most extraordinary 
examples of natural products making it to a marketable drug unchanged clearly emphasises the 
importance of continuing the search of new drugs using nature as a source. On average natural 
products represent 34 ± 9% of New Chemical Entity (NCE) approvals (from 1999 to 2014)28. Not 
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only are natural products used for treating various diseases but, nowadays play advantageous 
roles in understanding biological processes25. 
 
Figure 1.3: Structures of selected natural products namely morphine, emetine, coniine, 
penicillin, and salvinorin A. 
1.2.2 Natural Products as Chemical Probes of Cell Biology 
Substances that were identified as late as the 1970s are still influencing chemists and biologists 
to use the ‘native product’ either as probes for specific targets or as a treatment in its own 
right21. Natural products have been central to the discovery of novel drug targets and represent 
a unique source of chemical tools to investigate proteins and signalling networks25. It is 
believed that compounds found in nature are often far more superior to even the best 
synthetic moieties in terms of diversity, specificity, binding efficiency, and propensity to interact 
with biological targets25,29,30. It is these characteristics that have lead researchers to use natural 
products in studies that facilitate the exploration of a biological system (that is to use them as 
chemical probes) and not only for the identification of potential therapeutic agents31. Various 
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review articles25,32–36 have summarised the plethora of natural products used as chemical 
probes to explore biological phenomena and assemble biochemical pathways, below only a 
select few will be discussed (see Fig. 1.4 for structures of the natural products discussed below). 
The understanding of how natural products affect normal biological processes at the molecular 
level has often guided new strategies for drug design31. The relationship between histone 
deacetylases, transcription regulation and cell cycle progression was established by 
understanding the molecular targets of trichostatin A and trapoxin B31,32. This knowledge lead 
to the development of histone deacetylase inhibitors for the treatment of cancer at the 
transcription level31,37. Trichostatin A, initially isolated from Streptomyces hygroscopicus in 1976 
on the basis of its anti-proliferative activity38; and trapoxin B, a cyclic tetrapeptide isolated from 
the fungus Helicoma ambiens which caused cell cycle arrest in mammalian cells, were found to 
inhibit histone deacetylation39.  
The mechanism of information transfer or signalling through the cytoplasm of the cell is one of 
the great mysteries of cell biology. Natural products that inhibit this process offer a unique 
window into fundamental aspects of how extracellular molecules influence events34. 
Rapamycin, a macrolide lactone produced by Streptomyces hygroscopicus, and its derivatives 
have played a pivotal role in the clarification of several cellular processes including cell growth, 
proliferation, survival, protein synthesis, and transcription40,41. It was first identified as an 
antibiotic/anti-fungal agent but due to its immunosuppressive properties was rejected and later 
rediscovered for its potent immunosuppressive and anti-proliferative properties. In 1999 it was 
approved as an immunosuppressive drug42. Studies on the mode of action of rapamycin 
revealed a new signalling pathway which is central to cell growth31. Rapamycin was shown to 
bind to mTOR (mammalian Target Of Rapamycin), a protein which subsequently appeared 
critical for the regulation of major events regarding cell growth. This triggered more in-depth 
studies of mTOR and its essential function in cells was clarified thanks to the use of 
rapamycin31,43.  
The molecular mechanisms through which cyclosporine suppresses an immune response 
pioneered the field of chemical biology. Cyclosporine was isolated from the fungus 
Tolypocladium inflatum on the basis of its anti-fungal properties, but its spectrum was too 
narrow to be of any clinical use. Thereafter, its immunosuppressive action was found and it 
became the first immunosuppressive drug that allowed selective immunoregulation of T cells 
7 
 
without excessive toxicity44. Elucidating the mode of action provided insights into 
understanding the mechanism leading to T-cell activation. This natural product was shown to 
associate with intracellular receptors that inhibit the regulation of cytokine gene expression, 
leading to a general immunosuppressive activity31,34. Macrocyclic immunosuppressive natural 
products such as rapamycin and cyclosporine have been valuable not only as therapeutic agents 
but also as lead structures for studying the regulatory processes of cell proliferation33. 
Natural products have also played a crucial role in the identification and characterisation of 
thermo-sensitive ion channels31,45. For example, the mechanism through which capsaicin, the 
pungent ingredient of hot chilli peppers, elicits a hot sensation remained unknown for many 
years, until capsaicin was used as a molecular probe for pain/heat signal propagation32. Its 
receptor was cloned and named transient receptor potential vanilloid 1 (TRPV1)46, which is 
strongly activated by capsaicin and when neurons are subjected to temperatures above a pain-
threshold32. Additionally, this receptor was shown to be a heat-activated ion channel involved 
in pain sensation, opening a new field of research on temperature-dependent ion channels31,46 
and understanding the mechanisms involved in the heat-stimulated pain pathway32. Similarly, 
menthol was found to activate the cold-sensitive receptor TRPM8 in a comparable manner as 
its natural stimulus31,47. TRPM8 was later shown to be permeable to ions (Na+, K+, Ca2+, or Ba2+) 
under both natural and provoked stimuli31,48. 
Much of what is currently known about the structure and organisation of the mitotic spindle 
was determined by the use of small molecules, such as colchicine and taxol49. Generally, these 
compounds are tubulin-binding agents (e.g. taxol) and have been developed into successful 
cancer therapeutic agents25. 
In general, chemical probes are an essential component of research and are utilised to dissect 
complex biological processes, to wield temporal control over biochemical pathways, and to 
identify novel therapeutic targets. The studies above highlight the use of natural products as 
biological probes given their innate ability to interact with high affinity and selectivity with 
biological targets and will continue to map important biochemical networks and identify novel 
therapeutic strategies25. Biologically active natural products have proven to be invaluable in the 
exploration of systems that cannot be studied by traditional genetic manipulations32. 
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Figure 1.4: Structures of selected natural products that have played a significant role in 
chemical biology acting as chemical probes, namely trichostatin, trapoxin B, rapamycin, 
cyclosporine, capsaicin, menthol, colchicine, and taxol. 
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1.2.3 Main Steps Employed for the Study of Natural Products in Drug Discovery 
In the investigation of natural products, various crucial steps need to be followed, which will be 
briefly discussed below. 
(i) Plant Selection Criteria and Supply 
The criteria used for the selection of plants to be studied sets the course of the work. There are 
four basic types of approaches: randomised, ecological, chemotaxonomic, and ethno-directed 
approaches. The random approach consists of an indiscriminate selection and collection of 
plant species according to the plant availability. The second approach consists of observing the 
interactions between organisms in their ecological environment, such as observing animals in 
their eating habits could lead researchers to test certain plants. The chemotaxonomic approach 
consists of identifying groups of constituents present in plants, by considering the taxonomic 
organisation of these plants. The ethno-guided approach consists of selecting plant species in 
accordance to their traditional use. This allows collaboration between traditional healers, 
botanists and researchers50. The issue when working with natural products is that populations 
of plants possessing potent substances are in danger of becoming extinct especially if the active 
secondary metabolites are present in minor quantities – which is most often the case. For 
industrial exploitation of plant derived metabolites to be used as such or as starting material for 
synthesis, economically viable and ecologically responsible production is a necessity51. Finding 
alternative ways of producing the active compound isolated from nature may be difficult, due 
to the extreme complexity of chemistry that can be present in a natural compound such as 
taxol that was isolated in 1971 from Taxus brevifolia (Taxaceae) for its anti-cancer properties51. 
About two decades ago, the legalities of obtaining samples of plants, microbes, and animals 
were straightforward. A researcher could arrive at a field, collect samples and take them home. 
An example of this was the discovery of the anti-fungal compound, cyclosporine. A soil sample 
collected from employees of Sandoz during their business trips or holidays were catalogued and 
later screened. In 1970, the fungus Tolypocladium inflatum was isolated from two soil samples, 
thereby leading to the discovery of cyclosporine based on its anti-fungal properties. Nowadays, 
cyclosporine is used in organ transplant patients to prevent organ rejection due to its potent 
immunosuppressive properties44. However, in 1992, the Convention on Biological Diversity 
(CBD) was signed; which lead to various forms of regulations and legislation which control the 
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acquisition of biological materials and indigenous knowledge. The implementation of these 
regulations had a profound impact on academic and industrial research groups. Agreements to 
access biological materials required lengthy negotiations on intellectual property and benefit 
sharing. The CBD was conceived with the aim to facilitate a higher level of international 
collaboration, but it lead to several pharmaceutical companies abandoning their natural 
product screening efforts. Alternatively, there have been a number of successful cooperative 
agreements between academic groups, pharmaceutical industries and governmental 
institutions in biodiversity-rich countries51–53. Afterwards, the Nagoya Protocol was 
implemented for fair, reliable, simple, and transparent access regulations54. These provisions 
should be viewed as an opportunity to carry out natural product research in an ethical way, 
within an agreed legal framework, however lengthy the process may take54. In this sense it 
protects the institution or company involved from charges of biopiracy and in addition, 
provides the possibility of doing some good for a developing country51–53. 
(ii) Extraction of Plant Metabolites  
The study on medicinal plants starts with an efficient extraction procedure that plays a critical 
role in the outcome and also on the consequent assays performed. The term extraction, used in 
its pharmaceutical sense, involves the removal of plant secondary metabolites from the inert 
components by using selective solvents through standard procedures. A wide range of 
technologies with different methods of extraction is available nowadays. Both fresh and dried 
plant materials such as leaves, barks, roots, fruits, and flowers can be utilised for extract sample 
preparation; however pre-extraction preparation of plant samples such as drying (air-drying, 
oven-drying, freeze-drying) and grinding processes can influence the preservation of secondary 
metabolites in the final extract. Therefore, the selection of proper extraction procedures 
requires thorough evaluation that accomplishes the intended objectives of the research. There 
are various types of extraction methods which have their own principle, equipment needs, 
strengths and limitations13,55. Traditional methods such as maceration, percolation, and soxhlet 
extraction (hot continuous extraction) are commonly used at research settings or small level 
manufacturing. Accelerated Solvent Extraction (ASE)56 and supercritical fluid extraction are also 
being used in the extraction of plant materials. These methods are less common due to high 
cost despite the efficiency of the methods. On the other hand, following technological 
advances, modern extraction methods which increase yields with lower costs have emerged 
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such as Microwave-Assisted Extraction (MAE)57 and Ultrasound-Assisted Extraction (UAE)55,58. 
These extraction methods are usually applicable for selective needs such as extracting polar 
molecules and for large scale extraction at low cost. All the methods that employ solvents in 
their procedures (maceration, MAE, UAE and ASE) are critically influenced by the solvent 
types13; thus in these methods the selection of suitable solvent type and volume is crucial. For 
further discussion on the strengths and limitations of different extraction methods the reader is 
referred to13,59 and references therein. Extracts which are produced from various plant 
materials through different methods and solvents can be stored in stock solutions (typically 10 
mg/mL in DMSO) at lower temperatures; this is known as an extract library. It is a useful way to 
store extracts and repeatedly screen the collection of extracts for various biological activities60. 
(iii) Biological Screening 
Before pursuing the separation of pure compounds from plant extracts, biological screening 
(analysis on biological assay outcome) is carried out in order to assess the presence of active 
compounds in the extracts. Biological assay (also known as bioassay) is a test method employed 
to determine the biological activity of a substance such as a drug on tissue or cell lines (in vitro), 
or live animal or plants (in vivo). An analytical in vitro procedure used to detect, quantify and/or 
study the binding or activity of a biological molecule, such as an enzyme, is commonly known as 
a biochemical assay. Generally, bioassays (biochemical assays) are typically conducted to 
examine the biological activity of a substance on an organism, tissue, cell, or target protein 
(enzyme or receptor), via determining the relative strength of the induced biological 
response/changes on the target of interest while compared to a standard preparation (positive 
and negative controls). Biological assays can be qualitative or quantitative. Qualitative assays 
are used for assessing the physical effects or mechanism of action of a substance that may not 
be quantified. Quantitative assays involve estimation of the dose-response curve, which allows 
estimation of the concentration of a substance associated with a specific biological response. 
For example the half maximal inhibitory concentration (IC50) represents the concentration of a 
particular drug (inhibitor) that is required for 50% in vitro inhibition of a given biological process 
(biochemical function). Overall quantitative assays are essential for toxicological information, 
extract/compound screening (cell-based and/or isolated target screening61) or for developing 
drug candidates with therapeutic value. 
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A variety of assays can be used to evaluate or screen the selected in vitro activity of an extract 
or pure compound. However, on various screening results, a high number of false positives 
might be observed, this is due to the common presence of compounds with non-specific 
activities or interference with the assay format. Polyphenolic compounds, such as tannins, form 
tight complexes with metal ions and a wide array of proteins, while polysaccharides often give a 
false-positive result in most assays involving a purified protein. Saponins and fatty acids, widely 
distributed in plants, have the propensity to disrupt membranes causing a misleading result. In 
assays based on light measurements, pigments, ultraviolet (UV) quenchers and auto-
fluorescent compounds are prone to interfere with the readout of the assay51,62. 
(iv) Isolation of Active Constituents and Structure Elucidation 
Natural product extracts are composed of a complex mixture of various types of bioactive 
compounds and phytochemicals with different polarities. Therefore separation of bioactive 
pure compounds and their characterisation requires further processing utilising different 
chromatographic and structural elucidation techniques. Various chromatographic techniques 
exist such as silica gel column chromatography, sephadex chromatography, Thin Layer 
Chromatography (TLC), and preparative or semi-preparative High Performance Liquid 
Chromatography (HPLC). Each technique is based on the principle that certain compounds have 
different migration rates given a particular stationary and mobile phase. Separation is achieved 
by exploiting the affinities of different compounds for the mobile or stationary phases. More 
details on these techniques can be found in numerous reviews59,63,64. Furthermore, to 
characterise the effluent as it moves through the flow cell such as in terms of mass and/or 
functional groups (bonds), some of these chromatographic techniques are coupled to different 
detectors. For example, HPLC is most commonly combined with a UV-Vis absorbance detector 
(UV) and/or a mass spectrometer65. In addition to these, tracking activity in complex plant 
extracts using the bioassay-guided approach or the miniaturised approach (HPLC-based activity 
profiling) of small amounts of samples has been developed with the advancement of analytical 
techniques66–68. Throughout the research of this thesis, HPLC-based bioassay-guided activity 
profiling has been employed; thus this technique will be further discussed in section 1.3.2. Once 
pure compounds are obtained their chemical structure needs to be determined. One of the 
most common instruments used for this purpose is a nuclear magnetic resonance (NMR), which 
will be discussed in more detail in section 1.3.3. 
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Besides the aforementioned technological advancements, the isolation of a bioactive 
compound from natural products faces a number of technical challenges. These include 
variability of source material, difficulty of isolating the active constituents, possibility of 
isolating an already known active compound or otherwise uninteresting compounds, loss of 
bioactivity during the purification process, and costs of collection51,69. An extract may show a 
high activity and contain large quantities of only very few moderately active major constituents; 
or a moderately active extract could lead to minor compounds with high potent activity70. 
Extremely low yields of compounds that may be active make detection and identification 
challenging. The comparison of fractions generated, whether it is for finding similarities and/or 
differences in metabolites present in active/inactive fractions or for targeting isolation of 
unique compounds present in some fractions, may also be somewhat tricky depending on the 
number of fractions and the complexity or overlapping of compounds present in the fractions. 
At present, this process is tackled manually, which often results in overlooking of 
compounds51,68. Additionally, the complexity of structures poses difficulties for structural 
modifications and practical synthesis51,68. 
(v) Testing of Pure Compounds Against Intended Target 
Once pure compounds are obtained and their structures characterised, it is important to test 
their activity. Thus the biological response of pure metabolites should be tested in the bioassay 
that has been used for the extract screening (see section 1.2.3–iii). Following this step, pure 
metabolites will be further subjected to secondary bioassays (which assess their IC50, toxicity, 
and selectivity). After this, the drug candidate goes on to the drug development procedure 
which has been discussed in section 1.1. Identifying a potential drug candidate and processes 
that follow this step have quite a number of time consuming and labour intensive challenges. A 
lead compound that was discovered using the cell-based approach has to be subjected to mode 
of action studies because the molecular target is unknown10,25,71. There is a great need for new 
techniques to facilitate the rapid identification of cellular targets for biologically active natural 
products30. Recent advances in proteomics, three-hybrid systems, phage and mRNA display 
technologies, chemical synthesis, and affinity chromatography-based methods have greatly 
accelerated target identification10,25,72,73. However, most of these methods require 
derivatisation of the lead compound to facilitate either covalent interactions between the 
natural product and the target biomolecule or conjugation of the natural product to a read-out 
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tag such as biotin or a fluorophore10,25,71. This process often requires either total synthesis or 
semi-synthesis of lead structures. The functionalised natural product could suffer dramatic 
decrease in the desired bioactivity25. 
Overall, in the fields of natural products and drug discovery, advances in extraction and 
isolation techniques, biological screening methods, and the development of sensitive 
instrumentation that are employed for structure elucidation, provide a crucial benefit for the 
continual growth of novel bioactive molecule identification from natural products. Researchers 
are constantly working to provide new tools to make identification, functional annotation, and 
synthesis more straightforward. Even though the pharmaceutical industry expanded its 
resources to both high-throughput screening (HTS) and combinatorial chemistry which 
occupied a well-defined area in chemistry, overall in the last 30 years only 30% of NCEs were 
found to be synthetic, while 52% of these compounds were either a natural product, a mimic, 
or a chemical modification of an existing natural product pharmacophore28. Additionally, 
natural products are evolutionarily optimised as drug-like molecules and have been designed to 
interact with biomolecules, which is why so many natural products have gone on to become 
current drugs18,28,74. Forty percent of the chemical scaffolds published in the Dictionary of 
Natural Products database (Chapman & Hall) are absent from today’s synthetic chemistry75,76. 
Only about one-fifth of the ring systems found in natural products are represented in current 
trade drugs77. The declining number of NCEs showed that de novo combinatorial chemistry 
approaches in drug discovery over the past few years were not as efficient as expected and 
classified as structurally simplistic and poorly designed78,79. The power of nature’s small 
molecules far outweighs their challenges, and it has become clear that renewed interest in 
natural products is essential to the future of both biological studies and drug development25. 
1.3 Tracking Bioactivity in Extracts 
Interest in natural product-based drug discovery efforts experienced a decline in the 1980s and 
1990s due in part to the advent of combinatorial chemistry coupled with high-throughput 
screening methods. This however marked a decline in the number of new drug candidates80. 
With the advancement of new techniques used for tracking activity in complex plant extracts, 
natural products drug discovery was able to meet the demand of high-throughput screening 
and thus interest was rekindled25. 
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1.3.1 Bioassay-guided Approach 
Between the 19th century to around the 1980s natural product discovery relied mainly on 
traditional knowledge, pharmacological observations, well documented usage (evidence-based 
phytotherapy), and serendipity54. During these times, the classical approach for the study and 
isolation of natural products was used, which comprised of working on few plant samples, 
testing the extracts for observed activity and ‘blindly’ isolating as many pure compounds as 
possible. This classical phytochemical approach is basically based on testing of the extract 
initially, then carrying out numerous column chromatographic purification steps until a pure 
compound was obtained. Thereafter, pure compounds were tested for their activity. Generally, 
this approach targeted mainly the major compounds that were easier to purify and it was not 
always the case that the specific pure compound that was isolated happened to be the active 
compound. This approach also often lead to duplication of previously isolated compounds that 
were already known for a specific activity51. Moreover, the biological activity is frequently lost 
once the pure compound was isolated since it was not possible to know exactly which 
compound or substances gave rise to the initial observed activity of the extract. This major 
concern of loss in biological activity lead to the development of a new technique which 
implements activity testing throughout the separation process, which is known as the bioassay-
guided approach67. Generally, in modern natural product-based drug discovery processes, a 
common procedure to isolate active metabolites from an extract is based on bioassay-guided 
fractionation. This means through different chromatographic techniques, a given extract is 
separated into a number of smaller quantities (called fractions) in which the composition varies 
according to their physicochemical properties; and subsequently the biological activity of these 
fractions will be tested. On the fractions that exhibit activity, further fractionation will be 
carried out. This loop of separation and assaying method (also known as bioassay-guided 
approach) will step-by-step lead to isolation of active pure metabolites. Bioassay-guided 
approach is time consuming, however relative to the classical method it is an advanced 
approach that made natural product chemistry more targeted towards identification (and 
purification) of novel bioactive molecules81. Particularly, automated assays in microtiter plates 
allow testing of large numbers of samples in a short time; this makes bioassay-guided 
approaches more effective in terms of time and specification. Overall, equipped with an array 
of sensitive and rapid assays and advancement of analytical methods, natural product 
chemistry became more facilitated to explore the vast chemical wonders present in Nature82. 
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As highlighted in section 1.2.3–iv, there are various types of chromatographic techniques that 
are used for the separation of compounds from a given extract. Different chromatographic 
techniques have different separation performances51 and in some cases in order to obtain a 
decent amount of pure compound after numerous purification steps, a large amount of plant 
material is needed at the extraction point such as in the case of silica gel chromatography83. In 
addition, some of the classical chromatographic techniques do not allow dereplication of 
known bioactive molecules or otherwise uninteresting compounds51. Considering these and 
other issues, preparative or semi-preparative HPLC techniques which combines UV and MS 
becomes one of the most advantageous methods for separation and characterisation of 
compounds, along with activity localisation in extracts. 
1.3.2 HPLC-based Activity Profiling – Miniaturised Approach 
Natural products are extraordinary reservoirs of complex novel molecules, of which only one or 
several compounds may be responsible for the biological activity. Recent advances in analytical 
techniques opened new possibilities for natural product research84. It was imminent that 
localising activity in complex extracts at an early stage was an important step to further 
advance research with natural products. The combination of biological data with chemo-
analytical information obtained in parallel is key to localising the activity in extracts51. HPLC-
based activity profiling has been successfully implemented to overcome this major setback. This 
offline strategy is directly applicable to a broad range of mechanism-based and cellular assays, 
and has increased in popularity in the context of industrial natural product screening67. 
Miniaturisation of the approach combined with sensitive biological assays decreases the total 
amount of plant material required and allows researchers to work more effectively, thus 
decreases sample demand. 
During the HPLC-based activity profiling approach, on-line spectroscopy is linked with an off-
line bioassay in a microtiter format, via automated micro-fractionation in 96-well plates, 
followed by removal of solvent prior to biological testing62. The retrieval of spectroscopic 
information during the chromatographic separation, combined with database searches allows 
early dereplication of possibly known or otherwise uninteresting compounds62,85. Semi-
preparative HPLC fractionation of peaks of interest is thereafter undertaken for off-line 
microprobe NMR spectroscopy and high resolution mass spectrometry (HR-MS) data for 
scaffold and molecular formula prediction. Full structure analysis by NMR involves the 
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measurement of 1D 1H and 13C and 2D COSY, NOESY, edited HSQC and HMBC spectra, and 
additional experiments depending on the specific structural issues to be resolved51. This 
approach, which is depicted in Fig. 1.5, allows the interfacing of chemo-analytical and biological 
data allowing researchers to make significant advances in identifying the active compounds or 
at least the class of targeted molecules; thus making isolation and purification of the specific 
class of compounds more efficient (e.g. using alkaloid extraction technique to enrich alkaloidal 
compounds in a quick and easy step, or polyamide for separation of tannins and diaion for the 
removal of sugars, etc.). Detailed dereplication strategies are discussed in the review article by 
Dias and co-workers (2012)20. 
 
Figure 1.5: Overview of the setup and approach when using HPLC-based activity profiling of 
bioactive extracts62. 
Besides those which involve adsorption chromatography (e.g. HPLC)86, partition 
chromatography is a powerful tool in both early and advanced stages of the fractionation 
process70,87. Generally, Countercurrent Chromatography (CCC) and Centrifugal Partition 
Chromatography (CPC) are collectively referred to as Countercurrent Separation (CS)88. These 
techniques can handle complex polar or a-polar plant extracts equally well as purified fractions 
and sample amounts are versatile87. Basically, the principle is partitioning solutes between two 
immiscible liquid phases; separation is achieved due to the affinities of the solutes for the 
upper or lower liquid phases89. The attrition rates in loss of compounds during fractionation 
steps, as well as loss of bioactivity can be overcome with the use of CCC or CPC since no 
stationary phase is present (see Fig. 1.6) thus eliminating the chance of irreversible adsorption 
of compounds and perhaps loss of activity70. 
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Figure 1.6: One disc showing the chamber arrangement of the CPC instrument. Photo courtesy 
of Dr. Thomas Pfeiffer (AlphaCrom AG). 
1.3.3 Structure Elucidation and Absolute Configuration of Natural Products 
Structure elucidation is an important step for isolated molecules. Various techniques are used 
to determine the structure, such as UV spectroscopy, MS, and NMR, all of which when taken 
together can allow the relative configuration of a molecule to be established. UV absorption 
can be used to allocate compounds to certain classes of secondary metabolites due to the 
presence of characteristic chromophores which give specific patterns of maximal absorption66. 
Absorption for most natural products occurs in the range of 200 – 550 nm66, thus also 
encompassing the Visible region (which is from about 380 – 700 nm). Among all the HPLC 
detectors, UV is the simplest and most widely used, even though it has some limitations, 
particularly for natural products that do not possess a chromophore. Compounds that possess a 
weak chromophore (for example, one double bond as in the case of most triterpene glycosides) 
can be detected by UV at short wavelengths (λmax 203 nm); however the UV cut-off of certain 
solvents should be taken into consideration66. For compounds with weak/no chromophores 
evaporative light scattering detector (ELSD) can be employed. This technique can detect any 
analyte less volatile than the mobile phase. A light beam is directed onto the particles entering 
the detection cell and will cause scattering of the incident light which is detected by a 
photodiode or photomultiplier66. This technique also gives an estimate quantity of the 
compounds present, i.e. a higher peak represents a compound with a higher quantity present.  
Alternatively, MS provides important structural information online for example molecular 
weight, molecular formula (achieved with the use of HR-MS) and fragmentation patterns which 
are crucial for dereplication and characterisation of natural products66. Different ionisation 
sources and mass analysers are available, most commonly electrospray ionisation (ESI) and 
19 
 
atmospheric pressure chemical ionisation (APCI) are used for polar, labile and non-polar, 
thermally-stable molecules respectively. For mass analysers, single/ triple quadrupole, ion trap, 
and time-of-flight (TOF) spectrometers are commonly used. Generally TOF is routinely used for 
accurate mass measurements, and allows assignment of molecular formula with high 
confidence on sub-nanogram amounts of compound66. 
This information along with 1D 1H-NMR and 13C-NMR experiments, and 2D homonuclear (1H-1H-
COSY) and heteronuclear (1H-13C) correlation NMR experiments such as HSQC and HMBC are 
standard in determining the covalent structure of a small molecule. NOESY and ROESY 
experiments provide information of the 3D structure of a molecule and are used for the 
assignment of the relative configuration of the molecules. Sensitivity in NMR instruments is a 
major setback for identification of metabolites. Nonetheless, with the further development of 
NMR, in particular the advent of new probe technology and higher magnetic fields, structure 
elucidation on amounts less than a milligram has become a more routine process90. NMR is 
considered a leading non-destructive analytical tool in structural analysis91. These techniques 
can also be used for the quantification of specific compounds present in the extracts, for 
example, quantification by 1H-NMR (qHNMR). Some reviews on optimisation of parameters for 
qHNMR provide useful considerations for the quantification of constituents in an extract90,91. 
For natural products with chiral centres, determination of the absolute configuration (AC) is one 
of the most challenging features in the elucidation process92. AC is the spatial arrangement of 
the atoms of a chiral carbon and its stereochemical description. Determination of AC of chiral 
molecules is an important step in any field related to the pharmaceutical industry. The mainly 
used methods for AC assignment include X-ray crystallography, chiral derivatisation, or stereo-
controlled organic synthesis93. However, for X-ray crystallography a suitable single crystal is 
often difficult to obtain especially for some natural products, chiral derivatisation is not always 
possible on small amounts of sample, and chemical synthesis is hampered by the cost and 
challenges92,93. The use of electronic circular dichroism (ECD) has been shown to be a powerful 
chiroptical tool for the AC assignment of natural products with various chromophores since the 
1960s. CD is the phenomena of a chiral molecule that absorbs left and right circularly polarised 
light beams to a different extent. The principle is based on the comparison of experimental and 
calculated ECD spectra; i.e. the more closely they match, the more reliable the AC assignment 
can be drawn92. Vibrational circular dichroism (VCD) is the extension of ECD into infrared and 
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near-IR regions of the spectrum where vibrational transitions occur within the ground 
electronic state of the molecule94. This technique has many advantages since there is no need 
for single crystals, derivatisation, or UV-Vis chromophores – the latter being essential for ECD93. 
By comparing the sign and intensity of the experimental spectrum with the ab initio DFT 
calculated spectrum of a chosen configuration, one can unambiguously assign the AC of a chiral 
molecule. 
1.4 Emerging Targets 
Understanding the complexities that underline the interactions between the human body and 
different diseases or disorders is forever growing. The world of science is constantly unravelling 
new potential drug targets. Along with the advancement of technologies and techniques, 
researchers can carry out more in-depth investigations. Using the target-based drug discovery 
approach, identification of the target that is hypothesised that upon its inhibition or activation 
a therapeutic effect will be observed in the disease state should be well characterised – this 
information is then transposed into a model assay to screen for potential lead candidates4. 
With emerging targets – the impact of discovering a lead is tremendous to the advancement of 
science in the related field and to understanding the disease and its interactions on a deeper 
level. Researchers are now advancing drug discovery, particularly in the fields of hit 
identification, examination of new targets and exploration of novel chemical space4. The 
following subsections describe the targets of the projects that are encompassed in this thesis. 
1.4.1 Myotonic Dystrophy Type I 
1.4.1.1 Background 
Myotonic dystrophy type I (DM1) is a disabling neuromuscular disorder, characterised by 
progressive muscle wasting, weakening, cataracts, cardiac conduction defects and myotonia 
(see Fig. 1.7). Affected individuals have muscle weakness and difficulty with muscle relaxation 
after a sustained period of contraction95. DM1 has a prevalence of 1:8000 people worldwide 
and is genetically inherited95. Due to the many symptoms experienced by patients, DM1 is 
characterised as a multisystemic disorder. The condition is transmitted as an autosomal 
dominant trait and becomes more severe as the gene mutation is passed from generation to 
generation, a phenomenon known as anticipation96. 
21 
 
The underlying mechanism for anticipation was unknown for a long time however, with the 
discovery of a group of disorders associated with triplet repeat expansions in a variety of genes; 
the fundamentals of anticipation could be understood96.  
 
Figure 1.7: Major effects of Myotonic Dystrophy type 1. 
1.4.1.2 The Underlying Cause of DM1 
In the early 1990s the identification of a new class of disease-causing mutations caused 
considerable excitement in the scientific community. The mutations were inherited 
trinucleotide repeat expansions on the DNA level. There is a subset of genes, with trinucleotide 
repeats in which expansion of the number of repeats beyond a threshold leads to abnormal 
gene function96. The number or triplet repeat expansion is directly linked to the disease 
severity. Over 20 neurological diseases have now been assigned to this group. Each disease is 
associated with a single defective gene, which triggers the process of pathogenesis through 
aberrant expression or toxic properties of mutant transcripts or proteins. Although researchers 
have been making efforts to develop treatments for these diseases for nearly two decades, 
they remain incurable. Examples are fragile X syndrome which is an expansion of CGG in the 5’ 
untranslated region (UTR) of the FMR1 gene (Fragile X mental retardation 1 gene) or DM1 
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which is caused by an expansion of CTG codon in the 3’ UTR of the dystrophia myotonica 
protein kinase (DMPK) gene97,98 (see Fig. 1.8). DMPK is a protein kinase enzyme part of the rho 
family of kinases and forms a protein that is almost exclusively expressed in smooth, skeletal, 
and cardiac muscles in humans.  
 
Figure 1.8: Expansion of CTG repeats on the 3’ untranslated region of the DMPK gene (adapted 
from96). 
As depicted in Fig. 1.9, on the RNA level, expanded (CUG)n repeats form hairpin structures, 
which lead to ribonuclear inclusions. More specifically, the RNA with expanded (CUG)n repeats 
sequesters splicing-factors such as muscleblind-like 1 (MBNL1), which is involved in alternative 
splicing. Lack of available MBNL1 leads to miss-regulated alternative splicing of many other pre-
mRNA targets, which have been shown to be linked to the multisystemic defects associated 
with the DM1 pathology. 
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Figure 1.9: Underlying mechanism of DM1, showing the hairpin loop on RNA formed by 
expanded CUG repeats, which sequester MBNL1 leading to miss-splicing of pre-mRNA targets 
(adapted from97). 
MBNL1 proteins control the alternative splicing of specific exons during mammalian postnatal 
development99. This process is dysregulated in DM1 because MBNL1 is sequestered by (CUG)n 
RNAs expressed from mutant DMPK genes. This observation suggests that MBNL1 has a higher 
affinity for pathogenic RNAs rather than their normal splicing targets. However, it has been 
demonstrated that MBNL1 proteins preferentially recognize CG-rich RNA helices containing a 
pyrimidine mismatch on both normal splicing substrates and pathogenic RNAs. MBNL1 binds 
selectively to the stem region of the (CUG)n RNA which results in a stacked ring complex that 
effectively traps MBNL1 and inhibits its role as an alternative splicing factor during postnatal 
development99, an example of this is shown in Fig. 1.10. Thus, the splicing of a multitude of pre-
mRNAs is miss-regulated, including the skeletal muscle chloride channel (CLCN1)100, the insulin 
receptor (INSR)101, sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 1 (SERCA1)102, and cardiac 
troponin type 2 (TNNT2) pre-mRNA103. The miss-splicing of some of these pre-mRNAs can be 
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linked directly to a certain disease symptom, e.g. myotonia results from the miss-splicing of 
CLCN1 pre-mRNA.  
 
Figure 1.10: Mechanism of miss-splicing due to lack of MBNL1 (in blue), leading to exon 
exclusion or inclusion (disordered) mRNA in the insulin receptor (INSR) and cardiac troponin 
(TNNT2), respectively (adapted from97). 
1.4.1.3 Current Therapies and State of Research 
Current therapies include symptomatic therapy which involves visits to the neurologist, the 
cardiologist, ophthalmologist and endocrinologist, related to the symptoms of DM1. Presently 
there is no drug on the market with the ability to reverse the defects associated with DM1. 
Since there is no cure more focus is given to the management of individuals with DM1, which 
very much depends on the severity and includes vigilant cardiac monitoring and implantation of 
a pacemaker when indicated, cataract removal, and treatment of diabetes and of pain. 
Emphasis is on respiratory care and treatment of cardiological complications97. Early detection 
of cardiomyopathy in DM1 is important and treatment of the symptoms includes conventional 
use of diuretics, angiotensin-converting-enzyme inhibitors, and digitalis glycosides104. The most 
treatable symptom of DM1 is cataract development, which commonly begins in the second 
decade or later and is characterised by multicoloured lens opacities on slit-lamp examination104. 
Adaptation of assistive devices as the disease progresses is helpful97.  
The hairpin loops formed by expanded triplet repeats that bind and sequester MBNL1 proteins 
could be targeted by low molecular weight compounds with the idea of disrupting the hairpin 
structure, and thus interfering with MBNL1 binding. To date, many studies aiming to identify 
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small molecules targeting the MBNL1-CUGn complex have been focusing on synthetic 
molecules. Different therapeutic strategies involve development of agents degrading the toxic 
RNA or blocking its pathogenic interaction with proteins105 and have been tested in in vitro or in 
vivo experiments using animal models97. Synthesis of antisense oligonucleotides which are 
single stranded RNA complimentary to the target RNA are currently being followed. These 
target the DMPK-(CUG)n transcripts
106. Various other approaches include viral over-expression 
of MBNL1107, RNA interference108, ribozyme technology109, as well as peptides110, and small 
molecular compounds111,112. 
Pentamidine has been shown to improve splicing defects associated with DM1112. Biochemical 
experiments in cell and mouse model studies of the disease have indicated that pentamidine 
and related compounds may bind to the DNA-motif and inhibit transcription113.  
1.4.1.4 Natural Products and DM1 
Most of the described (CUG)n RNA targeting molecules are synthetic. Only a few natural 
compounds have been described, such as neomycin B112 and lomofungin114. Neomycin B was 
shown to disrupt MBNL1 binding to CUG repeats in vitro, however in tissue culture cells 
neomycin B was not able to reduce the formation of ribonuclear foci, nor release MBNL1 from 
the foci in the treated cells112. Lomofungin and its dimer dilomofungin were identified as 
inhibitors of MBNL1-(CUG)n binding. However, in secondary cellular assays the dimer actually 
increased the expression of CUGexp RNA and the monomer slightly rescued the splicing defects. 
These results showed the feasibility of identification of novel small molecules targeting toxic 
RNA, but also demonstrated that ligands for repetitive sequences may have unexpected effects 
on RNA decay114. The structures of these compounds, as well as the synthetic pentamidine are 
depicted in Fig. 1.11. 
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Figure 1.11: Structures of the compounds used in DM1 namely, pentamidine, neomycin B, and 
lomofungin. 
1.4.2 Tuberculosis 
1.4.2.1 Background 
Tuberculosis (TB) is a widespread infectious disease caused by various strains of mycobacteria, 
predominantly Mycobacterium tuberculosis (MTB) – which generally affects the lungs (see Fig. 
1.12). Despite the availability of multiple anti-TB drugs for over 50 years, TB remains the leading 
infectious killer worldwide, resulting in death of over 1.4 million people per year115. The 
emergence of multidrug resistant- (MDR-) and extensively drug resistant- (XDR-) TB strains 
warrants the need for new strategies at combating the disease. Globally in 2015, an estimated 
480 000 people developed MDR-TB, and an additional 100 000 people with rifampicin-resistant 
TB (RR-TB)115, while XDR-TB was detected in over 105 countries116. 
MTB is transmitted from person to person by droplets of air, particularly when people who 
have an active TB infection cough, sneeze, or otherwise transmit respiratory fluids through the 
air. Most infections do not exhibit symptoms, which is called latent TB. About one-third of the 
world’s population has latent TB. One in ten of these latent infections will eventually progress 
to the active disease, which if left untreated, kills more than 50% of those so infected. 
Individuals with compromised immune systems, such as people living with HIV, have an 
increased risk of falling ill116. The classical symptoms of an active TB infection are chronic 
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coughing with blood-containing sputum, fever, night sweats, fatigue, loss of appetite and 
weight loss116,117. 
The causative agent – MTB – is a very persistant pathogen, which can withstand weak 
disinfectants and survive in a dry state for weeks. MTB is a slow growing, obligate aerobe and 
has an extremely lipid-rich cell wall which may contribute to its pathogenesis118,119. MTB has 
developed various strategies to persist within the hostile environment of the host macrophage, 
thereby enabling it to survive120. Although most humans and experimental animals develop 
appropriate immune responses after infection, these immune responses do not reliably 
eradicate the bacteria. Instead, such responses cause MTB to adopt a clinically silent, latent 
state of infection, from which the bacteria can be reactivated121.  
 
Figure 1.12: Mycobacterium tuberculosis bacilli (MTB) as viewed under scanning electron 
micrograph and symptoms of a patient with an active MTB infection. 
1.4.2.2 Current Therapies 
Effective TB treatment is difficult due to the unusual structure and chemical composition of the 
mycobacterial cell wall (an impermeable waxy cell envelope), which hinders the entry of drugs 
and makes many antibiotics ineffective122, and thus only a few drugs have emerged in the past 
30 years123. The two most commonly used antibiotics for TB are isoniazid (INH) and rifampicin 
(RIF) however drug treatment regimens are long – lasting up to 2 years. Latent TB is usually 
treated with a single antibiotic, while active TB is treated with combinations of several 
antibiotics to reduce the risk of bacteria developing antibiotic resistance. Antibiotic 
combinations include INH, RIF, pyrazinamide (PZA) and ethambutol (EMB) (first-line drugs) for 
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at least 18 to 24 months (see Fig. 1.13 for their structures). INH is a prodrug which is activated 
by a bacterial catalase-peroxidase enzyme in MTB, and works by blocking fatty acid synthase 
thus inhibiting mycolic acids that are part of the resistant mycobacterial cell wall. PZA is also a 
prodrug that diffuses into the granuloma of MTB and stops its growth. EMB is bacteriostatic 
against actively growing TB bacilli. It obstructs the formation of the cell wall of MTB leading to 
increased permeability of the mycobacterial cell wall. First-line drugs have the greatest activity 
against mycobacterium and are particularly used in patients with active TB disease that have 
not had any previous TB drug treatments. 
A person with fully susceptible MTB may develop secondary (acquired) resistance during 
therapy because of inadequate treatment, lack of compliance to drug regimen, or using low-
quality medication. MDR-TB is defined as resistant to the two most effective first-line drugs 
(INH and RIF). XDR-TB, defined as MDR-TB plus resistance to three or more second-line drugs, 
currently has no treatment. For cases with MDR-TB, bedaquiline and linezolide (second-line 
drugs) are currently being used. The second-line drugs are only used to treat infections that are 
resistant to first-line therapy, for e.g. XDR-TB or MDR-TB infections. A drug is classified as 
second-line instead of first-line for one of three possible reasons, (i) it may be less effective 
than first-line drugs (e.g. p-aminosalicycylic acid), (ii) may have toxic side-effects (e.g. 
cycloserine), or (iii) may be effective, but unavailable in many developing countries (e.g. 
fluoroquinones). There are currently ten drugs that are approved by the FDA for TB treatment 
and various drug regimens exist124. As of 2016, delamanid has been introduced in combination 
with first-line and second-line drug regimens for the treatment of patients with MDR-TB125. 
Pretomanid is a drug currently under clinical evaluation123; and in the latest news of 2017, 
researchers have discovered a spiroisoxazoline family of Small Molecules Aborting Resistance 
(SMARt) that induce the expression of an alternative bioactivation pathway of ethionamide 
(ETH), which reverts the acquired resistance of MTB to this antibiotic123. 
The only available vaccine developed in the early twentieth century is Bacillus Calmette-Guérin 
(BCG), which is live, attenuated (virulence-reduced) Mycobacterium bovis. Even though the BCG 
vaccine has limited efficacy in preventing active TB, it was still administered to over 3.5 billion 
people121. There are several TB vaccines in Phase I and Phase II trials, however for the time 
being a vaccine that is effective in preventing TB in adults remains elusive116. 
29 
 
Despite all the advances made in treatment and management of TB, it still remains one of the 
main public health threats126. Even though there may seem to be many approved drugs for the 
treatment of TB, each drug has limited benefits and can only be used under specific conditions 
and duration. Repurposing an existing antibiotic class that is already known to be safe and 
effective in other infections but that has not demonstrated anti-TB activity is an attractive 
strategy as outlined in some recent reports122,127. 
 
Figure 1.13: Structures of first-line (isoniazid, pyrazinamide, and ethambutol), and second-line 
(bedaquiline, and linezolide) drugs used for Tuberculosis treatment128. 
Combating TB is a multi-faceted effort that requires improvement of various aspects such as 
diagnostics, vaccine development, development of new technologies, combination drug 
therapies, reduction of drug regimen time, reduction of antibiotic resistant TB strain 
emergence, discovery of new markers and mediators of human immune responses, finding new 
target strategies for combating TB in the human body, and growing commitments by funding 
agencies, regulatory offices and pharmaceutical companies to TB vaccine development. There is 
an unmet need for new drugs addressing novel MTB targets to provide different therapy 
options for patients with drug-resistant TB and also to shorten and simplify treatment of drug-
sensitive TB129. Ideally, these new drugs would be included in combination regimens tackling 
both drug-sensitive and drug-resistant TB, representing a paradigm shift towards a universally 
useful TB treatment regimen129. 
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1.4.2.3 The Target – Coronin-1 Inhibition 
Understanding host-mycobacterial interactions is important for identifying new targets that 
could potentially destroy MTB. To find new targets, studies should focus on the lifecycle of the 
pathogen once it has entered the host system and the interaction that takes place between the 
host’s immune system and mycobacterial infection.There are multiple stages in the human 
immune response to MTB and these distinct stages of MTB infection have been defined as an 
‘immunological life cycle’121. During an immune response to a foreign pathogen, most microbes 
– once internalised by macrophages – are rapidly transported to lysosomes in which they are 
destroyed. In contrast, pathogenic mycobacteria do not avoid capture by macrophages but 
rather prevent fusion of phagosomes to lysosomes, thereby surviving intra-cellularly for 
prolonged periods of time120. MTB have developed strategies to circumvent the normal 
trafficking routes in macrophages in order to increase their chances of survival by manipulating 
normal host cell biology119. This is a crucial point for the persistence of MTB because they 
manage to lie dormant inside the human body for prolonged periods of time. Efforts in 
understanding host-mycobacteria interactions have provided vital insights into these survival 
tactics119–121,130. 
Generally, once a pathogen is engulfed into macrophages, phagosomal content is delivered to 
lysosomes either by maturation or through vesicular traffic of intermediate vesicles. In contrast 
to normal phagocytosis, mycobacteria resist their lysosomal delivery once MTB is engulfed into 
macrophages119. The inhibition of lysosomal delivery is an active process exerted by the 
mycobacteria themselves119,131,132. Once mycobacteria are inhaled, they come in contact with 
the alveolar macrophages and are engulfed into vacuoles called phagocytes133,134. The entry of 
MTB into the macrophages involves binding to one or more specific receptor molecules and 
interaction with plasma membrane steroid cholesterol135. Cholesterol was shown to help 
increase the viscosity of the membrane that is in contact with the hydrophobic cell wall, 
thereby accelerating phagocytic uptake135. MTB use cholesterol-rich domains of the plasma 
membrane to enter the host cells135. 
Intensive research into the interaction between MTB and the immune system have lead to the 
discovery of a coat protein, known as coronin-1, which was found to be essential for the 
survival of MTB within macrophages in the human body120,136,137. Pieters et al. (2008) showed 
that killed mycobacteria were readily found in lysosomes, while living mycobacteria were found 
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in mycobacterial phagosomes (vacuoles that are morphologically distinct from lysosomes)130. By 
analysing different macrophage proteins present in phagosomes containing live mycobacteria, 
coronin-1 was consistently identified which was absent from phagosomes harbouring killed 
bacilli119,137. Coronin-1 was shown to prevent phago-lysosome fusion by regulating calcium-
dependent signalling processes130,138. After in situ killing of the bacilli coronin-1 initially 
associates with the phagosomal surface but is rapidly released concomitant with lysosomal 
degradation of the phagosome and its contents (see Fig. 1.14). Coronin-1 coated phagosomes 
may open novel perspectives for strategies designed to interfere with the normal course of 
MTB in the host cell119. In a coronin-1 knockout mouse model, macrophages lacking coronin-1 
did not display any abnormalities in their number or functional responses including 
proliferation, phagocytosis of beads and bacteria, migration, chemotaxis, activation, membrane 
ruffling, and morphology136,138. The coronin-1 deficient macrophages did however efficiently kill 
MTB upon mycobacterial challenge, which was found to occur through a defect in the 
Ca2+/calcineurin activation pathway138. Trimerisation of coronin-1 is a prerequisite for the 
mycobacterial-mediated calcineurin activation and subsequent mycobacterial survival139,140.  
The role of coronin-1 in the maintenance of immune cell diversity and function is extensively 
described in a review article by Jayachandran and Pieters (2015)136. The authors describe how 
various immune cells namely; macrophages, T cells, B cells, neutrophils, natural killer cells, 
dendritic cells, and mast cells are affected by coronin-1 deficiency136. The exact mechanism of 
coronin-1 retention at the mycobacterial phagosome remains to be elucidated, but may involve 
an enzyme (lipoamide dehydrogenase) that is secreted by MTB and is known to be involved in 
resisting toxic effects generated by the host cell141. Since activation-induced phosphorylation of 
coronin-1 acts as the molecular switch, manipulation of this pathway with therapeutics may be 
useful to induce cargo transfer to and elimination within lysosomes120,137,142,143. Therapeutic 
interventions in the inhibition of coronin-1 may provide an alternative mode to achieve 
pathogen clearance through manipulation of the host rather than trying to eliminate MTB from 
an infected phagosome143. A strategy in targeting the host rather than the pathogen may also 
help to overcome drug resistance, which is an increasing challenge in anti-TB efforts143. 
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Figure 1.14: Model describing the role of coronin-1 in intracellular survival of Mycobacteria. 
Phagocytosis triggers the recruitment of coronin-1 (yellow) around the particle to be ingested, 
possibly as a result of its initial association with microtubules (black lines) at the cell cortex. In 
the case of viable bacteria (violet), coronin-1 is actively retained on the phagosomal membrane, 
while it dissociates from the microtubule network, perhaps as a consequence of a 
conformational change. In contrast, during phagocytosis of killed bacteria (black) or after in situ 
killing of the bacilli, coronin-1 initially associates with phagosomes but is rapidly released 
concomitant with lysosomal delivery of the bacilli (adapted from137). 
1.4.2.4 Natural Products and TB 
Natural products represent a diverse and powerful tool for anti-TB drug discovery, in the form 
of potential anti-microbial leads, and as a means of identifying biochemical targets that are 
most vulnerable in the bacterium144. Natural products have long provided a rich source of 
effective anti-TB agents. Many drugs on the market that act against Mycobacterium are 
synthetic compounds or derived from natural products to increase their potency. The most 
commonly used first-line TB drug is RIF, which is a more stable, semi-synthetic product based 
on rifamycins. Rifamycins, which are produced by soil bacteria (Amycolatopsis rifamycinica) 
were discovered based on their antibiotic activity in 1957 by researchers in Milan. Rifampicin-
resistant mycobacteria develop quickly when the patient is given RIF without another antibiotic. 
Rifampicins are among the few drugs that can kill dormant strains of MTB128. The discovery of 
RIF was the biggest advance in TB chemotherapy. Prior to the use of RIF, the duration of anti-TB 
regimens with 2 or 3 different agents in combination was 18-24 months for active forms of TB 
and 9 months for latent TB122. Following the introduction of RIF to combination therapy with 3 
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other agents, the standard therapy duration was knocked down to only 6 months for active TB 
and 3 months for latent TB122,128.  
The discovery of streptomycin, produced by Streptomyces griseus, founded the age of TB 
therapy and is a second-line treatment commonly used in combination with INH, RIF and 
PZA129. Spectinomycin, a natural product isolated from Streptomyces, showed little activity 
against MTB, but was found to bind to an independent site on the ribosome than that of 
streptomycin127. Derivatives of spectinomycin, called spectinamides, have been shown to 
display potent anti-TB activity both in vitro and in mice122,127. Pyridomycin, a natural compound 
produced by Dactylosporangium fulvum, shows activity against MTB growing within 
macrophages and shows low toxicity to human cells and mice128,144,145. It was shown to have a 
dual action that eventually leads to the inhibition of mycolic acid synthesis in MTB144. 
Furthermore, majority of INH-resistant MTB are sensitive to pyridomycin128,144. The chemical 
structures of rifampicin, streptomycin, and pyridomycin can be found in Fig. 1.15. 
Griselimycin, a natural product isolated half a century ago from the same organism that 
produced streptomycin, was discovered to possess anti-mycobacterial activity, but showed 
poor pharmacological properties129,146; thus was not investigated further at that time. However, 
recently, a synthetic derivative has shown improved oral uptake and penetrates cells of the 
immune system that harbour MTB129. In combination with other drugs, the cyclohexyl 
derivative of griselimycin displayed a different mechanism of action, and high potency in vitro 
and in vivo147. This new series of derivatives have the potential to contribute to drug regimens 
for patients with both drug-sensitive and drug-resistant TB129. Another series of compounds 
emerging to tackle MTB are the synthetic analogues of the sansanmycin uridylpeptide natural 
products148. Earlier in 2017, Tran and co-workers created a library of synthetic sansanmycin 
analogues that possessed potent and selective inhibition of MTB both in vitro and in 
macrophages with MTB co-infection148. The analogues were shown to inhibit peptidoglycan 
biosynthesis148. 
Some of the most effective anti-TB antibiotics require bioactivation by MTB enzymes to acquire 
their anti-bacterial effect123. However, bioactivation of pro-antibiotics is vulnerable to 
mutational inactivation or attenuation of the corresponding bioactivating enzymes, as observed 
for INH-, PZA-, and ETH-resistant clinical isolates123. The bromotyrosine-derived 
spiroisoxazolines represent a structurally diverse class of physiologically active natural 
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products123. The compound SMARt-420 (see Fig. 1.15), a representative member of the 
spiroisoxazoline family has been recently discovered to induce the expression of an alternative 
bioactivation pathway of ETH, which reverts the acquired resistance of MTB to this antibiotic123. 
This first-of-its-kind molecule, is not only fully capable of reversing and clearing ethionamide-
acquired resistance in mice, but was also shown to increase basal sensitivity of bacteria to 
ethionamide123. 
 
Figure 1.15: Structures of the natural product compounds that have been recently discovered 
(SMARt-420, sansanmycin) or used (rifampicin, pyridomycin, streptomycin) for the treatment of 
TB. 
The Global Alliance for TB Drug Development (TB Alliance) has various ongoing joint research 
projects, however only a few of these projects aim at discovery of novel compounds from 
natural products. These studies mostly target MTB in phenotypic assays rather than target-
specific assays. Overall, current methods have led to numerous natural product lead 
compounds for which non-specific toxicity towards host cells other than the mycobacterium 
has been reported70. Simultaneous determination of cytotoxicity and selectivity during the 
process of fractionation of active principles is important in the course of discovering new anti-
TB leads70.  
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1.4.3 Lymphangiogenesis 
Interest in basic lymphatic research was boosted by the growing evidence that the lymphatic 
system contributes to a number of diseases, such as lymphedema, cancer metastasis, and 
different inflammatory disorders149. This emphasises the emerging importance of the lymphatic 
vasculature as a therapeutic target149. The formation of lymphatic vessel sprouts is one of the 
first and essential steps in the development of new lymphatic vessels.  
1.4.3.1 Formation of Lymphatic Vessels 
Lymphangiogenesis is the process through which new lymphatic vessels are formed. Lymphatic 
vessels are lined by Lymphatic Endothelial Cells (LECs) and are critical for health. They control 
tissue fluid homeostasis, immune surveillance, lipid transport, and inflammation150,151. Blood 
and lymphatic vascular systems partially develop by separate molecular mechanisms even 
though they are structurally related and function in concert152. To initiate lymphangiogenesis, 
selected tip cells from the wall of preexisting vessels send out protrusions and sprout into the 
extracellular matrix on their basolateral site. Lymphangiogenesis is induced by vascular 
endothelial growth factor (VEGF) -C and VEGF-D via VEGFR-3 signaling, which acts on LECs that 
differentiate from venous endothelial cells at mid-gestation151. After their formation, lymphatic 
vessels mature and remodel into a branched network that covers the skin and most internal 
organs of the body152. The formation of lymphatic vessel sprouts is one of the first and essential 
steps in the development of new lymphatic vessels. To initiate lymphangiogenesis, selected tip 
cells from the wall of preexisting vessels send out protrusions and sprout into the extracellular 
matrix on their basolateral site. This process is similar to the first steps of blood vessel 
angiogenesis153 and incorporates several mechanistic steps including cell–cell communication 
with neighbouring cells, cell polarisation, matrix degradation, migration, and invasion154. VEGF-
A, VEGF-C, VEGFR-3, neurophilin-2, and Notch signaling play an important role in mediating 
sprout formation153–155. The dorsolateral sprouting, migration, and survival of the first LECs and 
the formation of lymph sacs are dependent on VEGF-C151. VEGF-C co-receptor neurophilin-2 
(NRP-2)156 and the Eph tyrosine kinase ligand ephrin B2157 are required for efficient sprouting of 
lymphatic capillaries, while the Notch1-DII4 signaling pathway is essential for postnatal 
lymphatic development158 (see Fig. 1.16).  
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Figure 1.16: Origin of endothelial cells and assembly of the vasculature. Mesodermal cells in the 
early embryo differentiate into endothelial precursor cells (EPCs, angioblasts) and form 
aggregates, known as blood islands (left). Fusion of blood islands leads to the vasculogenic 
formation of honeycomb-shaped primary capillary plexi in the yolk sac and embryo itself. Blood 
circulation is established and primary plexi are remodeled into a hierarchical network of 
arterioles and arteries (red), capillaries (grey), and venules and veins (blue). The dorsal aorta 
and cardinal vein are directly formed through the assembly of angioblasts. The vasculogenic 
incorporation of circulating EPCs into growing blood vessels may contribute to regenerative or 
pathological neovascularization in the adult. Vascular smooth-muscle cells (vSMCs) are 
associated with arteries and veins, whereas capillaries are covered by pericytes (yellow). The 
first lymphatic endothelial cells (LECs) sprout from the embryonic veins, then migrate and form 
lymphatic sacs. Further steps of lymphangiogenic growth involve sprouting, branching, 
proliferation, differentiation and remodeling processes. The recruitment of lymphangioblasts 
from the adjacent mesenchyme has been speculated to be a further source of LECs. Blind-
ending lymphatic capillaries (green) feed into collecting vessels and ducts. These larger 
lymphatics are sparsely covered by SMCs (purple) and contain valves that prevent backflow155. 
1.4.3.2 Diseases Associated with Lymphangiogenesis 
A multitude of diseases are linked to an insufficient or overactive vasculature (vascular 
network)159. Among them are many inflammatory diseases, such as psoriasis160. Defects in 
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lymphatic vessel formation or function cause lymphedema151 and has recently been linked to 
chronic skin inflammation160, whereas excess lymphangiogenesis promotes cancer 
metastasis150,161 and organ transplant rejection162. Lymphatic vessels dynamically participate in 
inflammatory reactions, modulate immune responses and immune tolerance, and respond to 
increased fluid loads in tissues. They expand (but do not show sprouting lymphangiogenesis) 
during inflammation and their activation (induction of sprouting) reduces the severity of tissue 
inflammation, highlighting an emerging role of the lymphatic vasculature as a therapeutic 
target149,163. 
Lymphatic vessels allow the drainage of interstitial fluid from tissues164. Functional impairment 
of the lymphatic system results in reduced drainage of extravasated fluid and macromolecules, 
leading to a condition known as lymphedema which most commonly occurs in the 
subcutaneous space165. Edema formation, a cardinal sign of inflammation and clinically 
significant feature of inflammatory disease, results when the amount of leakage from inflamed 
blood vessels exceeds the capacity of lymphatic vessels for drainage164. Blocking VEGFR-3, that 
is mainly expressed on the lymphatic endothelium166, has been shown to enhance mucosal 
edema in a mouse model of chronic airway inflammation164, increase severity of chronic 
inflammatory arthritis in a mouse model167, and also prolong the course of inflammatory ear 
swelling in a mouse model for chronic skin inflammation168. Lymphatic insufficiency results in 
chronic fluid stasis with subsequent disruption of cutaneous tissue architecture and profound 
inflammation163. Lymphedema is characterised by adipose tissue and progressive tissue 
fibrosis169. The accumulation of protein-rich fluid in the tissues causes swelling of the 
extremities and is in most patients also associated with inflammatory reactions, fibrosis, 
overgrowth of adipose and connective tissues in the affected areas, increased risk of infection, 
and impaired wound healing149. Lymphatic injury (even minor lymphatic damage) acts as the 
initial trigger for the multistep procedure resulting in lymphedema163. It has been shown that 
lymphatic vessel morphology was profoundly altered during the course of lymphedema 
development and was associated with a gradual impairment of lymphatic vessel function and a 
distinct immune cell infiltration163.  
Lymphedema is a chronic, disabling, and disfiguring condition, which is classified into primary 
and secondary (acquired) lymphedema and is based on its cause149. Primary lymphedema 
further categorised by the age of onset as congenital (present at birth), praecox (very early), or 
38 
 
tarda (late onset), is a rare, autosomal dominant disorder with an estimated prevalence rate of 
1.15 per 100 000 patients in North America170. It originates from missense mutations affecting 
lymphatic development170,171. Milroy’s disease, a form of congenital lymphedema with 
autosomal dominance inheritance was ascribed to kinase-inactivating mutations in the VEGFR-3 
gene171,172. Secondary lymphedema, which is more frequent than the primary form, represents 
a common complication after operative procedures in oncologic surgery (such as lymph node 
dissection in the context of breast cancer or melanoma treatment173), or any other traumatic, 
inflammatory, or neoplastic disruption or obstruction of lymphatic pathways169. Up to 30% of 
women treated for breast cancer and around 20% of patients after lymph node dissection for 
melanoma develop lymphedema174. Secondary lymphedema has also been described after 
sentinel lymph node biopsies174. Radiation, infectious diseases (e.g. lymphatic filariasis) or 
chronic inflammation may also cause secondary lymphedema175. According to WHO report, 
over 15 million people were reported in 2014 to suffer from lymphedema because of lymphatic 
filariasis, making it the most important cause of secondary lymphedema in developing 
countries, while in industrialised countries, cancer treatment is the most frequent cause of 
secondary lymphedema176. Despite advances in all fields of surgery, physiotherapy (e.g. lymph 
drainage, compressive bandages) remains the standard symptomatic treatment for both 
primary and secondary lymphedema175.  
1.4.3.3 Natural Products and Lymphangiogenesis 
There has been reported benefit of coumarin (5,6-benzo-pyrone) in lymphedema, which is 
ascribed to its stimulatory effect upon cutaneous macrophages and, thereby, upon local 
proteolysis177. Coumarins stimulate other cellular elements of the immune system and may 
promote protein reabsorption177. Flavonol glycosides, particularly rutin derivatives, are thought 
to benefit lymphedema through protective effects on vascular endothelium and general 
improvement in the microcirculation169. Dietary restriction of long-chain triglycerides provides 
some relief of edema in patients178. 
Fatty acid β-oxidation (FAO) was shown to promote LEC proliferation through the same 
mechanism as vascular endothelial cell (VEC) proliferation. Endothelial cells oxidize fatty acids 
to produce acetyl-CoA for epigenetic modifications critical to lymphangiogenesis162. Fatty acids 
provide acetyl-CoA, which helps to sustain the Krebs cycle and histone acetylation that is 
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required for lymphangiogenesis162. Alternatively, statins were shown to inhibit lymphangiogenic 
sprouting in vitro, and in vivo for corneal and cutaneous lymphangiogenesis154.  
1.4.4 Chronic Heart Failure 
1.4.4.1 Background 
According to the New York Heart Association (NYHA), heart failure (HF) is classified into four 
different functional classes (I to IV). Patients are classified by a doctor based on their HF 
symptoms and functional limitations. The severity of HF depends on the ability of the heart to 
pump blood to the rest of the body. HF, which is often referred to as congestive or chronic 
heart failure (CHF), is a progressive and severe cardiovascular health condition, of which there 
is no cure for. Patients experience shortness of breath during daily activities, general tired or 
weak feeling, weight gain with water retention and swelling (edema) in the feet, legs, ankles 
(peripheral edema), and stomach (ascites), as well as troubles with breathing while lying down 
(pulmonary edema). The term ‘acute’ means rapid onset and ‘chronic’ refers to a long-term 
condition, which is usually kept stable by the treatment of symptoms. Current therapy – based 
on the NYHA classification – includes symptomatic therapy which consists of managing the 
symptoms, such as control of blood pressure, regular visits from cardiac nurses, attending 
specific exercise programs with specific lifestyle changes, and use of a pacemaker or 
implantable cardiac defibrillator179. Approximately 20 million people are affected worldwide, 
and at the age of 40 years the lifetime risk of developing HF is 1 in 5 (for both men and 
women)180. 
1.4.4.2 Underlying Pathology 
HF is a physiological state in which cardiac output is insufficient to meet the needs of the body 
and lungs. The basic pathophysiology in HF involves changes in neurohormonal system with 
increasing activity in rennin-angiotensin-aldosterone system (RAAS), which results in sodium 
retention (edema formation), and sympathetic activation (increase in heart rate and peripheral 
vascular resistance)181. There is a cascading effect resulting in myocardial fibrosis which leads to 
impaired relaxation and filling problems, and vascular fibrosis which leads to impaired arterial 
compliance as well as baroreceptor dysfunction and alterations in renal function181. 
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In CHF, endothelial hyperpermeability has been linked to edema formation. The endothelium 
plays a crucial role in various physiological and pathological processes182. Calcium ions are an 
important second messenger system in the endothelium and play a pivotal role in regulation of 
endothelial permeability183. The most important mechanisms that cause elevated calcium levels 
in the endothelium are moderated by the activation of phospholipase C (PLC) through G-
protein coupled receptors184,185 provoking the formation of inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol186. IP3 generates calcium depletion from the endoplasmic reticulum, whereas 
diacylglycerol activates calcium influx from the extracellular space through transient receptors 
potential (TRP) channels187. 
1.4.4.3 Crataegus species for Cardiovascular Disease 
Several species of hawthorn (Crataegus species) have been used in traditional medicine for a 
variety of purposes. The dried fruits (from Crataegus pinnatifida) are used as a digestive aid in 
Traditional Chinese Medicine (TCM), while other species such as C. laevigata are believed to 
strengthen cardiovascular function188,189. Hawthorn is one of the oldest known medicinal plants 
in the Western world190. The most prominent extract of Crataegus, called WS 1442, is an 
aqueous alcoholic special extract from leaves and flowers of C. monogyna/laevigata186. 
Crataegus extract WS 1442 is approved for the treatment of mild forms of CHF according to the 
New York Heart Association functional class II191. The Crataegus special WS 1442 extract has 
been evaluated for its function in cardiovascular disease, and its efficacy has been shown in 
various clinical trials192,193. Treatment with WS 1442 has been reported to improve ankle edema 
in CHF194,195. Studies into the underlying mechanism of action for Crataegus extracts are rare, 
even though considerable clinical knowledge exists186. In recent studies, WS 1442 was shown to 
prevent vascular leakage by affecting endothelial barrier-regulating systems196, thus protecting 
against edema formation via the inhibition of thrombin-induced endothelial barrier dysfunction 
in human endothelial cells197. Additionally, WS 1442 displayed a barrier-protective activity in 
vivo in a murine model of endothelial hyperpermeability196,197. Detailed investigations showed 
WS 1442 extract was able to prevent endothelial hyperpermeability via a dual mechanism196,197. 
The hawthorn extract inhibits the barrier-disruptive pathway by reduction of thrombin-induced 
intracellular calcium rise, PKC, and RhoA activity; while on the other hand barrier-protective 
signalling was activated by increasing cAMP levels, activation of Rap1/Rac1 signalling, and 
cortactin rearrangement at the borders of the endothelial cells (see Fig. 1.17)186,196,197.  
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Figure 1.17: Summary of the two pathways activated and inhibited by hawthorn extract that 
leads to the reduction of endothelial hyperpermeability (adapted from197). 
1.5 Aim of this Thesis 
Based on the discussion given so far, natural products have a crucial role in drug discovery and 
need to be continuously tested against various molecular targets that have emerged by the 
progress in genetics and molecular biology. Accordingly, the main objective of this thesis is to 
assess the role natural products play in key targets of four different disease areas. The 
approach known as HPLC-based activity profiling will be employed in each project to track 
activity and identify small molecules of natural origins that exhibit an interaction with the 
identified four emerging biological targets, which are: 
CUGn-RNA and MBNL1 complex: directed in disease area of Myotonic Dystrophy type 1 (this is 
referred to as the DM1 project; the investigation was carried out in collaboration with Prof. 
Sinnreich of the Neurobiology Department at the University of Basel), 
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Coronin-1 expression: directed in the disease area of Tuberculosis (this is referred to as the TB 
project; the research was conducted in collaboration with Prof. Pieters at the Biozentrum of the 
University of Basel), 
Lymphatic endothelial cells: directed in the disease area of lymphedema (this is referred to as 
the Lymphatic project; it was carried out in collaboration with Prof. Detmar of the 
Pharmacogenomics group at the ETH Zürich), and 
Thrombin: directed in the disease area of Chronic Heart Failure (this is referred to as CHF 
project; it was conducted in collaboration with Prof. Fürst from the Institute of Pharmaceutical 
Biology at the Goethe University in Frankfurt). 
The DM1 project focuses on identifying small molecules which have the ability to inhibit 
the formation of the pathogenic complex between CUGn-RNA and MBNL1 in a novel 
complex-inhibition assay. Results and discussion of this project will be presented in 
Chapter 2. 
The TB project targets the identification of small molecules of natural origin which have 
the ability to inhibit the expression of coronin-1 protein that has an essential role for the 
survival of MTB in the host cell. The results of this project will be addressed in Chapter 3. 
The Lymphatic project assesses the potential of plant secondary metabolites in 
promoting lymphatic vessel growth. Results and discussion of this project will be 
presented in Chapter 4. 
The CHF project focuses on characterising the secondary metabolites present in active 
sub-fractions of Crataegus species which have the ability to inhibit endothelial 
hyperpermeability. Results and discussion of this project will be addressed in Chapter 5. 
In Chapter 6 of this thesis, all materials and methods used for each project are described. 
Finally, concluding remarks and general outlook of the thesis will be presented in Chapter 7. 
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Chapter 2 
2. Results and Discussion: Myotonic Dystrophy type I 
As highlighted in section 1.5, the main focus of the DM1 project is to identify small molecules 
which have the ability to inhibit the formation of the pathogenic complex between CUGn-RNA 
and MBNL1, in a novel complex-inhibition assay. In the following sections, extract library 
screening and hit prioritisation, the results of prioritised plant extracts (Lamium album, Salvia 
miltiorrhiza and Peganum harmala) as well as isolated compounds and alkaloid library are 
presented. Finally, summarised discussion and conclusions of the DM1 project are given. 
2.1 Extract library screening and hit prioritisation 
A library containing just over 2100 plant and fungal extracts, selected based on their 
chemotaxonomy and/or traditional uses were screened in the complex inhibition assay at 100 
µg/mL and 100 µM, respectively. The results were analysed for optical density readout at 450 
nm (OD450) in a competitive binding ELISA assay. Extract prioritisation was based on the criteria 
of at least 50% CUG78-MBNL1 complex binding inhibition (effect shown as a decrease of OD450 
signal, high OD450 values represent no effect).  
Ten plant extracts were prioritised and further investigated for their active principles, namely 
methanol (MeOH) extract of roots from Peganum harmala (Nitrariaceae), ethyl acetate (EtOAc) 
extract of roots from Salvia miltiorrhiza (Lamiaceae), MeOH extract of leaves from Bathysa 
veraguensis (Rubiaceae), EtOAc extract of leaves from Lamium album (Lamiaceae), MeOH 
extract of the herb from Pistacia lentiscus (Anacardiaceae), MeOH extract of stems from 
Henriettella tuberculosa (Melastomataceae), MeOH extract of the leaves from Henriettella 
tuberculosa (Melastomataceae), MeOH extract of leaves from Casearia arborea 
(Flacourtiaceae), MeOH extract of leaves from Coccoloba spp. (Polygonaceae), and MeOH 
extract of aerial parts from Struthanthus orbicularis (Loranthaceae). 
Seven of the ten extracts belong to families that are commonly known to contain tannins, so to 
remove the possibility of false positive interactions due to tannins present in the extracts 
polyamide filtration was done and the resulting tannin-free fractions were tested. The tannin-
free fractions displayed no further activity thus the activity from these extracts could be 
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assigned to tannin interactions with protein-based screens. The 7 extracts subjected to 
polyamide filtration were from Bathysa veraguensis, Pistacia lentiscus, Henriettella tuberculosa 
stems and leaves, Casearia arborea, Coccoloba species, and Struthanthus orbicularis. As an 
example to exhibit the presence of tannins in various extracts, the figure below (Fig. 2.1) shows 
the HPLC-based activity profile of B. veraguensis MeOH extract overlaid with UV chromatogram 
at 254 nm. The HPLC-activity profile in Fig. 2.1 displays the activity spread over numerous 
fractions and also the characteristic tannin-like bump that is visible in the UV chromatogram at 
254 nm. 
 
Figure 2.1: HPLC-based activity profile of Bathysa veraguensis methanol extract displaying UV 
chromatogram at 254 nm (in black) on the y-axis on the left and OD450 signal (in red) on the 
right y-axis. 
After removal of tannins by filtration over polyamide, the resulting tannin-free extracts were 
tested and found to lose their activity (Fig. 2.2). Accordingly, the remaining three active extracts 
were the EtOAc extract of leaves from Lamium album, the EtOAc extract from roots of Salvia 
miltiorrhiza, and the MeOH extract of roots from Peganum harmala which were investigated 
further.  
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Figure 2.2: OD450 values for some extracts and their tannin free fractions tested at 100 μg/mL. 
2.2 Lamium album (Lamiaceae) 
Investigation of L. album was assigned as a second priority plant since only a minor effect was 
observed with the fractions. The maximum decrease in OD450 signal for L. album (but not high 
enough to be considered as a top priority) was observed in fraction 8 (minute 7.00-8.00) which 
corresponds to the compound auroside, an iridoid-glycoside (La-1). Fig. 2.3 below exhibits the 
structure of auroside along with HPLC-based activity profile of L. album EtOAc extract 
superposed with the UV chromatogram at 254 nm.  
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Figure 2.3: (a) HPLC-based activity profile of Lamium album EtOAc extract displaying UV 
chromatogram at 254 nm (in black) on the y-axis on the left and OD450 signal (in red) on the 
right y-axis. (b) peak-1: auroside structure. 
Though auroside was not active enough for further tests, its absolute configuration was 
determined to be 1S,5R,7S,8S,9R (see Fig. 2.4) for the aglycone.  
1 
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Figure 2.4: Overlay of experimental and calculated ECD spectra for auroside 1S,5R,7S,8S,9R and 
1R,5S,7R,8R,9S aglycone enantiomers. 
2.3 Salvia miltiorrhiza (Lamiaceae) 
The main activity for the EtOAc extract for S. miltiorrhiza was found in fraction 26 
(corresponding within the minute 26.00 to 27.00) which could be assigned to the two positional 
isomers that co-elute (compounds 4 and 5). HPLC-based activity profile of S. miltiorrhiza EtOAc 
extract overlaid with UV chromatogram at 254 nm as well as the structure of isolated 
compounds are shown in Fig. 2.5. 
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(a) 
 
 
(b) 
 
 1  2  3    
5  6  7  
Figure 2.5: (a) HPLC-based activity profile of Salvia miltiorrhiza ethyl acetate extract displaying 
UV chromatogram at 254 nm (in black) on the y-axis on the left and OD450 signal (in red) on the 
right y-axis. (b) The structure of isolated compounds which are represented by peak numbers 
on the profile: (peak-1) methyltanshinoate, (peak-2) cryptotanshinone, (peak-3) tanshinone I, 
(peak-4) 1,2-dihydrotanshinquinone I, (peak-5) methylenetanshinquinone, (peak-6) 
dehydromiltirone, and (peak-7) tanshinone IIA. 
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In general, difficulties in solubility of the compounds were experienced especially with 
compound 7 (tanshinone IIA). The dicarbonilic group of tanshinone IIA, isolated in a large 
amount from S. miltiorrhiza, and of the commercially available 9,10-phenanthrenquinone were 
transformed into oxazole and methyl-imidazole groups, respectively, by reductive amination 
with methyl amine198. The figure below (Fig. 2.6) shows the reaction on 9,10-
phenanthrenquinone and tanshinone IIA together with the resulting synthetic structures. The 
resulting compounds named PQ-I and TA-II were further tested in cell-based assays. These two 
molecules can be considered as part of a preliminary structure-activity relationship (SAR) study, 
where the imidazole and oxazole groups were introduced. 
 
Figure 2.6: Reaction on 9,10-phenanthrenquinone (top left) and tanshinone IIA (bottom left) 
and resulting synthetic structures (PQ-1 and TA-II). 
2.3 Peganum harmala (Nitrariaceae) 
The main activity of the extract from P. harmala was assigned to harmine (peak 3) between 
8.00-9.00 minutes (fraction 8) as depicted in the HPLC-activity profile in Fig. 2.7. Further Fig. 2.7 
shows the structure of isolated compounds which are represented by numbers on the HPLC 
profile. 
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(a) 
 
 
(b)  
   1  2  
3  4  
Figure 2.7: (a) HPLC-based activity profile of Peganum harmala methanol extract displaying UV 
chromatogram at 254 nm (in black) on the y-axis on the left and OD450 signal (in red) on the 
right y-axis. (b) The structures of isolated compounds which are represented by numbers on the 
profile: (peak-1) vasicine, (peak-2) harmol, (peak-3) harmine, and (peak-4) vasicinone. 
2.4 Isolated compounds, synthetic tanshinones, and alkaloid library 
All isolated compounds presented so far as well as a collection of selected in-house alkaloid 
compounds which are chosen based on the active scaffold of harmine were tested. As shown in 
Fig. 2.8, the complex inhibition assay results for isolated compounds exhibits that harmine, 1,2-
dihydrotanshinquinone I, and methylenetanshinquinone were the most active compounds, this 
1 
2 3 
4 
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is in line with their observed HPLC-based activity profiles. Moreover these results illustrate that 
the type of compounds that would more likely be active would be planar and nitrogen based. 
 
Figure 2.8: Complex inhibition results for isolated compounds (most active ones are depicted in 
red). The test concentration was 50 μg/mL.  
To overcome the issue of solubility experienced with the tanshinone compounds, two synthetic 
derivatives from S. miltiorrhiza were prepared (also refer to section 2.2). Moreover, the assays 
which measure the % of exon inclusion/exclusion in the gene coding for insulin receptor (INSR) 
and cardiac troponin (TNNT2), that are commonly miss-spliced by the lack of functional MBNL1 
in the DM1 disease were prepared at the Neurobiology Department, University of Basel. 
Utilising these assays, both synthetic derivatives of S. miltiorrhiza, three isolated active 
compounds (i.e., harmine, 1,2-dihydrotanshinquinone I, and methylenetanshinquinone) as well 
as a collection of selected in-house alkaloid compounds were tested. The structures of the 
collected alkaloids and the above assay test results are shown in Fig. 2.9 and Fig. 2.10, 
respectively. 
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coptisine   jatrorrhizine  epiberberine  8-oxoberberine 
 
   
(-)-eschscholtzine  (-)-californidine iodide  (-)-argemonine 
 
    
berberine   (+)-tazettine  (+)-haemanthamine 
 
  
(-)-galanthine   palmatine 
Figure 2.9: Structures of selected alkaloid compounds which are chosen based on the active 
scaffold of harmine. 
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Figure 2.10: Test results for alkaloid collection, three isolated active compounds (i.e., harmine, 
1,2-dihydrotanshinquinone I, and methylenetanshinquinone) and two synthetic derivatives of S. 
miltiorrhiza, in terms of – % of exon inclusion/exclusion for insulin receptor (INSR) and cardiac 
troponin (TNNT2) (the most active ones are depicted in red). RQ represents the relative 
quantification by qPCR. The test concentration for all experiments was 40 μM. 
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2.5 Discussion and conclusions 
Myotonic dystrophy type 1 (DM1) is a genetically inherited muscle disorder that is 
characterised by progressive muscle wasting and weakening, cataracts, and cardiac conduction 
defects. At present there is no cure or effective treatment for this disabling disease. In this 
context, a collection of about 2100 extracts from different plant and fungal strains were 
screened with a novel DM1-based biochemical assay for their ability to inhibit the formation of 
the pathogenic complex formed between (CUG)n-RNA and the splicing-factor muscleblind-like 1 
(MBNL1). From the ten extracts that were prioritised, 7 of them could be excluded due to false 
positives caused by interaction of tannins with protein based screens. Tannins are known to 
form non-specific interactions with protein-based screens, via reversible (ionic or H-bonding 
interactions) or irreversible (oxidative coupling) interactions. The remaining active extracts 
were from Lamium album, Salvia miltiorrhiza, and Peganum harmala. Auroside (La-peak-1) was 
identified from L. album. The compounds methyltanshinoate (Sm-peak-1), cryptotanshinone 
(Sm-peak-2), tanshinone I (Sm-peak-3), 1,2-dihydrotanshinquinone I (Sm-peak-4), 
methylenetanshinquinone (Sm-peak-5), dehydromiltirone (Sm-peak-6), and tanshinone IIA (Sm-
peak-7) were isolated from S. miltiorrhiza. From P. harmala vasicine (Ph-peak-1), harmine (Ph-
peak-3), and vasicinone (Ph-peak-4) were isolated from a previous study and were already 
available in-house, while harmol (Ph-peak-2) was identified via dereplication of data.  
The results of the complex inhibition assay showed that harmine, 1,2-dihydrotanshinquinone I, 
and methylenetanshinquinone were the most active compounds. Quantification of the results 
also showed that harmine had an IC50 at 135.5 ± 9.3 µM and a toxicity-IC50 at 123.3 ± 4.6 µM, 
while 1,2-dihydrotanshinquinone and methylenetanshinquinone had solubility issues but both 
of them displayed IC50 > 200 µM. To increase the solubility of these tanshinone compounds, two 
derivatives starting from 9,10-phenanthrenquinone and tanshinone IIA were synthesised 
(namely PQ-1 and TA-II) and tested. Additionally, based on the active scaffold of harmine, 
planar-nitrogen-based compounds (such as protoberberine alkaloids) were hypothesised to 
possess higher activity. Given that the target is a RNA hairpin loop, selected alkaloids from the 
in-house library were tested in assays which measure the % of exon inclusion/exclusion in the 
gene coding for INSR and TNNT2. The results from these experiments showed that the most 
active compounds were 8-oxoberberine for INSR, and coptisine and berberine for TNNT2 (see 
Fig. 2.10). Further study on berberine displayed that it had the most potent activity in the 
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complex inhibition assay with an IC50 of 86.3 ± 5.8 µM and 212.1 ± 18.3 µM toxicity-IC50, and it 
was able to restore splicing in TNNT2 by 75.1 ± 2.8%. Harmine was able to restore TNNT2 
splicing by 76.8 ± 1.6%. Even though the IC50 and toxicity-IC50 values are relatively close for both 
alkaloids, the compounds were effective for alternative splicing at concentrations significantly 
lower than their respective IC50 and toxicity-IC50 values
199. Besides these results, the compound 
screening showed that 1,2-dihydrotanshinquinone I, and methylenetanshinquinone had weaker 
activity in both INSR and TNNT2 assays than alkaloids, this might be due to poor solubility. The 
tanshinone-derivatives showed increased solubility but also increased toxicity and as a result 
their activities in restoring MBNL1 function were weaker. Accordingly, further medicinal 
chemistry optimisation of diterpenes is warranted.  
Overall, the identified alkaloids (i.e., harmine and berberine) were able to ameliorate certain 
aspects of the DM1 pathology, whereas the compounds from Salvia species (i.e., S. miltiorrhiza) 
exhibit certain activities which need further investigation. Notably, the main findings of this 
study exhibit that compounds with planar scaffolds which contained mostly nitrogen are more 
active. Given the planar nature of the active molecules and the target being RNA, it is 
speculated that compound activity is due to reversible intercalation to the RNA hairpin loop via 
electrostatic interactions, thereby blocking the binding of MBNL1 and allowing it to carry out its 
normal function. Considering the fact that most drugs derived from natural products being 
alkaloids or related compounds, thus the lead compounds found in this study may have the 
potential for drug discovery in RNA-mediated diseases. This study represents the first screening 
of natural products for DM1 targeted drug discovery efforts. In addition, this work has been 
presented at the Society for Medicinal Plant and Natural Product Research (GA) conference 
(Faleschini, et al., 2015) as well as parts of this study were published in Journal of Biological 
Chemistry (Herrendorff, et al., 2016)199.  
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Chapter 3 
3. Results and Discussion: Tuberculosis 
As stated in section 1.5, the TB project aims to identify small molecules of natural origin which 
have the ability to inhibit the expression of coronin-1 protein that has an essential role for the 
survival of Mycobacterium tuberculosis (MTB) within macrophages in the human body. In the 
following sections, extract library screening and hit prioritisation, the results of prioritised 
extracts: ethyl acetate extract of Dorstenia contrajerva and methanol extract of Pancratium 
littorale are presented. Lastly, summarised discussion on TB project and concluding remarks are 
given. 
3.1 Extract library screening and hit prioritisation 
A library containing approximately 2100 plant and fungal extracts, selected based on their 
chemotaxonomy and/or traditional uses were screened in the promoter based assay at 20 
µg/mL for 72 hours. The results were analysed for their Green Fluorescence Protein (GFP) and 
Red Fluorescence Protein (RFP) readouts. A decrease in GFP represents a molecule interacting 
with the promoter region of murine coronin-1, thus inhibiting/activating the expression thereof 
and resulting in a decreased/increased GFP readout respectively (on the analysis of this study a 
decrease in GFP signifies coronin-1 inhibition and thus an active substance). Whereas RFP 
represents non-specific interaction with the promoter region of cytomegalovirus (CMV), thus 
inhibiting/activating the expression thereof and resulting in a decreased/increased RFP 
readout, respectively (on the analysis of this study a decrease in RFP signifies a toxic substance). 
Extracts that showed a significant decrease in GFP and an insignificant decrease or no decrease 
in RFP at 20 µg/mL after 72 hours, were prioritised for further investigation. As depicted in Fig. 
3.1 (a) and (b), the ethyl acetate extract of Dorstenia contrajerva L. (Moraceae) displayed a 40% 
decrease in GFP and no decrease in RFP at 20 μg/mL, after 72 hours. Additionally, as showed in 
Fig. 3.1 (c) and (d), the methanol extract of Pancratium littorale Jacq. (Amaryllidaceae) 
significantly down regulated coronin-1 expression after 72 hours with ≥ 80% inhibition at 20 
μg/mL. 
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(a) 
  
(b) 
  
(c) 
  
(d) 
  
Figure 3.1: (a) GFP and RFP readouts (%) for Dorstenia contrajerva (Plate 25 well C1) at 20 
µg/mL after 72 hours, with 0.2% DMSO as a blank control and cycloheximide (1 µg/mL, CHX) as 
a negative control; and the re-evaluation is given on row (b). (c) GFP and RFP readouts (%) for 
Pancratium littorale (Plate 27 well B11) at 20 µg/mL after 72 hours, with 0.2% DMSO as a blank 
control and CHX (1 µg/mL) as a negative control; and its re-evaluation is given on row (d). 
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3.2 Dorstenia contrajerva (Moraceae) 
Following a validated procedure60,62, HPLC-based activity profiling was carried out on the 
extract library sample of D. contrajerva. This allows the correlation of spectroscopic data 
recorded online (PDA scanning from 210-400 nm) and offline (MS scanning from 160-1500 
m/z), with the biological information that are obtained from a time-based micro-fractionation 
and subsequent bioassay60,62. As shown in Fig. 3.2, the most prominent region of activity in the 
HPLC-UV chromatogram at 254 nm was seen at fraction 22 which corresponds to minute 21 – 
22 (on the HPLC profile); with a reduction by about 40% in GFP and less than 15% in RFP. This 
activity could be correlated with one major UV active peak eluting in fraction 22. In fractions 9 
and 10 (corresponding to minutes 8 to 10) the slight decrease in GFP (by about 15 to 20%: see 
Fig. 3.2) was assigned to minor constituents that were not identified. Additionally, increased 
toxicity of fractions 28 to 31 (minutes 27 to 31) was observed (which have RFP reduction above 
25%). 
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Figure 3.2: HPLC-based activity profiling for D. contrajerva on a C18 Sunfire column (3.0 x 150 
mm; 3.5µm; Waters), with a 5 to 100% B gradient in 30 minutes, and 5 minute 100% B isocratic, 
using a flowrate of 0.4 mL/min. Solvent composition was (A): H2O + 0.1% formic acid and (B): 
MeCN + 0.1% formic acid. Collection was 1 minute fractions starting from 0.00 to 31.00 
minutes. The micro-fraction results: %GFP (top panel), UV chromatogram at 254 nm (middle 
panel), and %RFP (lower panel). 
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Online spectroscopic information, database searches and offline NMR analysis were used for 
dereplication of the known compounds. The main compounds were identified to be two major 
furanocoumarins that have been previously isolated from D. contrajerva200. Bergapten201 was 
present in fraction 19 and another rather unusual furanocoumarin (also known as dorstenin200) 
was found to be the dominant compound in fraction 22, corresponding to the prominent 
activity shown during the HPLC-based activity profiling (see Fig. 3.2). Separation conditions 
were optimised for peak-based semi-preparative HPLC-UV collection and subsequent off-line 
microprobe NMR analysis (see Fig. 3.3). The two known compounds, bergapten and dorstenin 
were isolated (98% pure) and their structures were confirmed using NMR analysis. As 
previously described dorstenin was obtained as a racemic mixture of enantiomers200. ECD 
measurements were performed to determine the enantiomer obtained. No significant cotton 
effects were observed, thus confirming that dorstenin was obtained as a racemic mixture – as 
previously described. 
(a) 
 
(b)  
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Figure 3.3: (a) UV chromatogram at 254 nm showing retention times; (b) structures of two 
furanocoumarins that are isolated from D. contrajerva: peak-1: bergapten and peak-2: 
dorstenin. 
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Dorstenin (the main active compound) was tested at various concentrations (20, 10, 5, and 2.5 
µg/mL) for GFP and RFP readouts (see Fig. 3.4). However, even at these concentrations, activity 
of the pure compound could not be confirmed. Dorstenin only started to show a slight decrease 
in GFP at 20 µg/mL. Thus the main activity observed in fraction 22 could be either the presence 
of minor, potent compounds, or the high quantity of dorstenin present in fraction 22. 
(a) 
 
(b) 
 
Figure 3.4: (a) GFP and (b) RFP results of dorstenin after 72 hours at 20, 10, 5, and 2.5 µg/mL. 
DMSO was used as a blank control and a lead compound as a positive control (Post Control). 
During redissolution of the micro-fractions, the solvent type and volume required is a critical 
issue. Usually DMSO is used due its compatibility with biological assays and its solubilising 
properties. The volume for re-dissolution of the fractions should be half of the injection volume 
used during the fractionation, to enable the concentration of an active compound to be similar 
to that of the extract60. This is an arbitrary volume and is based on experience with setting up 
assays using the miniaturised HPLC-based activity profiling approach60. Since the distribution of 
the extract is unknown, the micro-fractions are taken up into the same volume; hence they are 
treated as if there is an equal distribution of the extract throughout the separation. 
Accordingly, the high activity found in fraction 22 (40% GFP reduction) was speculated to be 
one of two reasons, (1) presence of other minor compounds in fraction 22 that were not 
detected by UV, or (2) relative to other compounds, higher amount of dorstenin present in 
fraction 22, thus fraction 22 of the extract tested may have higher concentration of dorstenin. 
To identify the reason why the high activity was found in fraction 22, the above two 
speculations are independently examined.  
Investigation of fraction 22 using TLC and NMR showed that the fraction did not contain 
additional minor or undetected compounds that could give rise to the potent activity which is 
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seen during the micro-fractionation (see Fig. 3.5). Also, for comparison purposes fraction 19 
(which contains bergapten) was investigated, utilising TLC and NMR (see Fig. 3.5). 
(a) 
 
(b) 
 
Figure 3.5: (a) TLC at 254 nm (green), 366 nm (black) and sprayed with Godin’s reagent (grey) 
for the extract (abbreviated as “A” on the plate), fraction 19 (abbreviated as “19” on the plate), 
and fraction 22 (abbreviated as “22” on the plate) are given. (b) The 1H-NMR of fraction 22 
showing dorstenin > 95% pure. 
The first speculation given above, which is the presence of minor active compounds, could be 
excluded as a possible reason for the activity in fraction 22. On the other hand, micro-
fractionation is performed on a miniaturised scale and determining the weight of each fraction 
is not possible, therefore, micro-fractions are resuspended in the exact same amount and 
treated in the same way. If a compound happens to be present in a higher amount than other 
substances in an extract (which may be the case when working with nature), a higher weight 
63 
 
will be present in the well – resulting in this fraction being tested at a much higher 
concentration, since re-dissolution of the fractions are treated equally. Subsequent 
quantification of the pure compounds should be followed up to determine the relative 
concentration that the compounds were tested at. In this context, to examine the second 
speculation which states about the amount of dorstenin in fraction 22, bergapten and dorstenin 
concentration present in the library sample were quantified using UV and 1H-NMR. This would 
allow the calculation of the concentration that fraction 22 may have been tested during the 
micro-fractionation, and provide a possible reason for the observed activity seen in Fig. 3.2.  
Quantification of the two furanocoumarins was done via UV detection at a λmax of 310 nm. The 
calibration curve for bergapten (with mean coefficient of determination, R2: 0.994), and 
dorstenin (with R2: 0.999) is shown in Fig. 3.6. Using the calibration curve for bergapten and 
dorstenin, it was calculated that the extract library contains these compounds with 4.6% and 
12.4%, respectively.  
(a) 
 
 
 
y = 32748783x 
R² = 0.9941 
0.00
200.00
400.00
600.00
800.00
1000.00
1200.00
1400.00
1600.00
1800.00
2000.00
0.00 0.10 0.20 0.30 0.40 0.50 0.60
A
re
a 
(u
V
*s
ec
) 
x 10000 
Concentration (mg/mL) 
Bergapten 
64 
 
(b) 
 
Figure 3.6: Calibration curves for (a) bergapten, and (b) dorstenin, with their mean coefficients 
of determination. 
The second quantification (using 1H-NMR) was done for comparison purposes with that of the 
UV quantification. Reference signals for integration were δ = 7.32 (bergapten), δ = 6.09 
(Internal Standard: IS), and δ = 5.54 (dorstenin). The amount of the two compounds was 
calculated, using the equation below: 
If 
𝐼𝑥
𝐼𝑦
=
𝑁𝑥
𝑁𝑦
 therefore 𝑁𝑥 =  
𝐼𝑥 × 𝑁𝑦
𝐼𝑦 ×𝑁𝑥
 × 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑚𝑜𝑙 𝑓𝑟𝑜𝑚 𝐼𝑆 
The equation above allows the calculation of the number of moles of compound 𝑥. Where 𝐼𝑥 is 
the integration of proton signal of compound 𝑥, 𝑁𝑦 is the number of protons giving rise to the 
IS proton signal, 𝐼𝑦 is the integration of proton signal of IS, and 𝑁𝑥 is the number of protons 
giving rise to compound 𝑥 proton signal. Thereafter, the number of moles of compound 𝑥 can 
be used to calculate the weight of the compound and thus the % present in the sample91. An 
example of the signals used for integration is shown in Fig. 3.7.  
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Figure 3.7: 1H spectrum of D. contrajerva extract library sample (0.5 mg) with 1,3,5-
trimethoxybenzene (0.03 mg) as IS, showing representative 1H signals used for quantification of 
bergapten and dorstenin. 
From the calculations of the three 1H-NMR quantification samples, the amounts of bergapten 
and dorstenin present in the extract library sample were 3.4% and 11.6%, respectively. Possibly 
due to analytical error, these values are slightly lower than the quantification by UV however 
their averages are in a similar range of about 4.0% and 12.0% for each compound. These 
quantification analyses on the library sample allow the calculation of bergapten and dorstenin 
concentration that are present in fraction 19 and fraction 22.  
Using the above mass contribution analysis, bergapten and dorstenin contributions on fraction 
19 and fraction 22 were found to be 41.2 µg, and 112.0 µg, respectively. Taking into 
consideration the re-dissolution and dilutions used for the assay, during the HPLC profiling, 
fraction 19 was tested at 20.6 µg/mL and fraction 22 was tested at 56 µg/mL. At this 
concentration (56 µg/mL) fraction 22 was active. However, the extract library sample was 
initially tested at 20 µg/mL, this means based on the above mass contribution quantification – 
bergapten concentration is 0.92 µg/mL and dorstenin concentration is 2.5 µg/mL. These 
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concentrations are much lower than the testing that had been done during the HPLC profiling, 
accordingly as seen in Fig. 3.4 dorstenin is not active. 
These results corroborate that fraction 22 only possessed a high activity due to the high 
amount of dorstenin in the extract. It should be taken into consideration that HPLC-based 
activity profiling is a qualitative analysis used to track bioactivity and lead investigators towards 
the potentially active compounds. It is crucial to follow up with testing of the pure compounds 
after identification to determine the concentration at which they are active. Additionally, the 
observed collective activity of the extract could be due to synergistic interactions of all the 
substances together. This can be corroborated with the slight increase in activity (decrease in 
GFP) seen in fractions 9 and 10, also the affect of the late eluting compounds (fractions 30-35) 
that show a decrease in GFP. Collectively they contribute to the overall activity (20% decrease 
in GFP) observed with the extract. Therefore, it is not always possible to isolate a single active 
substance that contributes to the overall potency observed with the whole extract.  
An additional way to overcome the issue of varying abundance of compounds in an extract is to 
perform a larger fractionation (using semi-preparative quantities, i.e. macro-fractionation) and 
subsequently weighing the resulting fractions. This allows all fractions to be tested at the same 
concentration since the weight of each fraction is known. As shown in Fig. 3.8 one minute 
fractions were collected on a semi-preparative basis and resulting weights were obtained. All 
fractions were then tested at the same concentration (10 µg/mL, Fig. 3.8), and correlated to 
online UV data. Fig. 3.8 now shows the lack of activity for compound dorstenin (now in fraction 
21) and the overall minor activity spread over all fractions. The activity of the extract therefore 
possibly comes from a synergetic effect of all constituents present in the extract as observed 
during the micro-fractionation (Fig. 3.2, the slight decrease of GFP in fractions 9 and 10, and 
also in the later eluting fractions that showed a decrease in GFP and RFP). Overall, the mass 
contribution analyses as well as the results shown in Fig. 3.8 confirm that the high activity of 
dorstenin observed in Fig. 3.2 was due to the high amount of the compound present.  
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Figure 3.8: Semi-preparative HPLC-UV for D. contrajerva. Collection was 1 minute fractions 
starting from 0.00 to 35.00 minutes. The UV chromatogram at 254 nm (top panel) and GFP 
(lower panel) of the resulting fractions are given. All fractions were tested at 10 µg/mL.  
3.3 Pancratium littorale (Amaryllidaceae) 
HPLC-based activity profiling was carried out on the extract library sample of P. littorale and 
results are depicted in Fig. 3.9 and 3.10 below. This profiling was performed twice using 
different columns and conditions adapted for the separation of the more polar compounds 
since the highest GFP reduction was observed in the early eluting fractions from the first round 
of activity profiling (fractions 8 – 10, approximately 27-37% MeCN). During the second round of 
activity profiling, distinct active (fractions 14 – 16, approximately 28.2-33.6% MeCN) and toxic 
(fractions 21 – 24, 40.7-47.9% MeCN) regions could be distinguished. Further detailed 
investigation into the region of activity (using ESIMS and NMR data collected offline) led to the 
identification of alkaloids as the active constituents. It was speculated that under acidic 
conditions (the use of formic acid in the mobile phase), the alkaloidal compounds are charged 
and thus less retained on the C18 stationary phase and found in the early eluting fractions. 
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Figure 3.9: HPLC-based activity profiling for P. littorale on a C18 SunFire column (3.0 x 150 mm; 
3.5µm; Waters), with a 5 to 100% B gradient in 30 minutes, and 5 minute 100% B isocratic, 
using a flowrate of 0.4 mL/min. Solvent composition was (A): H2O + 0.1% formic acid and (B): 
MeCN + 0.1% formic acid. Collection was 1 minute fractions starting from 0.00 to 31.00 
minutes. The micro-fraction results: %GFP (top panel), UV chromatogram at 254 nm (middle 
panel), and %RFP (lower panel). 
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Figure 3.10: HPLC-based activity profiling for P. littorale on an Aqua C18 column (4.60 x 250 
mm; 5µm; Phenomenex), with a 5 to 50% B gradient in 30 minutes, using a flowrate of 0.4 
mL/min. Solvent composition was (A): H2O + 0.1% formic acid and (B): MeCN + 0.1% formic 
acid. Collection was 1 minute fractions starting from 1.00 to 30.00 minutes. The micro-fraction 
results: %GFP (top panel), UV chromatogram at 254 nm (middle panel), and %RFP (lower 
panel). 
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The methanolic extract was further processed to remove the sugars and enrich the alkaloidal 
compounds using diaion and liquid-liquid extraction, respectively. Thereafter, the enriched 
alkaloid fraction was separated on a diol cartridge. Finally, separation conditions of fractions 
from the diol column were optimised on a RP column regulated at pH 9.0 (see chapter 6). After 
each enrichment step, the activity was assessed to make sure that GFP reduction was 
maintained (not lost during each process) with stable RFP [see Fig. 3.11 (a) and (b)]. 
(a) 
 
(b) 
 
Figure 3.11: (a) GFP and (b) RFP results after each separation step. G+R: background green and 
red fluorescence of untreated cells, G+R (DMSO/10): DMSO control, CHX: cycloheximide as 
negative control, diaion H2O: sugar containing portion, diaion MeOH: extract without sugar part 
which was subjected to alkaloid extraction: Lipophilic, alkaloid and water phases are from the 
alkaloid enrichment step. 
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After semi-preparative isolation, 15 isoquinoline alkaloids including three new congeners were 
structurally characterised. Their corresponding retention times are shown in the UV 
chromatogram at 254 nm (Fig. 3.12).  
(a) 
 
(b)  
 
Figure 3.12: (a) HPLC-UV chromatogram at 254 nm of the alkaloid-enriched fraction with 
retention times of compounds isolated (the numbers in black indicate the spectrum-peak 
number), and (b) structures of isolated compounds with their codes and peak number. 
Separation condition was performed using a gradient of 2 to 100% B in 30 minutes, and 5 min 
at 100% B on the Reprosil-Pur Basic-C18 column. Solvent composition was (A): H2O + 0.1% NH3 
solution, and (B): MeCN + IPA + 0.1% NH3 solution (8:1:1) using a flowrate of 0.4 mL/min. 
Dataf ile Name:pH9_Pl_AE_DCM ret_.lcd
Sample Name:Pl_AE_DCM ret_pH9
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 min
0.00
0.25
0.50
0.75
1.00
1.25
mAU(x100)
pH9_Pl_AE_DCM ret_.lcd 254nm,4nm 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
K2 (2) M1 (3)G2 (1) K4 (4)
H11 (5) H15 (8)I10 (6) I14 (7)
K6 (9) K7 (10) H18 (11) K9 (12)
G16 (14) I19 α/β mix (15)G17 (13)
72 
 
The isolated compounds are (1) 8-demethoxy-lycoranine F, (2) 8-O-demethyl-homolycorine, (3) 
pseudo-lycorine, (4) 8-O-demethyl-lycorenine, (5) 7-demethoxy-10-O-methyl-hostasine, (6) 
carinatine, (7) lycorine, (8) 10-O-methyl-hostasine, (9) 10-deoxy-3-hydroxy-6-hydroxy-
hippeastidine, (10) narcissidine, (11) 1-O-acetyl-pseudo-lycorine, (12) 8-O-demethyl-6-O-
methyl-lycorenine, (13) 3-O-acetyl-narcissidine, (14) 10-deoxy-6(α)-hydroxy-hippeastidine, and 
(15) 6-hydroxy-hippeastidine202. 
The structure elucidation, NMR correlations of the three new compounds (compounds 9, 4, and 
1 on Fig. 3.12), and biosynthetic pathway of the isolated alkaloids from P. littorale are described 
next. Of the 15 compounds, three new congeners as well as 12 already known alkaloids were 
isolated. The known alkaloids were identified by comparison with published spectroscopic and 
physical data as (2) 8-O-demethyl-homolycorine203, (3) pseudo-lycorine204, (5) 8-demethyoxy-
10-O-methyl-hostasine205, (6) carinatine206, (7) lycorine206, (8) 10-O-methyl-hostasine205, (10) 
narcissidine207, (11) 1-O-acetyl-pseudolycorine204, (12) 8-O-demethyl-6-O-methyl-lycorenine205, 
(13) 3-O-acetyl-narcissidine208, (14) 10-deoxy-6(α)-hydroxy-hippeastidine209, and (15) 6-
hydroxy-hippeastidine209.  
Compound 9 (K6, 0.50 mg) was isolated as an amorphous, yellow solid with a pseudomolecular 
ion at 306.1706 [M+H]+ on HRESIMS consistent with the molecular formula of C17H23NO4 
(calculated for C17H24NO4
+: 306.1700) and a positive optical rotation ([α]D +25.7, c 0.05, CHCl3). 
Preliminary data showed that compound 9 was related to 10-deoxy-6(α)-hydroxy-hippeastidine 
(compound 14) with one major difference, the demethylation of the methoxy at position 3 
resulting in a hydroxyl function. The 1H-NMR spectrum exhibited two aromatic singlets at δ6.73 
and δ6.68 assigned to protons H-7 and H-10. Two singlet proton signals at δ3.70 and δ3.73 
indicating two methoxy groups were assigned to positions 13 and 14 by HMBC correlations with 
C-8 and C-9 and NOESY with H-7 and H-10, respectively (Fig. 3.13). The methoxy groups were 
assigned by HMBC correlations to the quaternary carbons C-8 and C-9 and also NOE 
correlations between H-13 to H-7, and H-14 to H-10. The quinoline nucleus was established as 
follows: an oxygenated proton singlet at δ4.82, with the respective carbon signal at δ88.3 was 
assigned to position 6, through its HMBC correlation to the aromatic ring (HMBC with C-10a) 
and NOESY with H-7 and to a protonated carbon (C-4a). It was noted that H-6 had correlations 
with (α)- and (β)-orientations, thus suggesting a mixture of diastereomers. The remaining 
signals to complete the structure were two pairs of methylene groups, H-11 (δ1.39, δ2.07) and 
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H-12 (δ2.59, δ3.14), that connected the nitrogen and the bridgehead quaternary carbon C-10a. 
An aliphatic proton signal at δ3.06 was assigned to H-4a. The latter proton (H-4a) was part of an 
8 proton spin system (H-1–H-4a) consisting of 3 diastereotopic methylene groups H-1 (δ1.58, 
δ2.39), H-2 (δ1.44, δ1.83), H-4 (δ1.14, δ1.67), and an oxygenated methyne resonating at δ3.40 
and located at position 3 by COSY. The relative configuration of the molecule was assigned as 
follows: the J couplings of H-3 δ3.40 dddd (11.2, 9.5, 4.0, 3.6) and H-4a δ3.06 dd (12.0, 5.1) and 
their NOESY correlations indicated their 1,3 diaxial relationship and cofacial orientation. The 
main differences of the 1H NMR spectrum of 9 compared to hydroxy-hippeastidine (15) were 
the presence of the aliphatic proton signal at δ3.40 (H-3) suggesting the presence of a hydroxy 
group instead of a methoxy as in the case of hydroxy-hippeastidine; and the deoxygenation of 
the hydroxyl at H-10 resulting in an aromatic singlet signal instead of no proton signal; and the 
additional hydroxy at position H-6 with a singlet signal. The NOE correlation between H-4a and 
H-3 suggests the β-orientation for the hydroxy group at C-3 (since both protons are in the α-
position). On the other hand, H-6 showed NOESY contacts with H-12 but no dipolar coupling to 
H-4a, thus suggesting the relative configuration of compound 9 as depicted in Fig. 3.13. 
Significant NMR correlations as well as 1H and 13C spectroscopic data for compound 9 are 
shown in Fig. 3.13, and Table 3.1, respectively.   
Two singlet sp3 hybridized carbons at chemical shifts δ55.1 and δ55.3 indicating two methoxy 
groups at positions C-13 and C-14. HMBC correlations to the quaternary carbons C-8 and C-9 at 
δ147.6 and δ148.9 were assigned. Additional three quaternary carbons were assigned at 
positions C-6a, C-10a and C-10b with δ127.8, δ141.3 and δ41.3 chemical shifts, respectively. 
The carbons directly attached to the tertiary nitrogen C-4a, C-6 and C-12 experience a slight 
downfield shift compared to their aliphatic counterparts however not more deshielded than 
their oxygenated version. The pairs of alkaloids with a hydroxy substituent at C-6 appear as a 
mixture of diastereoisomers and are not separable by HPLC210. Closer inspection of the NMR 
spectra showed that the molecule was not pure. In particular, an oxygenated proton signal at 
δ5.45 with the corresponding carbon at δ86.0 indicated the presence of approx. 24% of the 
epimer at C-6 bearing the hydroxy function in beta configuration. The chemical instability of the 
emiaminal proton C-6, that is in equilibrium with the corresponding open form, can explain the 
coexistance of the two epimers. A similar case has been observed by Shitara et al. (2014) for 10-
deoxy-6α-hydroxyhippeastidine209.  
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Figure 3.13: Significant NMR correlations and atom numbers of compound 9. HMBC 
correlations are shown in red and NOE correlations are shown in green. 
Table 3.1: 1H and 13C spectroscopic data for 3-O-demethyl-10-deoxy-6-hydroxy-hippeastidine 
(compound 9) from Pancratium littorale, (DMSO-d6; 500 MHz for 1H and 13C extracted from 1H-
13C 2D inverse detected experiments; δ in ppm) 
 Compound 9 (K6) 
Position δH mult (J in Hz) δC, type (from HSQC, HMBC) 
1 1.58 ddd (13.6, 12.5, 4.2) 
2.39 ddd (13.6, 3.0, 3.3) 
25.6, CH2 
2 1.44 m 
1.83 m 
30.5, CH2 
3 3.40 dddd (11.2, 9.5, 4.0, 3.6) 67.0, CH 
4 1.14 ddd (12, 12, 12) 
1.67 ddd (12, 5.1, 4.01) 
35.9, CH2 
4a 3.06 dd (12.2, 5.1) 58.9, CH 
6 4.82 s 88.3, CH 
6a - 127.8, qC 
7 6.73 s 112.1, CH 
8 - 147.6, qC 
9 - 148.9, qC 
10 6.68 s 105.5, CH 
10a - 141.3, qC 
10b - 41.3, qC 
11 1.39 m  
2.07 m  
33.7, CH2 
12 2.59 ddd (13.3, 9.0, 6.0) 
3.14 dddd (13.3, 10.0, 6.0, 3.7) 
46.1, CH2 
8-MeO (13) 3.70 s 55.1, O-CH3 
9-MeO (14) 3.73 s 55.3, O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
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Compound 4 (K4, 1.15 mg) was isolated as an amorphous, yellow solid with a positive optical 
rotation ([α]D +82.4, c 0.11, CHCl3). Compound 4 had a molecular formula of C17H21NO4, based 
on HRESIMS (m/z 304.1547 [M+H]+; calculated for C17H22NO4
+: 304.1543). By comparing the 1H 
NMR spectrum to that of known lycorenine type alkaloids, compound 4 was assigned to this 
scaffold. Key characteristics of the 1H NMR spectrum are the two singlets for the para-oriented 
aromatic protons at δ6.71 and δ6.72 (H-7 and H-10). A singlet resonating at δ5.70 with the 
corresponding carbon at δ89.9 characteristic for a hemiacetal proton was attributed to H-6 by 
HMBC correlation H6/H10 and H7/H6. Two singlets integrating for 3 protons each suggested 
the presence of two methyl groups, one more deshielded at δ3.74 and the other at δ1.97. The 
CH3 signal at δ3.74 is a methoxy and attached to C-9, according to lycorenine type HMBC 
correlations to the quaternary C-9 and NOE correlation between H-10 and H-14. The other 
singlet is an N-CH3 and is part of the D-ring, according to HMBC correlations to C-4a and C-12 
and NOE correlations to H-4a. Due to the absence of an additional methoxy singlet at C-8 a 
hydroxy substituent was assigned. Hemiacetal alkaloids always show the substituent at C-6 in α-
disposition210 therefore H-6β appears as a singlet at δ5.70. The majority of compounds belong 
to a single enantiomeric series containing a cis B/C ring junction210, which is corroborated by 
the small coupling constant J1-10b (approx. 1.2-1.5). Ring C contains a vinylic proton H-3 at δ5.37 
and diastereotopic protons (δ2.12, δ2.56) attached to a CH2 at position C-2. The two protons 
attached to C-2 exhibit NOE correlations with H-1. Quaternary carbons were assigned to 
positions C-4, C-6a, C-8, C-9 and C-10a based on HMBC correlations. This compound was named 
8-O-demethyl-lycorenine. NMR correlations as well as 1H and 13C spectroscopic data for 
compound 4 are shown in Fig. 3.14, and Table 3.2, respectively. Using the NOE correlations, 
relative configuration was established for the hydroxy position at C-6 in α-disposition (a strong 
correlation was seen between H-6 and H-4a).  
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Figure 3.14: Significant NMR correlations and atom numbers of compound 4. HMBC 
correlations are shown in red and NOE correlations are shown in green. 
Table 3.2: 1H and 13C spectroscopic data for 8-O-demethyl-lycorenine (compound 4) from 
Pancratium littorale, (DMSO-d6; 500 MHz for 1H and 13C extracted from 1H-13C 2D inverse 
detected experiments; δ in ppm) 
 Compound 4 (K4) 
Position δH mult (J in Hz) δC, type (from HSQC) 
1 4.21 dd (6.0, 1.5) 64.9, CH 
2 2.12 ov 
2.56 ov 
30.8, CH2 
3 5.37 br m 114.4, CH 
4 - 140.0, qC 
4a 2.55 ov 66.4, CH 
6 5.70 s 89.9, CH 
6a - 113.4, qC 
7 6.71 s 113.7, CH 
8 - 144.7, qC 
9 - 145.8, qC 
10 6.72 s 112.8, CH 
10a - 127.7, qC 
10b 2.23 dd (9.5, 1.2) 43.2, CH 
11 2.31 m 
2.38 m 
27.4, CH2 
12 2.13 ov 
3.00 ov 
55.7, CH2 
13 1.97 s 43.4, N-CH3 
9-MeO (14) 3.74 s 55.4, O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
Compound 1 (G2, 0.69 mg) was isolated as an amorphous, yellow solid with a positive optical 
rotation ([α]D +47.0, c 0.06, CH3OH) and a molecular formula of C16H17NO4, based on HRESIMS 
(m/z 288.1237 [M+H]+; calculated for C16H18NO4
+: 288.1230). Compound 1 showed similar 
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signals as compound 4 on H-11, -12, -4, -3, -2, and -1. The lack of the singlet signal at H-6 and 
the replacement with a quaternary carbon at C-6 corroborated with HMBC correlations of H-7 
to C-6, suggested the oxidation of the hemiacetal to a lactone ring. Additionally compound 1 
lost the methyl substituent attached to the nitrogen in ring D, thus resulting in the presence of 
a secondary amine. Compound 1 is similar to the homolycorine core structure and thus was 
named 8-O-demethyl-lycoranine F. Noteworthy NMR correlations as well as 1H and 13C 
spectroscopic data for compound 1 are shown in Fig. 3.15, and Table 3.3, respectively. 
 
Figure 3.15: Significant NMR correlations and atom numbers of compound 1. HMBC 
correlations are shown in red and NOE correlations are shown in green. 
Table 3.3: 1H and 13C spectroscopic data for 8-O-demethyl-lycoranine F (compound 1) from 
Pancratium littorale, (DMSO-d6; 500 MHz for 1H and 13C extracted from 1H-13C 2D inverse 
detected experiments; δ in ppm) 
 Compound 1 (G2) 
Position δH mult (J in Hz) δC, type (from HSQC) 
1 4.84 dd (4.8, 2.0) 75.1, CH 
2 2.38 m  
2.63 m  
30.6, CH2 
3 5.50 br m 114.1, CH 
4 - 140.0, qC 
4a 3.13 br d (10.0) 58.5, CH 
6 - 164.6, qC 
6a - 115.2, qC 
7 7.33 s 115.2, CH 
8 - 146.2, qC 
9 - 152.2, qC 
10 7.00 s 110.5, qC 
10a - 135.9, qC 
10b 2.67 dd (10.0, 2.0) 40.8, CH 
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11 2.38-2.48 m 29.3, CH 
12 2.79 ddd (10.2, 8.5, 8.3) 
3.02 m 
43.2, CH2 
13-MeO 3.86 s 55.5, O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
Utilising the NOE correlations as depicted in Fig. 3.15, relative configuration was established 
and ECD was measured to determine the absolute configuration. The measured ECD spectrum 
was compared to calculated spectra of the compound called lycoranine F in Ang et al., (2015)211 
and thus the absolute configuration was confirmed as 1R,4aS,10bS (see Fig. 3.16). 
 
Figure 3.16: Measured ECD spectrum (experimental) from 190 to 400 nm showing positive and 
negative cotton effects. 
Biosynthesis of Amaryllidaceae alkaloids is the result of several intramolecular oxidative 
couplings of precursors related to norbelladine. Norbelladine is formed through combination of 
3,4-dihydroxy-benzaldehyde with tyramine. Methylation of norbelladine results in 4’-O-
methylnorbelladine – which undergoes three types of oxidative couplings: ortho-para’, para-
para’, and para-ortho’202 (see Fig. 3.17).  
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Figure 3.17: 4-O-methylnorbelladine and the three oxidative coupling reactions namely ortho-
para’, para-para’, and para-ortho’, adapted from202,212. 
The formation of compounds 1 and 4 result from lycorenine scaffold (also known as 
homolycorine scaffold when a lactone ring is present instead of a hemiacetal), with 
demethylation in position C-8 (for both compounds 1 and 4) resulting in a hydroxy group. 
Compound 1 arises due to oxidation of the hydroxyl group at C-6 resulting in a lactone ring, and 
demethylation of the N-CH3 resulting in a secondary nitrogen (NH). The formation of lycorenine 
scaffold results from norpluviine – a precursor of lycorine. Norpluviine is oxidised at the 
benzylic position to yield a cyclic hemi-aminal group. The rotation of C-10a–C-10b bond of the 
amino aldehyde intermediate, followed by hemiacetal formation and methylation202,213(see Fig. 
3.18). Compound 9 is classified as a crinine skeleton, which is formed through a para-para’ 
coupling of 4’-O-methylnorbelladine. Compound 9 differs from crinine at positions C-8 and C-9 
with the opening of the methylenedioxy ring and oxidation at position C-6 resulting in a hydroxy 
substituent202,212 (see Fig. 3.19). Haemanthamine is the enantiomeric skeleton of crinine. 
Haemanthamine is the precursor for tazettine, montanine and narciclasine skeletons. 
80 
 
 
Figure 3.18: Biosynthetic pathway from norpluviine to lycorenine scaffold for compounds 1 and 
4202. 
 
Figure 3.19: Biosynthetic pathway from norpluviine to crinine scaffold for compound 9202. 
All the above mentioned isolated compounds (1 – 15), along with galanthine, tazettine and 
haemanthamine (from the in-house compound library) were tested at 5 and 10 μg/mL for 48 
and 72 hours in the promoter-based assay (GFP/RFP). The GFP and RFP readout for each 
compound after 72 hours at 5 μg/mL are shown in Fig. 3.20.  
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(a) 
 
 
(b) 
 
 
Figure 3.20: (a) GFP and (b) RFP results for P. littorale compounds, along with galanthine, 
tazettine and haemanthamine at 5 μg/mL for 72 hours.  
In Fig. 3.21, the three most active and the four most toxic compounds with their structures are 
shown. The compounds in the graph display a significant decrease of GFP. Here the 
distinguishing factor is by how much RFP is decreased causing toxicity or activity. Compounds 
H18 (11), K4 (4) and K6 (9) after 72 hours show only a slight RFP reduction (approximately 0 to 
20%), while G2 (1), I10 (6), I14 (7) and haemanthamine all showed increased RFP reduction 
(between 30 to 40%). 
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(a) 
 
(b)  
K4 (4)  K6 (9)  H18 (11)  
G2 (1)  I10 (6)  I14 (7)  
haemanthamine (Hae)  
Figure 3.21: (a) GFP and RFP results for most active (4, 9, 11) and most toxic (1, 6, 7, Hae) 
compounds at 5 μg/mL for 72 hours. Cycloheximide (CHX) was used as a negative control and a 
lead compound for the positive control. (b) Structures of the compounds with their codes and 
peak numbers. 
Based on the GFP/RFP results, preliminary structure-activity estimations can be established 
from the observations of key structural features between the different scaffolds. In Fig. 3.22 to 
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Fig. 3.26, the compounds are classified based on their scaffolds and structural features are 
presented.  
(a) 
 
(b)  
M1 (3)  H18 (11)  I10 (6)  
I14 (7)  galanthine (Gal)  
Figure 3.22: (a) GFP and RFP results of compounds with lycorine skeleton, compounds 3, 6, 7, 
11 and galanthine at 5 μg/mL for 72 hours. (b) Structures of the compounds with their codes 
and peak numbers. 
In Fig. 3.22, GFP and RFP results of compounds with the lycorine skeleton, namely 3, 6, 7, 11, 
and galanthine (Gal) with their corresponding structures are shown. The methylenedioxy group 
at C-8 and C-9 on lycorine (7) and the presence of the hydroxy group on position 1 on ring C 
contribute to toxicity (in compounds 3, 6, and 7); while acetylation of the hydroxyl group on C-1 
resulted in a slight reduction of toxicity (11). Furthermore, the opening of the methylenedioxy 
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ring, resulting in two methoxy groups at C-8 and C-9 lead to a generally inactive compound (e.g. 
Gal) with a very minor decrease in GFP and RFP. 
GFP and RFP results of compounds with the narcissidine skeleton, namely 10, and 13 with their 
corresponding structures are shown in Fig. 3.23. These compounds possess a low activity 
(minor GFP reduction around 25%) which may be due to the opening of the methylenedioxy 
ring. Acetylation of the hydroxyl function at position C-3 in compound 13 displayed a slight 
increase of activity (approximately 25% GFP reduction) compared to compound 10 (with only 
20% GFP reduction). 
(a) 
 
(b)  
 K7 (10)  G17 (13)  
Figure 3.23: (a) GFP and RFP results of compounds with narcissidine skeleton, compounds 10 
and 13 at 5 μg/mL for 72 hours. (b) Structures of the compounds with their codes and peak 
numbers. 
In Fig. 3.24, GFP and RFP results of compounds with lycorenine skeleton, namely 1, 2, 4, and 12 
with their corresponding structures are illustrated. In the lycorenine skeleton, the presence of a 
secondary nitrogen (compound 1) showed increased toxicity. Reduction of the lactone ring 
(compound 2) to a hemiacetal predominantly increased activity (compound 4) and methylation 
of the hydroxy substituent of the hemiacetal group resulted in a decrease of activity 
(compound 12).  
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(a) 
 
(b)  
   K2 (2)  K4 (4)  
K9 (12)  G2 (1)  
Figure 3.24: (a) GFP and RFP results of compounds with lycorenine skeleton, compounds 1, 2, 4 
and 12 at 5 μg/mL for 72 hours. (b) Structures of the compounds with their codes and peak 
numbers. 
GFP and RFP results of compounds with crinine skeleton, namely 9, 14, 15, and haemanthamine 
(Hae) with their corresponding structures are shown in Fig. 3.25. In crinine skeleton, the 
presence of the hydroxy function at C-3 improved activity significantly (compound 9), while the 
presence of the methylenedioxy ring showed increased toxicity (Hae). 
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(a) 
 
(b)  
  K6 (9)  G16 (14)  
I19 (15)  haemanthamine (Hae)  
Figure 3.25: (a) GFP and RFP results of compounds with crinine skeleton, compounds 9, 14, 15 
and Hae at 5 μg/mL for 72 hours. (b) Structures of the compounds with their codes and peak 
numbers. 
The last skeleton of the isolated compounds is hostasine (compounds 5 and 8). GFP and RFP 
results of these compounds with their corresponding structures are shown in Fig. 3.26. The 
removal of the methoxy group at C-7 on compound 5 lead to increased toxicity (RFP reduction 
was 15% more than compound 8). 
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(a) 
 
(b)  
 
 H11 (5)  H15 (8)  
Figure 3.26: (a) GFP and RFP results of compounds with hostasine skeleton, compounds 5 and 8 
at 5 μg/mL for 72 hours. (b) Structures of the compounds with their codes and peak numbers.  
The next step is to confirm the activity seen in the GFP/RFP assay with western blotting, which 
quantifies the amount of coronin-1 protein present, when treated with the compounds. This 
allows us to see by how much the compounds are down-regulating coronin-1 on the protein 
level. The three most active compounds (4, 9, and 11), some of the toxic compounds (5, 6 and 
7), and the enriched alkaloid fraction were all examined in the western blot (see Fig. 3.27). 
These preliminary results revealed that the three most active compounds (4, 9, and 11) and 
toxic/alkaloid fraction were found to not interact with the down-regulation of coronin-1 on the 
protein level but rather by unexplained mechanisms might be directly interacting with GFP as 
quenching agents. The compounds seem to interfere directly with GFP fluorescence and thus 
mislead the results as coronin-1 inhibitors. Moreover, on an assay with western blotting, 
compound 4 no longer displayed its initial activity seen in the first round of 72 hour testing. 
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Figure 3.27: Western blot for coronin 1 (green) and actin (red) controls from the total lysate of 
GFP-RBL cells incubated with various compounds mentioned (K4/4, K6/9, H18/11, H11/5, I10/6 
and I14/7) as well as the alkaloid fraction (Alk Ext) in comparison with positive control 999. 
Actin serves as the loading control. Licor imaging system was used to develop the results and 
coronin1/actin ratio analysed using Image Studio Lite Software. 
The samples tested were also viewed by electron microscopy to visualise the state of the cells 
after incubation with test samples and GFP/RFP readout. As seen in Fig. 3.28, the cells seem to 
decrease in number and some are apoptotic. Therefore, the compounds might be cytostatic at 
the concentrations tested and cause cell proliferation to decrease. 
 
Figure 3.28: Cells viewed with electron microscope after addition of compounds mentioned 
(K4/4, K6/9, H18/11, H11/5, I10/6 and I14/7) and the alkaloid fraction (Alk Ext) in comparison 
with cycloheximide (CHX: toxic) and DMSO blank. 
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3.4 Discussion and conclusions 
Tuberculosis is a widespread infectious disease caused by MTB transmitted through droplets of 
air. Globally, in 2015, about 1.4 million people died from the disease115. Combating the 
pathogen is problematic since multidrug resistant strains have emerged. A coat protein known 
as coronin-1 was found to be essential for the survival of MTB within macrophages in the 
human body137,138. In this context, an assay based on coronin-1 downregulation in model cell 
lines was established and used to screen an in-house library of plant and fungal extracts. 
Among various extracts, the ethyl acetate extract of Dorstenia contrajerva L. (Moraceae) 
displayed a 40% decrease in GFP and no decrease in RFP at 20 μg/mL, after 72 hours. In 
addition, a methanol extract from the bulbs of Pancratium littorale Jacq., (Amaryllidaceae) 
significantly decreased GFP after 72 hours (≥ 80% inhibition at 20 μg/mL). Bioactivity tracking by 
HPLC-based activity profiling, a miniaturised approach which combines bioactivity data with 
structural information from online HPLC-UV and offline HPLC-MS, microprobe NMR analyses, 
led to the identification of active constituents: alkaloids from P. littorale and furanocoumarins 
from D. contrajerva.  
The furanocoumarin dorstenin was only active during the micro-fractionation due to its high 
amount in the extract, as quantified using UV and 1H-NMR. Thus, the overall activity of D. 
contrajerva extract could possibly come from a synergetic effect of all constituents present. 
After preparative isolation of P. littorale, 15 alkaloids including three new congeners were 
structurally characterised and tested in the GFP/RFP assay. Three compounds, 8-O-demethyl-
lycorenine (4), 3-O-demethyl-10-deoxy-6-hydroxy-hippeastidine (9), and 1-O-acetyl-
pseudolycorine (11) showed the most potent activity (decreases higher than 50% in GFP at 5 
μg/mL) as compared to the other isolated alkaloids. These activities were comparable with the 
positive control which exhibited 60.7% decrease in GFP. On the other hand, 9-demethoxy-
lycoranine F (1), 8-demethoxy-10-O-methylhostasine (5), carinatine (6), lycorine (7), 
pseudolycorine (3), and haemanthamine (hae) demonstrated toxicity. Based on these results, 
structure-activity relationship cannot be established; however it is possible to extrapolate some 
general rules. For example, the presence of a secondary nitrogen and methylenedioxy group 
consistently displayed increased toxicity, while a hemiacetal ring and acetylation of some 
hydroxy functions were more active. Besides these, further biochemical investigations showed 
that the three most active compounds mentioned above (4, 9, and 11) are not active in 
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downregulating coronin-1 at the protein level determined by western blotting. This exhibits 
that these compounds were not active in inhibiting coronin-1 expression. This may open a 
question through which mechanism they are able to induce GFP reduction, currently this is not 
fully understood but it might be through direct interaction with GFP via acting as quenching 
agents. Furthermore, this study examined coronin-1 inhibiting capabilities of some of the 
compounds which exhibited toxicity (in RFP) as well as the alkaloid fraction via western blot. 
These test results showed that even the toxic compounds were not active in inhibiting coronin-
1 expression. 
Compounds examined in this study may provide useful tools for chemical biology aspects as 
future chemical probes. However, considering the GFP assay and western blotting contradictory 
results, this study would like to remark the importance of re-evaluating the GFP assay usage for 
coronin-1 inhibition test. Accordingly, to better understand the interactions of compounds from 
natural origins with that of GFP, the compounds ability to interfere with GFP fluorescence and 
other GFP-expressing promoter constructs, more specific tests are ongoing. Besides these, to 
confirm coronin-1 expression on a genetic level when treated with the compounds, this study 
recommends the need of RT-PCR tests. 
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Chapter 4 
4. Results and Discussion: Lymphangiogenesis 
As highlighted in section 1.5, the Lymphatic project aims to assess the potential of plant 
secondary metabolites in promoting lymphatic vessel growth. In the following sections, extract 
library screening and hit prioritisation, prioritised extract (dichloromethane extract of Daphne 
giraldii) test results, projected analysis, and characterisations are presented. Lastly, summarised 
discussion on Lymphatic project and concluding remarks are given. 
4.1 Extract library screening and hit prioritisation 
To identify potential inducers of lymphatic vessel growth [i.e., which have the ability to induce 
sprouting of Lymphatic Endothelial Cells (LECs)], a phenotypic screening for 1952 plant and 
fungal extracts was carried out, via a 3D sprouting assay. The screening results shows that 
extracts that are prepared from root bark of Daphne giraldii via DCM, EtOAc, and MeOH as well 
as Patrinia scabiosifolia MeOH extract were more active (see Fig. 4.1). However, due to issues 
of reproducibility, Patrinia scabiosifolia extract was dropped from the prioritisation, and the 
study proceeded with Daphne giraldii extracts.  
 
Figure 4.1: Sprouting results (n = 2) of extract library screening showing seven active extracts 
from five plant species (at 10 μg/mL), with 0.1% DMSO as negative control and I. germanica 
MeOH extract as positive control. 
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4.2 Daphne giraldii (Thymelaeaceae) 
Among active extracts shown in Fig. 4.1, Daphne giraldii MeOH extract displayed the highest 
activity; accordingly it was further subjected to HPLC-based activity profiling (see Fig. 4.2). The 
profiling results exhibit varying degrees of an increase in sprouting on fractions 22 to 29 
corresponding to minutes 23.00 – 30.00. Since no compounds possessing UV absorbance were 
identified in fractions 22 to 29, based on the UV chromatogram, it becomes challenging to 
assign activity to compounds eluting in this region. The activity of Daphne giraldii MeOH extract 
on lipophilic region of the chromatogram lead to the reasoning that these lipophilic compounds 
might be present in dichloromethane extract (i.e., DCM extract) in higher quantities. Therefore, 
further investigations were undertaken on the DCM extract. 
(a) 
 
(b) 
 
Figure 4.2: (a) Number of sprouts per bead of each micro-fraction (n = 3) with a DMSO blank 
(CTRL) and I. germanica extract (IE: positive control, at 10 μg/mL). (b) HPLC-UV profile (at 254 
nm) for D. giraldii MeOH extract. This was performed using a C18 SunFire column (3.0 x 150 
mm; 3.5µm; Waters), with a 5 to 100% B gradient in 30 minutes, and 5 minute 100% B isocratic, 
using a flowrate of 0.4 mL/min. Solvent composition was (A): H2O + 0.1% formic acid and (B): 
MeCN + 0.1% formic acid. Collection was 1 minute fractions starting from 1.00 to 30.00 minutes 
(29 fractions). 
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Large scale extraction and fractionation of DCM extract was followed up. For dereplication, a 
macro-fractionation of the DCM extract was done with a combination of time- and peak-based 
collection, these fractions were tested, and their activity was found distributed throughout the 
fractions. At this point, identification of the compounds responsible for the activity was not 
possible. Thus starting with normal phase flash chromatography, a follow up separation scheme 
was employed. Using the separation scheme (which employed a normal phase silica gel 
cartridge) 8 fractions (Dgi-A to Dgi-H) were collected and tested in the sprouting assay. The 
results on Fig. 4.3 show that fractions E to H (Dgi-E, Dgi-F, Dgi-G, Dgi-H) were most active. 
 
Figure 4.3: Sprouting results (n = 3) of normal phase fractions A to H, and the DCM extract of D. 
giraldii (Dgi Ext), with positive and negative controls. 
To trace activity of each fraction and identify the types of compounds present, HPLC-based 
activity profiling was carried out (see Fig. 4.4 a – h). Also to dilute out the activity and further 
pinpoint the major active regions, two dilution factors were applied to the micro-fractions (1x 
and 10x dilutions). The trend observed on activity profiles of fractions E, F, G and H indicates 
that more major compounds with higher UV absorbance and generally more polar in nature did 
not show any significant stimulation of LECs. However, the more non-polar region with 
compounds possessing a weaker chromophore (low UV absorbance) and possibly much lower 
in quantity were higher inducers of sprouting in LECs. This in overall indicates that activity is 
generally observed in the region with minor, non-polar compounds.  
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Figure 4.4: HPLC-based activity profiles of normal phase fractions E, F, G, and H, with positive 
and negative controls. HPLC-UV trace at 254 nm in black and HPLC-ESIMS trace in positive 
mode shown in red. Dark blue activity bars represent sprouting activity for the 1 time dilution, 
while light blue activity bars represent sprouting activity for the 10 times dilution factor. (a) 
Fraction E (1x dilution), (b) Fraction F (1x dilution), (c) Fraction G (1x dilution), (d) Fraction H (1x 
dilution), (e) Fraction E (10x dilution), (f) Fraction F (10x dilution), (g) Fraction G (10x dilution), 
(h) Fraction H (10x dilution). 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
(g) 
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On the other hand, based on a previously reported study214 as well as our results shown in Fig. 
4.5,  a  daphnane  type  orthoester  diterpene  called  daphnetoxin,  which  was  isolated  from 
another Daphne  species  (D.  gnidium),  is  active  in  inducing  lymphatic  vessel  growth.  Thus  to 
compare the activity of the fractions (E, F, G, and H) this compound was used as a reference. 
The  retention  time  of  daphnetoxin  in  the  HPLC‐MS  chromatogram  is  tR  22.5 minutes;  this 
corresponds  to  the  activity  of micro‐fraction  22  in  samples  E  and  F, which  implies  that  the 
activity on micro‐fraction 22 (E and F) is due to the presence of daphnetoxin.  
(a) 
(b) 
Figure 4.5: Daphnetoxin activity on LEC sprouting in (a) µM range from 0.3 to 10, and (b) range 
of 0.1 to 100 nM. 
The profiling of DCM extract with  their elution  time on  the HPLC  separation as well as peak 
numbers  representing  isolated  compounds  on  the  HPLC‐UV‐MS‐ELSD  chromatograms  are 
shown  in  Fig.  4.6  (a).  Fig.  4.6  (b)  exhibits  the  structures  of  daphnetoxin  and  all  isolated 
compounds from the DCM extract.  
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(a) 
 
(b)  
1 2 3  
4 5  
Figure 4.6: (a) HPLC chromatograms (ESI+, ESI-, ELSD, and UV at 254 nm) of Daphne giraldii 
DCM extract with their elution time on the HPLC separation and peak numbers representing 
isolated compounds. (b) Structures of daphnetoxin and all isolated compounds from the DCM 
extract: (peak-1) daphnetin, (peak-2) daphnetin dimethyl ether, (peak-3) chrysoeriol, (peak-4) 
daphneolone, and (peak-5) daphnetoxin. 
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With the exception of daphnetoxin, compounds managed to be isolated in this study (from 
DCM extract) are not from the regions that exhibited activity on Fig. 4.4. Besides these, several 
literature reports exhibited that plants which belong to the family Thymelaeaceae are well-
known to contain numerous derivatives of phorbol esters (tigliane family of diterpenes). Thus 
correlating literature and our results which exhibited a-polar nature and lower UV absorbance 
properties – it was speculated that the main molecules giving rise to the observed activity were 
due to daphnetoxin-related compounds. 
Based on the results discussed so far, the region of interest becomes a-polar compounds. Thus 
to work on a-polar compounds and reduce the complexity of the fractions, the next step is to 
try to remove major interfering compounds (higher UV absorbing and more polar) from each of 
the main fractions Dgi-E, -F, -G, -H. Separation on RP-HPLC usually results in a large loss of 
sample and its optimisation is not always optimal to obtain pure compounds in a single run; 
thus, for enrichment of the a-polar compounds (which have low UV absorbing nature), 
Centrifugal Partition Chromatography (CPC) was used. CPC is a series of channels linked in 
cascade by ducts, and aligned in disks in a circle around a rotor. This setup is submitted to a 
constant centrifugal field by setting the rotor in motion215. The main advantage of this 
technique is the complete recovery of the injected sample since the phases are made up of 
immiscible liquids. Sample Dgi-E, -F, -G, and -H were separated on CPC. Subsequently, based on 
similarity analysis via HPLC-UV-MS, the resulting fractions were combined (Dgi-E-a to -i, Dgi-F-a 
to -i, Dgi-G-a to -j, and Dgi-H-a to -k) and tested for sprouting of LECs (see Fig. 4.7). The results 
on Fig. 4.7 show that – with the exception of E-a and E-b – all fractions significantly induced 
sprouting on LECs. This might be due to insufficient phase separation of the CPC run which 
allowed the distribution of trace amounts of potent compounds throughout all fractions. The 
most active CPC fractions were G-b, G-a, E-d, and H-j (with 2.9, 2.2, 2.1, and 2.0 sprouts/bead, 
respectively) as well as their weights were 3.8, 23.3, 45.9, and 21.4 mg, respectively.  
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(a) 
 
(b) 
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(c) 
 
(d) 
 
Figure 4.7: Sprouting results (10 μg/mL; n = 3) of CPC fractions from (a) E, (b) F, (c) G, and (d) H, 
with respective weights obtained and CPC profiles with estimation of fraction elution times. 
As aforementioned, even while employing CPC, trace amounts of potent compounds were 
distributed throughout all fractions; this created a challenge for the determination of 
similarities/differences among CPC fractions, via analysing HPLC-UV-MS-ELSD and 1H-NMR. Due 
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to these circumstances, the fraction analysis of this study focused on one CPC fraction that met 
the criteria of (a) enough yield, (b) less complex, and (c) higher activity. Fig. 4.8 exhibits an 
overlay of 1H-NMR spectra from the three most active CPC fractions (E-d, H-j, and G-b), as well 
as an overlay of HPLC-MS-ELSD-UV profiles of the four most active CPC fractions (E-d, H-j, G-b 
and G-a). From this figure, it can be seen that CPC fraction E-d is the least complex sample. 
Considering this and other criteria mentioned above, the chosen CPC fraction was E-d, which 
had 45.9 mg yield, sprouting of LECs ≥ 2, as well as one major compound (via HPLC-UV-MS-ELSD 
and 1H-NMR analysis). 
(a) 
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Figure 4.8: (a) Overlay of 1H-NMR spectra of E-d, H-j, and G-b, and (b) overlay of HPLC-MS-ELSD-
UV profiles of E-d, H-j, G-b and G-a. 
To narrow down the activity, E-d was fractionated by a combination of time- and peak-based 
HPLC-UV chromatography into a further 11 fractions (E-d-1 to E-d-11, see Fig. 4.9 a). These 
fractions were tested at three concentrations 10, 1.0, and 0.1 μg/mL (see Fig. 4.9 b, c, d). 
Activity was consistently located in the a-polar region of the separation. Fractions E-d-9, E-d-10, 
and E-d-11 were the most active at 10 μg/mL, while E-d-11 still showed potent activity at 1.0 
μg/mL. Moreover, each fraction from E-d (E-d-1 to -11) was analysed by HPLC-UV-ELSD-MS and 
1H-NMR. The 2D-NMR analysis showed that the main compound present in fraction E-d-5 
(which was marginally active, sprouting ≈ 2 at 10 μg/mL) is 7,8-dimethoxy-coumarin (or 
daphnetin dimethyl ether). On the other hand, the structural analysis illustrated that the major 
compound present in fraction E-d (especially in E-d-8) was daphneolone (an oxidised chalcone), 
which was not the active constituent (see Fig. 4.9 b, c, d). Due to the presence of more than 
two compounds, low signal-to-noise (S/N) ratio (≤ 100 S/N) from 1H-NMR, and low yield of 
fractions (≤ 1.0 mg), further structural elucidation from E-d fractions (E-d-9, -10, -11) was not 
possible. As shown in Fig. 4.6 (b), daphnetin and chrysoeriol were isolated from DCM extract. 
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These compounds are also found in CPC fraction E-a (which is inactive fraction) however they 
were not present in any of the E-d sub-fractions.  
(a) 
 
 
(b) 
 
(c) 
 
(d) 
 
  
Figure 4.9: (a) E-d semi-preparative HPLC-UV separation on a RP C18 column at 320 nm and 
sprouting results tested at (b) 10, (c) 1.0, and (d) 0.1 μg/mL with 0.1% DMSO as negative control 
and Iris extract (10 μg/mL) as positive control. 
In HPLC-MS, the main peaks observed in E-d-9 to E-d-11 had m/z ratios lower than that of 
tigliane diterpenes (m/z 365 [M+H]+), and daphnane diterpenes (m/z 315 [M+H]+) core 
structures; thus, these main compounds might not be diterpene derivatives, as well as at this 
point their activity cannot be defined. Therefore, to further fractionate active E-d fractions (E-d-
9, -10, -11), based on time- and peak-based separation (see Fig. 4.10 a, b, c), semi-preparative 
HPLC-UV methods were optimised. Particularly these fractions were tracked via their UV 
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signatures at different wavelengths: E-d-9 was tracked by 254, 205, and 280 nm; for E-d-10 270, 
205, and 320 nm were used and for E-d-11 254, 290, and 320 nm were used. All the sub-
fractions of E-d active fractions (i.e., E-d-9-1 to -10; E-d-10-1 to -6; E-d-11-1 to -9) were tested at 
10 and 1.0 μg/mL (Fig. 4.10 d, e). The most active sub-fractions were E-d-9-10, E-d-10-6, and E-
d-11-9 which were the 100% B region from each separation. Additional sub-fractions from E-d-
11 were also active namely -4, -5, -7, and -8 at 10 μg/mL as well as E-d-11-6, -7, -8, and -9 were 
still active at 1.0 μg/mL. Major activity was again consistently observed in the lipophilic region 
of the separation.  
(a) 
 
(b) 
 
(c) 
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(d) 
 
(e) 
 
Figure 4.10: Semi-preparative HPLC-UV sub-fractionation of (a) E-d-9, (b) E-d-10, and (c) E-d-11 
at 254 nm and sprouting results of each sub-fraction tested at (d) 10, and (e) 1.0 μg/mL with 
0.1% DMSO as negative control and Iris extract (10 μg/mL) as positive control. 
The sub-fraction E-d-10 contained three unresolved peaks each with a different λmax namely, at 
320 nm (1st peak, m/z 307 [M+H]+), 270 nm (2nd peak, m/z 311 [M+H]+), and 205 nm (3rd peak, 
m/z 313 [M+H]+). All sub-fractions were analysed using 1H-NMR, which showed that all sub-
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fractions from E-d-9 to E-d-11 were a mixture of compounds (i.e., no pure compounds were 
obtained). This was due to insufficient separation possibilities given the low amounts of each 
fraction and the close-elution of the compounds. Common pseudo-molecular masses found in 
these fractions were 307 [M+H]+, 311 [M+H]+, and 313 [M+H]+ and were speculated to be the 
active compounds. Nevertheless they were found to be inactive in sub-fractions E-d-9-7 and E-
d-10-4 which contained these masses at the same retention times in a higher quantity (see Fig. 
4.11). This implies that on sub-fractions E-d-10-4, E-d-11-3, and E-d-9-7 these masses are also 
not active. This means that these common peaks could be excluded from the activity found in 
10-6, 11-4, and 11-5.  
 
Figure 4.11: HPLC-UV-ELSD-MS chromatograms of sub-fractions E-d -10-4, -10-6, -9-7, and -9-
10.  
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4.2.1 Projected analysis on composition of Daphne giraldii active micro-fractions 
Based on the discussion given so far, identifying pure active compounds was challenging, mainly 
due to low amounts of active fractions and quite close-elution of the compounds. Therefore in 
this section the study presents different projected analysis on the composition of D. giraldii 
active micro-fractions. APCI-MS analysis did not provide further insight, thus as an alternative 
technique for detection of the active and inactive common metabolites present on D. giraldii 
micro-fractions, GC-MS analysis was used. GC-MS analysis indicates that benezenepropanol was 
present in both active and inactive micro-fractions, thus this common metabolite could not be 
responsible for activity.  
Analysis using in-house developed clustering scripts216 showed the presence of daphnetoxin in 
all of the active micro-fractions (E-d-9-10, 10-6, 11-6, 11-7, 11-8, 11-9) as well as in two inactive 
micro-fractions (E-d-9-1, -9-3) (Fig. 4.12 b). Micro-fraction E-d-11-6 contains a higher intensity 
of daphnetoxin shown in the Bayesian plot which can be corroborated by MS data (extracted 
m/z 483 [M+H]+ of daphnetoxin in 11-6). The presence of daphnetoxin in inactive -9-1 and -9-3 
samples is rather low and cannot be seen by visual inspection of MS data. It should be taken 
into consideration that this clustering method of data representation has only recently been 
developed and there are still certain aspects that need optimisation, e.g. the normalisation of 
data with reference to an internal standard. In this context, the presence of daphnetoxin in 
these inactive micro-fractions might be due to the lack of optimisation in the clustering scripts, 
in any case this needs further insight. Utilising clustering scripts, some commonalities among 
active micro-fractions and inactive micro-fractions were made (see Fig. 4.12 a and b). Basically, 
active micro-fractions showed commonality due to the presence of the polymer PEG classified 
by characteristic ‘mountain’ pattern with m/z signals in increments of 44 (as seen in Fig. 4.11). 
However, inactive micro-fractions showed commonality by the presence of the main UV 
absorbing and MS ionising compounds (m/z 307, 311, 313 [M+H]+). 
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(a) 
 
(b) 
 
Figure 4.12: (a) Bayesian clustering zoomed in to 1 x 107 of all micro-fractions; (b) Bayesian 
clustering plot with grouped micro-fractions. 
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Utilising NMR instruments with strong magnets (such as with 800 MHz), full structure 
elucidation can be achieved for samples which have approximately 1-2 μg amounts. However 
this study uses 500 MHz NMR instrument, thus below 100 μg is too low for full structure 
elucidation. For instance, to assess the detection capabilities of the NMR used in this study, 1.0 
μg and 1.0 mg of pure daphnetoxin were prepared and run in 1-mm NMR tube, then using 
standard measuring times (128 scans) 1H-NMR were acquired. The 1H-NMR spectra for 1.0 μg 
and 1.0 mg experiments were shown in Fig. 4.13. As shown in Fig. 4.13 the signals for 1.0 mg-
1H-spectrum were clear, however for 1.0 μg experiments the instrument can barely detect 
daphnetoxin signals. Though the active micro-fractions found in this study contain trace 
amounts of daphnane derivatives, these NMR experimental results illustrated that structure 
elucidation and quantifying trace amounts of daphnetoxin (and its derivatives) via 500 MHz 
NMR from the active micro-fractions is challenging; nonetheless to a certain degree their 
presence can be traced. For example, Fig. 4.14 exhibits the overlay of 1H-NMR spectra of 
daphnetoxin, E-d-11-6, and E-d-11-7. In line with the outcome of clustering analysis, the results 
in Fig. 4.14 illustrated that even with the low S/N ratio of the spectra; some signals of 
daphnetoxin can be identified in 11-6 and 11-7.  
 
Figure 4.13: Overlay of 1H-NMR spectra of 1 μg (grey) versus 1 mg (red) of daphnetoxin in a 1-
mm NMR tube measured in DMSO-d6.  
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Figure 4.14: Overlay of 1H-NMR spectra for daphnetoxin (black), E-d-11-6 (red), and E-d-11-7 
(green) in DMSO-d6. 
As mentioned previously daphnetoxin is active in inducing lymphatic vessel growth and it was 
used as a reference for comparing with the activities of D. giraldii fractions. Added to this, the 
clustering analysis (given above) exhibited the presence of daphnetoxin in all D. giraldii active 
micro-fractions (E-d-9-10, -10-6, -11-6, -11-7, -11-8, -11-9). However the concentration of 
daphnetoxin in these active micro-fractions was small. These circumstances raise a question 
that are these micro-fractions active because they contain trace amounts of daphnetoxin? In 
order to answer this, it is important to determine a minimum effective concentration (min EC) 
of daphnetoxin. This is also crucial to make an evidence-based speculation on which type of 
compound(s) were responsible for activities seen in micro-fractions E-d-9-10, E-d-10-6, E-d-11-
6, E-d-11-7, E-d-11-8 and E-d-11-9. To determine min EC of daphnetoxin, LECs sprouting was 
conducted with varying concentrations of daphnetoxin (see Fig. 4.15). The results in Fig. 4.15 
illustrated that the min EC for daphnetoxin was 10 nM, which is 4.82 ng/mL. Also, the EC50 
values for daphnetoxin as well as for more active micro-fractions (i.e., E-d-11-7, and E-d-11-9: 
see Fig. 4.10 d, e) were calculated. As shown in Fig. 4.15 (a–e), the EC50 values for daphnetoxin, 
E-d-11-7, and E-d-11-9 were found to be 11.67 nM (5.77 ng/mL), 0.6092 μg/mL (609.2 ng/mL), 
and 1.345 μg/mL (1345.0 ng/mL), respectively. The EC50 values for daphnetoxin implies that, in 
terms of daphnetoxin, an EC50 of 0.6092 μg/mL is equivalent to 1.4 μg in 152.0 μg of the 
sample. Based on these min EC and EC50 results and analyses, this study speculated that trace 
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amounts of daphnetoxin present on Daphne giraldii active micro-fractions could be (or at least 
one of) the main contributing factors for activities seen on Fig. 4.10 d, e. 
(a) 
 
(b) 
 
(c) 
 
  
(d) 
 
(e) 
 
Figure 4.15: Calculated EC50 values for (a) daphnetoxin, and micro-fractions (b) E-d-11-7 and (c) 
E-d-11-9. (d) Actual values of sprouting used in the calculation of EC50 for daphnetoxin (positive 
control at 10 μg/mL), and (e) for micro-fractions E-d-11-7 and E-d-11-9 (positive control and D. 
giraldii extract at 1.0 μg/mL). 
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Besides daphnetoxin (and its derivatives), relating the results of this study with that of 
literature and other databases, it is also possible to make inclusion/exclusion projections on the 
composition of D. giraldii active micro-fraction components. Based on the results found so far 
and literature reviews, it is rational to exclude compounds of high UV absorbing, polar in 
nature, coumarins, and chalcones as contributors for the observed activities; but it is not 
possible to exclude diterpene derivatives or fatty acids. For instance, Fig. 4.16 shows an overlay 
of 1H-NMR spectra for a fatty acid, daphnetoxin, and active micro-fraction E-d-10-6. The figure 
exhibits the presence of fatty acid signals in E-d-10-6 which has high sprouting activity. 
Considering the fact that common fatty acids are present in many a-polar extracts of plants, if 
the activity on Fig. 4.10 comes from fatty acid, it would have to be a less common fatty acid 
and/or unique to D. giraldii. 
 
Figure 4.16: Overlay of 1H-NMR spectra for a fatty acid mixture, E-d-10-6, daphnetoxin, and a 
pure fatty acid (palmitic acid). 
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4.3 Discussion and conclusions 
To identify natural molecules that have a potential to induce lymphatic vessel growth, a 
phenotypic screening (3D sprouting assay) was conducted on an extract library which 
comprised 1952 plant and fungal extracts. Of all the extracts that were tested, the DCM, EtOAc, 
and MeOH extracts from Daphne giraldii were identified as potent inducers of LEC sprouting. 
Among these three, more activity was noted on MeOH extract; accordingly further HPLC-based 
activity profiling was carried out on this extract. During the micro-fractionation of the MeOH 
extract, activity was localised in the lipophilic region of the HPLC separation. This lead to the 
reasoning that these lipophilic compounds might be present in DCM extract at higher 
quantities, thus the study was carried out based on DCM. With the DCM extract, separation on 
normal phase silica gel was used to obtain eight fractions, of which, four were active (namely 
fractions: E, F, G, H). To refine the regions of activity on these fractions, further HPLC-based 
activity profiling and tests on the 3D sprouting assay were carried out. This profiling 
consistently exhibited that prominent sprouting of LECs are located in the a-polar regions of the 
micro-fractions. Accordingly to enrich the a-polar and low UV absorbing compounds from the 
silica gel-fractions (i.e., E, F, G, H), CPC was used and the resulting CPC sub-fractions were 
tested. The test results show sprouting activities were spread throughout all CPC sub-fractions. 
This might be due to insufficient phase separation in the CPC chambers which lead to leaking of 
minute amounts of potent, a-polar compounds in each of the CPC sub-fractions. Unlocalised 
activities found on CPC sub-fractions became a challenge for selecting any of the CPC sub-
fractions for isolation of the active compounds. As a result various other factors had to be 
employed for selection, such as higher yield, less complex, and higher activity. The CPC sub-
fraction which is named as E-d, met the above selection criteria and step-by-step this sub-
fraction underwent a series of assaying and time-peak-based HPLC-UV semi-preparative-
fractionations, until the micro-fractions weighed ≤ 100 μg. Since activities were localised in a-
polar and low UV absorbing regions, following the test results in each round of HPLC-
fractionations, the E-d micro-fractions which possessed compounds with UV absorbing 
properties and MS ionisation were excluded from the list of targeted micro-fractions. Similar to 
the sub-fractions, activity was consistently found in the late eluting micro-fractions (lipophilic 
regions). Thus polar compounds can be excluded as the constituents responsible for activity. 
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Compounds such as daphnetin dimethyl ether and daphneolone were isolated from E-d micro-
fractions, however these compounds eluted outside the lipophilic regions, thus they were 
found to be constituents not responsible for activity. Overall, after all HPLC-UV-fractionation 
steps that E-d micro-fractions went through, it remained challenging to identify pure a-polar 
compounds that are responsible for observed activities. This is mainly due to two reasons, (a) 
minor concentrations of complex micro-fractions that results setbacks on their detectable 
signatures such as via NMR, and (b) presence of a wide array of minor metabolites structurally 
related to each other, thereby it becomes difficult to separate the NMR signature of individual 
constituents without interference; as well as to isolate them on semi-preparative RP-HPLC. 
Generally, if a fraction is ≤ 2.0 mg then separation of the compounds should be done on 
analytical scale and not semi-preparative. This has its drawbacks since many injections have to 
be done so as to not overload the column and loss of sample has to be taken into 
consideration. However, when the compounds are closely related, the separation would be 
better on an analytical HPLC column. Additionally, microprobe NMR analysis has a significant 
advantage for detecting small amounts of compounds, however is has instrument dependent 
minimum limitations. Considering the sensitivity of the NMR instrument used in this study (500 
MHz) and minor sample amounts it became difficult to analyse compounds responsible for 
activity. In order to identify trace amounts of constituents via improving S/N ratios in NMR, 
more sensitive instruments should be employed; for example NMR which have increased 
magnetic field strength (such as 800 MHz instead of 500 MHz), enhanced coil quality and that 
can operate at lower temperatures (such as 0.3-mm microprobe or 1.7-mm cryoprobe)217.  
Though, for aforementioned reasons, the study could not certainly identify and provide the 
structure of active constituent(s) which are responsible for observed activity; it provides a 
projected analysis on composition of D. giraldii active micro-fractions. Generally, D. giraldii 
belongs to the family Thymelaeaceae, which is well known to contain daphnetoxin and other 
daphnane type orthoester diterpenes. Particularly, various activities of daphnetoxin are well 
documented214 thereby activities observed in this study could possibly be related to the 
presence of these compounds. Daphnetoxin which was previously isolated in another study was 
used as a reference compound in this study. It displayed potent sprouting activity. Although 
daphnetoxin concentration in active micro-fractions was small, it might at least be one of the 
compounds responsible for observed activity. In order to support this, the minimum effective 
concentration (min EC) and EC50 of daphnetoxin was determined. Additionally, to correlate the 
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EC50 of daphnetoxin with that of daphnetoxin presence in the micro-fractions, EC50 for micro-
fractions E-d-11-7 and -11-9 were determined. The results of these experiments support a 
projection that trace amounts of daphnetoxin present in D. giraldii active micro-fractions could 
be (at least one of) the main contributing factors for observed activities. Furthermore, analysis 
of 1H-NMR spectra for a fatty acid, daphnetoxin, and active micro-fraction showed the presence 
of fatty acid signals in active micro-fractions. Studies such as, Wong et al., (2016) have 
described the essential role of fatty acid β-oxidation (FAO) in endothelial cells to generate 
acetyl-CoA for histone acetylation that is required for lymphangiogenesis162. LECs use FAO to 
proliferate and for regulation of lymphatic marker expression during differentiation. Dietary 
modulation of fatty acids or supplementation with metabolites could be used to promote 
lymphangiogenesis in pathological conditions such as lymphedema162. Typical fatty acid signals 
could be seen in some active micro-fractions. However, if ubiquitous fatty acids were 
contributors to the observed activity, then more lipophilic extracts would have been active 
during the extract library screening. Based on this hypothesis, ubiquitous fatty acids would 
probably not be the main contributors of activity. However, unique fatty acids present in D. 
giraldii which have not yet been identified may play a role in the overall observed activity of the 
fractions and extract.  
An extract may show an activity which might be due to: (1) one active metabolite present with 
large quantities; or (2) a number of moderately active constituents at reasonable 
concentrations which act together; or (3) a number of constituents present in minor 
concentrations but are potent in inducing active responses70. The study on D. giraldii for 
inducers of LEC sprouting can be classified into the third case, where minor compounds with 
potent activity are present. In such cases, to identify compounds that are responsible for 
activity, large amounts of optimally prepared extracts are needed. This will allow bioassay-
guided refined separations to end up with suitable amounts of pure compounds for 
identification. While using large amounts of extracts, this study recommends the use of 
partition chromatography (such as CCC and CPC) for making the initial fractionations. These 
chromatographic techniques can reduce time needed for isolation of active metabolites and 
provide different advantages such as lack of irreversible adsorption to a stationary phase and 
loss-free fractionations70,88.  
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Chapter 5 
5. Results and Discussion: Chronic Heart Failure 
As stated in section 1.5, the CHF project focuses on characterising secondary metabolites 
present in active sub-fractions of Crataegus species, which contribute to the further use of 
Crataegus in the treatment of mild forms of CHF. In the following sections, Crataegus fraction 
test results in a Fura-2 calcium imaging cell assay are presented. Lastly, a brief discussion and 
concluding remarks are given. 
5.1 Crataegus extract WS 1442 
Crataegus (hawthorn) extract (Dr. Willmar Schwabe's Hawthorn Extract WS® 1442) is widely 
used as an adjuvant treatment for mild forms of CHF according to the New York Heart 
Association functional class II191. Its mechanism of action was recently investigated and 
Crataegus was shown to reduce endothelial hyperpermeability via two pathways, (1) inhibition 
of thrombin-induced [Ca2+] influx, and (2) cortactin activation. It was also previously shown that 
the Crataegus special WS 1442 extract significantly reduced thrombin-evoked macromolecular 
permeability196. This study aims to characterise Crataegus extract WS 1442 active constituents 
that interact with the underlying molecular mode of action. The study was conducted in 
collaboration with the Goethe University, Frankfurt, Germany. The Crataegus special extract 
WS 1442 was provided by Dr. Willmar Schwabe Gmbh & Co. KG (Karlsruhe, Germany). It is a dry 
extract from hawthorn leaves with flowers using ethanol as the extraction solvent197.  
In a previously reported study218, to determine the exact constituents that gave rise to this 
observed effect, the WS 1442 extract was separated into four fractions using Sephadex (LH-20), 
namely: [1] water (fraction A), [2] ethanol (fraction B), [3] methanol (fraction C) and [4] acetone 
(fraction D). Bauhart (2013)218 subsequently tested these fractions for their ability to prevent 
vascular leakage and edema formation197. On test results of Bauhart (2013) fraction B was 
shown to block the thrombin-induced [Ca2+] influx pathway, while fraction C was shown to 
protect against endothelial barrier dysfunction via cortactin activation218. Moreover, Bauhart 
(2013) partitioned the Crataegus ethanolic extract in H2O and EtOAc in a separating funnel. 
Then after, the EtOAc portion was evaporated and nine fractions from a silica gel open column 
were obtained and tested (Fractions E-1 to E-9)218. In addition, Bauhart (2013) isolated 4 
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triterpenes from E-3 fraction (namely: corosolic acid, pomolic acid, oleanolic acid, and ursolic 
acid). These isolated compounds were tested and found to be inactive218.  
 
Figure 5.1: Changes in [Ca2+]i detected by fluorescence microscopy using Fura-2-AM (2 μM) in a 
static tempered system, with thrombin addition (1 U/mL) at time point 1.0 min after 
experiment initiation and treatment with fractions E-7 and E-8 (10 μg/mL) for 30.0 min. One 
representative experiment out of 3 independently performed experiments (n = 3) is 
depicted197. 
The current study is basically a follow up of Bauhart (2013)218. Thus, this study tested the 
activity of these fractions from the silica gel open column (E-1 to E-9) and only two fractions (E-
7 and E-8) were found to be active (sees Fig. 5.1). Thereby these fractions were further 
separated by semi-preparative HPLC-UV, with a combination of peak- and time-based 
fractionation. Peak- and time-based fractionation of these two fractions (i.e., resulting sub-
fractions from E-7 and E-8) is shown in Fig. 5.2. The sub-fractions were tested and it was found 
that only E-8-4, E-8-5 and E-8-6 were active (see Fig. 5.3), whereas sub-fractions from E-7 did 
not possess any activity.  
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Figure 5.2: HPLC-UV chromatograms for active fractions E-8 (at 288 nm) and E-7 (at 247 nm) 
and resulting fractions based on peak- and time-based fractionation. 
 
Figure 5.3: Changes in [Ca2+]i detected by fluorescence microscopy using Fura-2-AM (2 μM) in a 
static tempered system, with thrombin addition (1 U/mL) at time point 1.0 min after 
experiment initiation and treatment with fractions E-8-4, E-8-5 and E-8-6 (10 μg/mL) for 30.0 
min. One representative experiment out of 3 independently performed experiments (n = 3) is 
depicted197. Only active sub-fractions are shown. 
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5.2 Discussion and conclusions 
In most literature, hawthorn (Crataegus) extract is recommended as an oral treatment option 
for chronic heart failure219. Extracts of different Crataegus species are used as an adjuvant 
therapy for patients with CHF. The Crataegus WS 1442 extract is approved for treatment in 
patients with NYHA class II symptoms191. Based on positive inotropic, antiarrhythmic, 
vasodilating, and cardioprotective properties193,219,220, the efficacy of the extract WS 1442 has 
been shown in various clinical trials192,221. In a previously reported study (Bauhart, 2013)218, 
Crataegus ethanolic extract was partitioned in H2O and EtOAc, subsequently, the EtOAc portion 
was evaporated and nine fractions from a silica gel open column were obtained (Fractions E-1 
to E-9). Following Bauhart (2013), this study tested the activity of these fractions and the results 
exhibited that only E-7 and E-8 were active. Due to the limited amount of these active fractions 
(E-7 and E-8), only semi-preparative separations were done. Fraction E-7 was separated into 8 
sub-fractions, while E-8 was separated into 9 sub-fractions which were all submitted for testing. 
Sub-fractions from E-7 did not show any activity, while sub-fractions E-8-4, E-8-5 and E-8-6 were 
active (see Fig. 5.3). Further purification of constituents could not be achieved due to the small 
amounts of sub-fractions obtained. Thus, to characterise the compounds present in these 3 
active sub-fractions, HPLC-MS, GC-MS and NMR (1H and 2D) analyses were carried out. These 
integrated analyses indicated that E-8-4, -5, and -6 main constituents were fatty acids and 
triterpenes. Particularly, in all active sub-fractions, fatty acids (stearic acid and palmitic acid) 
were detected; while triterpene (hyptatic acid A) was detected in E-8-5. This discussion would 
like to remark that on Bauhart (2013) 4 triterpenes were isolated from fraction E-3 (namely: 
corosolic acid, pomolic acid, oleanolic acid, and ursolic acid); however the test results on these 
pure compounds exhibited that they are inactive. Furthermore, based on NMR and GC-MS 
analysis, this study finds that active sub-fraction E-8-5 is composed of 50% hyptatic acid A and 
40% fatty acids (stearic acid and palmitic acid)197. This study obtained stearic acid and palmitic 
acid as references, as well as through collaboration with a Chinese colleague a pure form of 
hyptatic acid A was acquired. All these pure compounds were tested and found to be inactive. 
Considering the fact that constituents which comprise almost 90% of active sub-fraction E-8-5 
were not active in their pure form, the observed activity strongly relies on the 10% E-8-5 
constituents. Although the main active constituents remain to be identified, the findings of this 
study evidently exhibits that unidentified minor constituent with potent activity or minor 
constituents with moderate activity which act synergistically, were the main reasons for 
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observed activity. To certainly identify the molecule(s) responsible for observed activity and to 
assess their biological interactions, this study recommends the need of further studies on large 
amounts of optimally prepared Crataegus extracts which allows the researcher to end up with 
suitable amounts of fractions after refined separations. This work has been published in Journal 
of Planta Medica (Fuchs, et al., 2017)197.  
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Chapter 6 
6. Materials & Methods 
6.1 General approach 
Accelerated Solvent Extraction (ASE): Extracts for library screening and HPLC-based activity 
profiling were prepared with an ASE 200 extraction system with solvent module (Dionex) by 
extraction with ethyl acetate and methanol, sequentially or petroleum ether, dichloromethane 
and methanol sequentially. Extraction was performed following a validated method222. 
Approximately 3.00 g of ground plant material was weighed out and mixed with approx. 2.00 g 
silaceous earth (depending on the plant material size and stickiness). This was packed into an 
ASE cell with filter at the bottom of the cell. The solvent extraction method was setup according 
to which sequential extraction was needed. Parameters used were preheat for 1.00 min, heat 
for 5.00 min, static for 5.00 min, flush with 100% solvent, and purge for 120 sec. The pressure 
was set at 120 bar, temperature was 70 °C, and three cycles of extraction was done with each 
solvent. Solvents that were used include petroleum ether, ethyl acetate (EtOAc), methanol 
(MeOH), and dichloromethane (DCM). Sequential extractions were setup with solvents of 
increasing polarity. 
High Performance Liquid Chromatography (HPLC)-based activity profiling: The in-house 
extract library samples were submitted to HPLC-based activity profiling for further 
characterisation of the active compounds. HPLC-based activity profiling was performed on a 
Waters 2695 Alliance Separation Module equipped with a Waters 996 Photodiode Array 
Detector and a C18 SunFire column (3.0 x 150 mm; 3.5 μm; Waters). The mobile phase 
consisted of H2O (A) and MeCN (B), both with the addition of 0.1% formic acid. A gradient of 5-
100% B in 30 min, with 5 min 100% B was applied. The flowrate was 0.4 mL/min. 900 μg of 
extract were injected in three portions (10 mg/mL, 3 x 30 μL injections) and time-based micro-
fractions were collected into a deep well 96-well microtiter plate with a fraction collector Gilson 
FC204. The microtiter plate was dried in a Genevac EZ-2 evaporating system at 35 °C overnight.  
Scale-up for Isolation: Percolation of between 200-300 g of ground plant material was packed 
into a glass column and saturated with the first solvent of extraction (usually EtOAc), this was 
left for 1 hour to extract and then the column was eluted for about 3 hours and thereafter left 
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overnight to extract. Extraction with the first solvent was done for about 24 hours, then the 
column was left to dry until the next solvent (usually MeOH) was poured into the column for 
extraction and left for 1 hour before eluting the solvent through. The second round of 
extraction was usually done for 48 hours. Each extract was evaporated to dryness on the 
rotatory evaporator (Büchi). Each extract that was active (100 mg/mL; 10 mg/inj x 5) was then 
separated by HPLC-UV on a semi-preparative scale using an Agilent 1100 Series HPLC system 
equipped with Diode Array Detector (DAD) and SunFire prep C18 column (10 x 150 mm; 5 μm; 
Waters). Other columns used were an Atlantis dC18 (10 x 150 mm; 5 μm; Waters), and an Aqua 
C18 (10 x 250 mm; 5 μm; 125A; Phenomenex). Peak-based fractionation using an optimised 
method for each extract was done and resulting fractions were evaporated. TLC, HPLC-UV-MS, 
and microprobe NMR data was collected on the resulting fractions to determine the class of 
compounds that are responsible for the activity. Using database searches (such as the 
Dictionary of Natural Products, DNP) and the data collected from various analyses, the class of 
compounds and sometimes the active compounds could already be identified. 
Nuclear Magnetic Resonance (NMR): 1H-NMR and 2D (HSQC, HMBC, COSY and NOESY) spectra 
of compounds were recorded on a 500 MHz Avance III spectrometer (Bruker BioSpin) equipped 
with a 1-mm TXI microprobe at 18 °C. Around 0.5 to 1.0 mg of sample is dissolved in 5 to 10 μL 
of deuterated solvent and centrifuged into a 1.0 mm NMR tube (1.0 x 103.5 mm SampleJet 
tube, Bruker), which is then capped and labelled. Deuterated solvents are from Armar 
chemicals. 1H-NMR standard measuring time is 128 scans (± 10.00 min) and depending on S/N 
ratio, 2D measurements are setup with appropriate number of scans. Standard pulse sequences 
of the software package Topspin 3.0 were used. For measurements of 13C-NMR spectra, a 5-mm 
BBO probe is used at 23 °C, with 5.0 or 3.0 mm NMR tubes (depending on sample amount; e.g. 
for 5mm tubes: ≥ 10 mg in ca. 500 μL solvent, and 3 mm tubes: ≤ 10 mg in 100 μL solvent).  
HPLC – Ultraviolet (UV) – Mass Spectrometry (MS) – Evaporative Light Scattering Detector 
(ELSD): A Shimadzu HPLC system (LC-20 AD) equipped with DAD (SDP-M20A module), triple 
quadrupole mass spectrometer (LCMS-8030) and ELSD (Alltech 3300) detectors was used for 
recording the UV, ESIMS and ELSD traces of each sample. Generally, extracts at 10 mg/mL (5-10 
μL/injection), fractions at 5 mg/mL (5 μL/injection) and compounds at 1 mg/mL (3-5 
μL/injection) are prepared. Spectra are recorded with UV scanning from 190 – 400 nm, MS +/- 
switching scanning from 160 – 1500 m/z, capillary voltage: 4.0 V (3.0 V in negative mode), scan 
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speed: 6000 u/sec, event time: 0.150 seconds, nebulising gas flow 3 L/min, DL temperature 350 
°C, heat block temperature 400 °C, and drying gas flow 15 L/min. ELSD was operated at 2.5 
L/min nitrogen flow, 55 °C temperature, and 8 detector gain. 
High resolution mass spectra were recorded on a Bruker micrOTOF time-of-flight mass 
spectrometer with ESI interface (Bruker Daltonics) connected to an 1100 series HPLC Agilent 
system (HPLC-TOF-ESIMS). A reference solution consisting of sodium formate 0.1% (m/v) in 
isopropanol:H2O (1:1) containing 5 mM NaOH was used for calibration. Data acquisition and 
processing was performed using HyStar 3.0. 
Electronic Circular Dichroism (ECD) + optical rotation (αD): For ECD, an Applied Photophysics 
Chirascan CD spectrometer with Pro-Data V2.4 software at the Biophysics facility (Biozentrum, 
University of Basel) was used for measurements. HPLC grade solvents (Scharlau) such as MeOH, 
or MeCN (cut-off wavelength ≤ 205 nm) were used for dissolving compounds. Blank 
measurement for background with solvent was done before and auto-subtracted from 
measurements with compounds. Concentration used is specific to the compound and depends 
on the UV absorbance. Wavelength range can be setup according to each compound (generally, 
205 – 400 nm), with 1 nm bandwidth. For optical rotation measurements, a Jasco P-2000 
polarimeter (BrechBühler) with Spectra Manager software and temperature control 
(BrechBühler) was used with HPLC grade solvents (MeOH or CHCl3, Scharlau). Blank 
measurements for background with solvent was done before and automatically subtracted 
from the measurements with compounds. Generally, 1.2 mg of compound is dissolved in 1.2 mL 
of solvent and carefully added to the cell without the addition of bubbles. Measurements were 
performed at room temperature (24 to 25.5°C). 
6.2 DM1 project 
Plant material: 10 plant extracts were prioritised and analysed for their activity in the DM1 
project, namely MeOH extract of roots from Peganum harmala (Zygophyllaceae), EtOAc extract 
of roots from Salvia miltiorrhiza (Lamiaceae), MeOH extract of leaves from Bathysa veraguensis 
(Rubiaceae), EtOAc extract of leaves from Lamium album (Lamiaceae), MeOH extract of the 
herb from Pistacia lentiscus (Anacardiaceae), MeOH extract of stems from Henriettella 
tuberculosa (Melastomataceae), MeOH extract of the leaves from Henriettella tuberculosa 
(Melastomataceae), MeOH extract of leaves from Casearia arborea (Flacourtiaceae), MeOH 
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extract of leaves from Coccoloba spp. (Polygonaceae), and MeOH extract of aerial parts from 
Struthanthus orbicularis (Loranthaceae). 
Micro-fractionation for activity profiling: For all 10 prioritised extracts a first round of micro-
fractionation was performed as described above using the extract library sample. Fractions (60 
s each) were collected from 1.00 to 30.00 min with a Gilson FC204. A second round of micro-
fractionation for P. lentiscus, H. tuberculosa (leaves and stems), Coccoloba spp., and S. 
orbiculariswas performed using an Atlantis dC18 column (5 μm; 4.6 x 150 mm; Waters). The 
mobile phase consisted of H2O (A) and MeCN (B), both with the addition of 0.1% formic acid. A 
gradient of 0-40% B in 30 minutes with a flowrate of 0.5 mL/min was applied. Fractions (60 s 
each) were collected from 0.00 to 30.00 min and dried on the Genevac overnight. The dried 
fractions were taken up in 16 μL of DMSO and 2 μL of this was used in the CUG78-MBNL1 
inhibition assay. 
Polyamide filtration: For filtration over polyamide, ASE extracts of P. lentiscus, C. arborea, B. 
veraguensis, H. tuberculosa (leaves and stems), Coccoloba spp., and S. orbicularis (approx. 25-
50 mg each) were suspended in 2.00 mL 1:1 H2O:MeOH and eluted through an activated 
polyamide cartridge (Chromabond, 6 mL / 1000 mg) using a vacuum chamber. Samples were 
eluted with 20 mL 1:1 H2O:MeOH and again with 20 mL MeOH through the cartridge, combined 
and evaporated to dryness.  
Lamium album semi-preparative isolation: Methanol ASE extract of L. album (Lamiaceae) 
leaves was dissolved in DMSO (50 mg in 500 μL, 6 mg/inj). Semi-preparative purification of the 
main UV active peak was collected using an Agilent 1100 Series HPLC system equipped with 
Diode Array Detector (DAD) and SunFire prep C18 column (10 x 150 mm; 5 μm; Waters). The 
mobile phases were H2O (A) and MeCN (B). An isocratic method at 10% B in 20 min was used 
with UV detection at 233 nm. The fraction was dried under vacuum using a rotavap (Büchi), and 
freeze dried after organic solvent was removed. The compound in the fraction was identified as 
aureoside (3.74 mg).  
Salvia miltiorrhiza extraction: S. miltiorrhiza radix (Lamiaceae) was obtained from China 
(voucher specimen number: 289). A percolation of EtOAc on ground plant material (406.26 g) 
was done for 48 hours and resulting extract (4.61 g) was dried under reduced pressure on the 
rotatory evaporator (see Fig. 6.1).  
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S. miltiorrhiza normal phase open column: 4.30 g of the EtOAc extract was loaded onto an 
open silica gel column (6.5 x 60 cm) with starting conditions 95:5 hexane:EtOAc. The column 
was run isocratic for 3 column volumes, and then sequential portions of hexane:EtOAc 90:10, 
50:50, 10:90, and finally with the introduction of MeOH in portions of 90:10 and 0:100 
(EtOAc:MeOH). Fractions were combined based on TLC profiles and evaporated to dryness 
resulting in 17 fractions (A to Q). Fraction H (192.0 mg) crystallised in MeOH to give tanshinone 
IIA (100 mg), while fraction J (32.1 mg) crystallised in MeOH to give a mixture of the positional 
isomers – 1,2-dihydrotanshinquinone I and methylenetanshinquinone (20 mg). 
S. miltiorrhiza semi-preparative purification of compounds: Fractions F, L, N and O were 
optimised for separation. Fraction F (12.3 mg) was separated on a semi-preparative scale using 
a SunFire prep C18 column (10 x 150 mm; 5 μm; Waters) on an Agilent 1100 Series HPLC system 
equipped with Diode Array Detector (DAD). The mobile phase consisted of H2O (A) and MeCN 
(B) and the flowrate was set at 4.0 mL/min. An isocratic method of 75% B in 15 min was 
applied; UV detection was recorded at 254 nm. The peak eluting at 9.25 min was elucidated as 
dehydromiltirone (3.1 mg). Fraction L (8.4 mg) was separated using an isocratic method at 70% 
B for 15 min, the peak eluting at tR 9.1 min was identified as tanshinone I (2.69 mg). The 
compound methyltanshinoate (tR 10.8 min; 1.1 mg) was separated from fraction N (42.7 mg) 
using an isocratic method at 60% B in 20.00 min. Cryptotanshinone (tR 12.3 min; 2.37 mg) was 
separated from fraction O (30 mg/mL) using an isocratic method of 63% B in 15 min.  
Separation of positional isomers: The separation of the positional isomers (1,2-
dihydrotanshinquinone I and methylenetanshinquinone) was obtained using a Nucleodur 100-5 
NH2 column (4 x 250 mm; 5 μm; Macherey-Nagel; analytical scale) in normal phase with 
solvents C:D (hexane:IPA). The optimised separation was achieved with isocratic 100% C in 10 
min. Compounds eluted at tR 1.95 and 2.67 minutes. For preparative scale separation a 
Nucleodur 100-5 NH2 (21 x 250 mm; 5 μm; Macherey-Nagel) was used in normal phase.  
Synthetic tanshinone IIA derivatives: The dicarbonilic group of tanshinone II A, isolated in large 
amount from S. miltiorrhiza, and of the commercially available 9,10-phenanthrenquinone were 
transformed into oxazole and methyl-imidazole groups, respectively, by reductive amination 
with methyl amine198. Resulting synthetic compounds were coded as TA-II and PQ-1 
respectively.  
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CUG78-MBNL1 inhibition assay: Test plates were prepared according to a validated 
procedure199 and is briefly described here. Test substances were added at appropriate 
concentrations to 45 μL incubation buffer. Wells were washed with anti-HIS antibody and plates 
were incubated for 1 hour. Various wash steps preceded the incubation time and the 
colorimetric reaction was performed at 30 °C and 700 rpm for 5 min and stopped with 70 μL of 
0.15 M H2SO4/well. The optical density was read at λmax 450 nm with a plate reader. 
 
Figure 6.1: Isolation scheme for Salvia miltiorrhiza and resulting compounds. 
Compound data: 
Auroside223 (La_1): yellow, amorphous solid; [α]D = -99.7 (c, 0.1 in CH3OH)
224. 1H NMR data, see 
Table A1 in Appendix; ESIMS m/z 429.0 [M + Na]+; tR: 7.9 min. 
Methyltanshinoate (Sm_N2): orange, amorphous solid; [α]D = -91.5 (c, 0.02 in CHCl3). 
1H NMR 
data, see Table A2 in Appendix; ESIMS m/z 339.2 [M + H]+; tR: 23.8 min. 
Cryptotanshinone (Sm_O2): yellow-orange, fine needles; [α]D = -35.6 (c, 0.06 in CHCl3). 
1H NMR 
data, see Table A2 in Appendix; ESIMS m/z 297.2 [M + H]+; tR: 25.4 min. 
Tanshinone I (Sm_L2): red-yellow, fine needles; [α]D = -1319.6 (c, 0.13 in CHCl3). 
1H NMR data, 
see Table A2 in Appendix; ESIMS m/z 277.1 [M + H]+; tR: 25.8 min. 
1,2-dihydrotanshinquinone I (Sm_J_XTL): purple, fine crystalline powder; [α]D = -1989.0 (c, 0.1 
in CHCl3). ESIMS m/z 279.1 [M + H]
+; tR: 26.7 min. 
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Methylenetanshinquinone (Sm_J_XTL): purple, fine crystalline powder; [α]D = -5050.5 (c, 0.1 in 
CHCl3). ESIMS m/z 279.1 [M + H]
+; tR: 26.7 min. 
Dehydromiltirone (Sm_F1): red, amorphous solid; [α]D = -6.62 (c, 0.08 in CHCl3). 
1H NMR data, 
see Table A2 in Appendix; ESIMS m/z 281.2 [M + H]+; tR: 27.7 min. 
Tanshinone IIA (Sm_H_XTL): red-orange, amorphous solid; [α]D = -12.3 (c, 0.09 in CHCl3). 
1H 
NMR data, see Table A2 in Appendix; ESIMS m/z 295.2 [M + H]+; tR: 28.4 min. 
6.3 TB project 
Plant material: Dried roots of Dorstenia contrajerva L. (Moraceae) was obtained from Parque 
Nacional Soberania, camino de Plantacion, Panama (Florpan No. 5683). Dried bulbs of 
Pancratium littorale Jacq. (Amaryllidaceae) were obtained from Costa Arriba, Cuango, Colón, 
Panama (Florpan No. 5518). A voucher specimen for each plant was deposited in the 
Pharmaceutical Biology Division at the University of Basel (plant number 837 and 836, 
respectively).  
Extraction: For D. contrajerva, 158.3 g of the plant material was powdered by cryomilling, 
mixed with quartz sand and extracted by percolation at room temperature sequentially with 
EtOAc (extracted over the duration of 48 hours with 5 L of solvent) and methanol (allowed to 
extract overnight and percolated the day after with 5 L of solvent). The extracts were 
evaporated to dryness under reduced pressure to yield 3.23 g (2.04% yield) and 3.31 g (2.10% 
yield), respectively. 
For P. littorale, 301.5 g of the plant material was powdered by cryomilling, mixed with quartz 
sand and extracted by percolation at room temperature sequentially with ethyl acetate 
(extracted over the duration of 48 hours) and methanol (extracted over the duration of 48 
hours). The extracts were evaporated to dryness under reduced pressure to yield 3.34 g (1.1% 
yield) and 45.05 g (14.9% yield), respectively. 
Micro-fractionation for activity profiling: For both extracts the first round of micro-
fractionation was followed as described above with collection of 31 fractions of 60 s each, 
starting from min 0.00 until 31.00 with a Gilson FC204. The dried fractions were taken up in 4 
µL of DMSO, and diluted into 16 µL media (1:5 dilution) which was used in the promoter based 
screening assay. For the micro-fractions – where the weight is not known – each well was 
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treated in the same way, 2 µL of the 5x diluted solutions were added to 198 µL cell suspension, 
which made up a total volume of 200 µL. Therefore the micro-fractions were further diluted by 
1:100 times for their final concentration. 
A second round of micro-fractionation for P. littorale was performed using an Aqua C18 column 
(250 x 4.60 mm; 5μm; Phenomenex). The mobile phase consisted of H2O (A) and MeCN (B), 
both with the addition of 0.1% formic acid. A gradient of 0-50% B in 30 minutes with a flowrate 
of 0.6 mL/min was applied.  
Isolation of furanocoumarins: 100 mg of the ethyl acetate extract of D. contrajerva was 
dissolved in 1.0 mL of MeOH. This solution was prefiltered through a small C18 cartridge (under 
vacuum) to remove very lipophilic compounds. The remaining extract was dried under nitrogen 
flow and redissolved in DMSO (at 25 mg/mL). Semi-preparative purification of the two main UV 
active peaks were collected using an Agilent 1100 Series HPLC system equipped with Diode 
Array Detector (DAD) and SunFire prep C18 column (10 x 150 mm; 5 μm; Waters). The mobile 
phases were H2O (A) and MeCN (B). A gradient of 5-100% B in 30 min with a 5 min 100% B, UV 
detection was done at 254 and 310 nm. Fractions were dried under vacuum using a rotavap 
(Büchi), and freeze dried after organic solvent was removed. The two compounds (bergapten 
and dorstenin) crystallised out of solution and NMR data were recorded at 500 MHz with a 1-
mm TXI probe for structure elucidation. 
Quantification of bergapten and dorstenin by UV: for the UV quantification of the two major 
furanocoumarins in D. contrajerva, the Alliance 2695 system coupled with a DAD 996 was used. 
Wavelength was 310 nm and calibrators (0.05, 0.1, 0.2, 0.25 and 0.5 mg/mL) were prepared 
from the pure compounds previously isolated as described above. All calibrators and samples 
were injected in triplicates and mean ± SD was calculated (acceptable range of SD was ± 15%). 
Quantification by 1H-NMR: 1H NMR spectra were recorded at 18 °C in DMSO-d6 (Armar 
Chemicals, Switzerland) on a Bruker Avance IIITM 500 MHz NMR spectrometer equipped with a 
1-mm TXI probe. Data were processed with Topspin 3.2 software (Bruker). For quantification of 
the two Dorstenia compounds, 1,3,5-trimethoxybenzene (>99 pure, Sigma-Aldrich) was used as 
internal standard. Quantitative 1H NMR was carried out using the pulse program zg30 (Bruker) 
with a recycle delay of 20 sec (>5xT1). Two dummy scans, 128 scans, and a sweep width of 11 
ppm, covering 64 K data points, provided the FID. Processing of the spectra included zero filling 
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(x1) and multiplication of the FID by an exponential decay apodization function of 0.3 Hz prior 
to Fourier transformation. A digital filter (baseopt; Bruker) improved the automatic baseline 
correction, which was performed before signal integration. Reference signals for integration 
were δ = 7.32 (bergapten), δ = 6.09 (IS) and δ = 5.54 (dorstenin). 
The sample was prepared and measured in triplicate as follows.  
50 μL (0.5 mg) of the extract library sample (10 mg/mL) was transferred into an HPLC vial and 
lyophilised over night on the freeze dryer, this was prepared in triplicate. A stock solution of the 
internal standard, 1,3,5-trimethoxybenzene (in DMSO-d6, 10 mg/mL) was prepared. The dried 
extract samples were then taken up in 9.7 μL DMSO-d6. 3 μL of the internal standard (1.78x10-4 
mmol/L) was added as a reference to each sample to make a total volume of 10 μL and 
transferred into an NMR tube for measurement.  
Macro-fractionation for D. contrajerva activity profiling: 47.5 mg of extract was dissolved in 
DMSO at a concentration of 25 mg/mL and centrifuged for 15 min at 14.5 rpm. Supernatant 
was removed and injected onto a semi-preparative SunFire prep C18 column (10 x 150 mm; 5 
μm; Waters) using an Agilent 1100 Series HPLC system equipped with Diode Array Detector 
(DAD). The mobile phase consisted of H2O (A) and MeCN (B). A gradient of 5-100% B in 30 min 
with 5 min isocratic at 100% B, UV detection was recorded at 254 and 310 nm. Flowrate used 
was 4.0 mL/minute. Two injections of 400 μl (25 mg) and time-based fractions (1.00 
minute/fraction) were collected into 6 mL test tubes (rack 21) from 0.00 to 35.00 minutes (35 
fractions) using a Gilson FC204. Test tubes were directly dried in the Genevac EZ-2 evaporating 
system at 27 °C overnight and transferred into small vials for exact weights. The dried fractions 
were dissolved at a concentration of 10 mg/mL and tested in the promoter based screening 
assay at 10 and 5 μg/mL on the cells. 
Diaion filtration of P. littorale extract: 45.05 g of the extract was suspended in 800 mL H2O (pH 
3.0) and loaded onto column packed with diaion (HP-20). Extract was eluted slowly to allow 
adsorption onto beads. Column was then eluted with 3 volumes (about 4 L) of H2O (pH 3.0) to 
wash out sugar portion. Methanol was used thereafter as eluent to collect the remaining 
extract and acetone was used to wash the diaion column after use (see Fig. 6.2).   
Alkaloid extraction: Using 3.09 g of the remaining methanol extract after diaion, enrichment of 
alkaloids was done in two portions (1.31 g first round and 1.78 g second round). Briefly, the 
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extract was suspended in 200 mL of 0.25 M H2SO4 solution (pH 3.0) and partitioned in a 
separating funnel with CHCl3 (200 mL x 3) to remove the lipophilic compounds. The aqueous 
portion was then basified to pH 10.0 with NH3 solution (about 2-3 mL). The alkaline aqueous 
solution was then partitioned with DCM (200 mL x 3, NaCl was added to break the foamy layer 
formed in between) to collect the enriched alkaloid portion. The remaining aqueous portion 
was neutralised before freeze drying.  
Diol cartridge of alkaloid portion: The alkaloid portion (261.1 mg) was loaded (in 3.0 mL 
starting conditions) onto a Sepacore diol cartridge (40-63 μm; 40 g; 16 bar; Büchi) using the 
PuriFlash system (Interchim PuriFlash 4100 module). Normal phase chromatography was used 
with a solvent system of MeOH (B), DCM (C), and IPA (D) following the elution gradient starting 
at 0:99:1 (B:C:D) to 0:80:20 (B:C:D) in 100 min, then 0:0:100 (B:C:D) for 60 min, and held for 5 
min, thereafter 10:90:0 (B:C:D) in 5 min, and 20:80:0 (B:C:D) in 25 min, and finally 50:50:0 
(B:C:D) for 45 min to elute remaining compounds out. A flowrate of 5 mL/min was setup and 
collection volume was 6 mL/tube. Fractions were combined based on TLC profiles and 
evaporated to dryness on the rotavap (Resulting in 13 diol fractions). 
Semi-preparative HPLC-UV-MS for isolation of alkaloid compounds: For each resulting diol 
fraction separation conditions were optimised on a reverse phase analytical column (Reprosil-
Pur Basic-C18; 3.0 μm; 150 x 3.0 mm; Dr Maisch) under basic conditions (pH 9.0). Separation 
was performed on a semi-preparative scale with the column Reprosil-Pur 100 Basic-C18 (5.0 
μm; 150 x 10.0 mm with pre-column 30.0 x 10.0 mm; Dr Maisch) on an Agilent 1100 Series 
equipped with DAD (scanning 190-400 nm) and MSD (scanning 150-1500 m/z). Solvent system 
was made up of H2O adjusted to pH 9.0 with NH3 solution (A) and 8:1:1 of MeCN:IPA:solution A 
(B) and the flowrate was set to 4.0 mL/min.  
Diol fractions G to I, K, and M were optimised for separation. A gradient of 5-32% B in 17.00 
min, 32% B isocratic for 10.00 min and 100% B for 5.00 min was applied for the separation of 
fraction G (27.85 mg in 500 μL DMSO, 5 mg/inj). For fraction H (31.51 mg in 600 μL, 5 mg/inj), a 
method of 5-20% B for 5.00 min, 20-24% B until 21.00 min, 24-38% B for 1.00 min, 38-42% B in 
2.00 min and 100% B for 5.00 min was used. A separation method of 2-9% B in 5.00 min, 9% B 
isocratic for 5.00 min, 9-15% B in 1.00 min, 15-42% B for 16.00 min and 100% B for 5.00 min 
was applied for fraction I (16.46 mg in 400 μL DMSO, 2 mg/inj). The separation method for 
fraction K (41.86 mg in 700 μL DMSO, 6 mg/inj) was 2-46% B in 14.00 min, 46-52% B in 1.00 
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min, 52% B isocratic for 5.00 min, and 100% B for 5.00 min. Detection for fraction K, and M was 
only UV at λmax 254 and 290 nm. Fraction M (15.3 mg in 400 μL DMSO, 4 mg/inj) was separated 
using a method of 2-15% B for 5.00 min, 15-18% B in 4.00 min, 18-19% B in 2.00 min, 19-22% B 
in 3.00 min, 22-23% B in 3.00 min, 23-31% B in 5.00 min, 31-32% B in 1.00 min, 32-35% B in 1.00 
min, and 100% B for 5.00 min.  
 
Figure 6.2: Isolation scheme for Pancratium littorale and resulting compound codes and 
numbers. 
RBL GFP (Coronin-1 promoter) and RBL RFP (CMV promoter) cells: Stably transfected Rat 
Basophil Leukemia (RBL) with Green Fluorescence Protein (GFP) expression under control of 
coronin-1 promoter was generated by transfecting a promoterless plasmid containing the 
essential 1.5 kb promoter element of coronin-1 upstream of destabilised GFP (Clonetech). 
Likewise, a promoterless plasmid with an early cytomegaloviral (CMV) promoter driving the 
expression of Red Fluorescent Protein (RFP) served as internal control for non-specific 
promoter inhibition and toxicity during the screening. The promoter sequences were verified by 
sequencing (Microsynth).  
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Western blotting: RBL-GFP cells were seeded at a density of 50’000 cells/well on a 96 well plate 
in a volume of 200 µl of phenol red free RPMI media supplemented with 8% fetal bovine serum 
and penicillin (100 U/ml), streptomycin (100 mg/ml) and L-glutamine (2 mM) along with 
compounds and vehicle controls. The cells were incubated in a humidified incubator at 37 oC for 
72 hrs and later they were replenished with freshly prepared compounds and further incubated 
for another 48 to 72 h. Subsequently, the cells were washed in Phosphate Buffered Saline (PBS) 
and lysed in RIPA lysis buffer (0.1% SDS, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate, 
1mM MgCl2, 100 mM NaCl, 1mM EDTA) with protease and phosphatase inhibitors (Roche). 
Protein amounts were estimated using a BCA kit (Thermo) and equal protein amounts (15 μg 
per lane) were loaded onto a 12.5% SDS-PAGE and run under denaturing condition, transferred 
onto a nitrocellulose membrane and immunoblotted with rabbit anti-coronin-1 antibody 
(Serum 320, 1:5000, in-house generated) and mouse anti-actin antibody (mAB H1501, 1:5000, 
Merck Millipore) followed by Infrared dye-tagged secondary antibodies (LI-COR) and imaged 
using an Odyssey CLx system (LI-COR). Coronin-1/actin ratiometric analysis of Western blot data 
was performed using Image Studio Lite Software. 
Synergy plate reader: RBL-GFP cells were seeded at a density of 50’000 cells/well on a 96 well 
plate in a volume of 200 ml of phenol red free RPMI media supplemented with 8% fetal bovine 
serum and penicillin (100 U/ml), streptomycin (100 mg/ml) and L-glutamine (2 mM) along with 
compounds and vehicle controls. The cells were incubated in a humidified incubator at 37 oC 
and at indicated time points, the GFP fluorescence intensity was measured using a Synergy H4 
hybrid microplate reader system (Biotek).   
Compound data: 
Bergapten (DcA1): white, fine needles; [α]D = +0.03 (c, 0.04 in CHCl3). 
1H NMR data, see Table 
A3 in Appendix; ESIMS m/z 217.0 [M + H]+; tR: 18.45 min. 
Dorstenin (DcA2): yellow, amorphous solid; [α]D = -7.76 (c, 0.09 in CHCl3). 
1H NMR data, see 
Table A3 in Appendix; ESIMS m/z 369.2 [M + H]+; tR: 21.5 min. 
8-demethoxy-lycoranine F (Pl_G2, 1): yellow, amorphous solid; [α]D = +47.0 (c, 0.06, CH3OH). 
1H 
NMR data, see chapter 4; HRESIMS (m/z 288.1237 [M+H]+; calculated for C16H18NO4
+: 
288.1230); tR: 7.2 min. 
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8-O-demethyl-homolycorine (Pl_K2, 2): yellow, amorphous solid; [α]D = +43.71 (c, 0.05, CHCl3). 
1H NMR data, see Table A4 in Appendix; ESIMS m/z 301.9 [M+H]+; tR: 7.7 min. 
pseudo-lycorine (Pl_M1, 3): yellow, amorphous solid; [α]D = +2.38 (c, 0.09, CH3OH). 
1H NMR 
data, see Table A6 in Appendix; ESIMS m/z 289.8 [M+H]+; tR: 10.1 min. 
8-O-demethyl-lycorenine (Pl_K4, 4): yellow, amorphous solid; [α]D = +82.4 (c, 0.11, CHCl3). 
1H 
NMR data, see chapter 4; HRESIMS (m/z 304.1547 [M+H]+; calculated for C17H22NO4
+: 
304.1543); tR: 10.8 min.  
7-demethoxy-10-O-methyl-hostasine (Pl_H11, 5): white, amorphous solid; [α]D = -38.28 (c, 0.05, 
CHCl3). 
1H NMR data, see Table A5 in Appendix; ESIMS m/z 347.9 [M+H]+; tR: 11.5 min.  
Carinatine (Pl_I10, 6): white, amorphous solid; [α]D = -28.56 (c, 0.02, CHCl3). 
1H NMR data, see 
Table A6 in Appendix; ESIMS m/z 303.8 [M+H]+; tR: 11.7 min.  
Lycorine (Pl_I14, 7): white, solid precipitate; [α]D = -9.07 (c, 0.07, CHCl3). 
1H NMR data, see Table 
A6 in Appendix; ESIMS m/z 287.9 [M+H]+; tR: 12.0 min. 
10-O-methyl-hostasine (Pl_H15, 8): yellow, amorphous solid; [α]D = -70.52 (c, 0.08, CHCl3). 
1H 
NMR data, see Table A5 in Appendix; ESIMS m/z 377.9 [M+H]+; tR: 12.5 min. 
10-deoxy-3-hydroxy-6-hydroxy-hippeastidine (Pl_K6, 9): yellow, amorphous solid; [α]D = +25.7 
(c, 0.05, CHCl3). 
1H NMR data, see chapter 4; HRESIMS (m/z 306.1706 [M+H]+; calculated for C-
17H24NO4
+: 306.1700); tR: 13.0 min. 
Narcissidine (Pl_K7, 10): dark yellow, amorphous solid; [α]D = -49.65 (c, 0.1, CHCl3). 
1H NMR 
data, see Table A7 in Appendix; ESIMS m/z 333.9 [M+H]+; tR: 14.1 min. 
1-O-acetyl-pseudo-lycorine (Pl_H18, 11): yellow, amorphous solid; [α]D = -60.0 (c, 0.06, CHCl3). 
1H NMR data, see Table A6 in Appendix; ESIMS m/z 331.8 [M+H]+; tR: 15.0 min. 
8-O-demethyl-6-O-methyl-lycorenine (Pl_K9, 12): dark yellow, amorphous solid; [α]D = +130.8 
(c, 0.11, CHCl3). 
1H NMR data, see Table A4 in Appendix; ESIMS m/z 317.8 [M+H]+; tR: 15.5 min. 
3-O-acetyl-narcissidine (Pl_G17, 13): yellow, amorphous solid; [α]D = -146.16 (c, 0.05, CHCl3). 
1H 
NMR data, see Table A7 in Appendix; ESIMS m/z 375.9 [M+H]+; tR: 15.8 min. 
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10-deoxy-6(α)-hydroxy-hippeastidine (Pl_G16, 14): yellow, amorphous solid; [α]D = +6.44 (c, 
0.027, CHCl3). 
1H NMR data, see Table A8 in Appendix; ESIMS m/z 319.8 [M+H]+; tR: 16.0 min.  
6-hydroxy-hippeastidine (Pl_I19, 15): white, amorphous solid; [α]D = +19.3 (c, 0.014, CHCl3). 
1H 
NMR data, see Table A8 in Appendix; ESIMS m/z 335.9 [M+H]+; tR: 16.2 min. 
6.4 Lymphatic project 
Plant material: Dried root bark of Daphne giraldii (Thymelaceae) was obtained (500 g) from 
Bozhou herbal market in Bozhou city, Anhui, China. A voucher specimen for the plant was 
deposited in the Pharmaceutical Biology Division at the University of Basel (plant number 351).  
Extraction: For D. giraldii, 474.61 g of plant material was powdered by cryomilling before 
extraction by percolation at room temperature sequentially with DCM (extracted over 48 hours 
with 4 L of solvent), EtOAc (extracted over 48 hours with 4 L of solvent) and MeOH (extracted 
with 4 L of solvent over 48 hours). The extracts were evaporated to dryness under reduced 
pressure to yield 13.34 g (2.8% yield), 8.23 g (1.7% yield), and approximately 60 g (approx. 12% 
yield), respectively (see Fig. 6.3).  
Micro-fractionation for activity profiling: For D. giraldii extract, the first round of micro-
fractionation was followed as described above with collection of 29 fractions of 60 s each, 
starting from min 1.00 until 30.00 with a Gilson FC204. The dried fractions were taken up in 50 
μL of DMSO and diluted 1:100 times with the medium. All test samples were further diluted 
(1:10 times) and tested in the 3D sprouting assay (total volume per well is 160 μL). 
Micro-fractionation on the 4 active normal phase fractions (Dgi-E, Dgi-F, Dgi-G, Dgi-H) from the 
silica column was performed to localize the region of activity in each. This was performed using 
a C18 SunFire column (3.0 x 150 mm; 3.5 μm; Waters) on a Shimadzu HPLC system equipped 
with DAD (SPD-M20A, Shimadzu), ELSD (3300, Alltech), and ESIMS (LCMS-8030, Shimadzu). The 
mobile phase consisted of H2O (A) and MeCN (B), both with the addition of 0.1% formic acid. A 
gradient of 5-100% B in 30 min, with 10.00 min 100% B isocratic was applied. The flowrate of 
0.4 mL/min was applied. Fractions were collected time-based starting from 2.00 until 35.00 min 
(33 fractions of 60 s each). UV trace was tracked online, while ELSD and ESIMS was recorded 
offline after fractions were collected. The dried fractions were tested at a 1x and a 10x dilution 
in the 3D sprouting assay. 
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Normal phase column chromatography: The DCM extract was dry loaded (adsorbed to silica) 
onto a pre-packed silica cartridge (Si-HP, 30 μm, 120 g, 20 bar, Interchim PuriFlash) using the 
PuriFlash system (Interchim PuriFlash 4100 module). A solvent system of MeOH (B), Hexane (C), 
and EtOAc (D) following the elution gradient in Table 6.1. A flowrate of 30 mL/min was setup 
and collection volume was 15 mL/tube (30 sec). UV was recorded at 254 nm and scanning from 
220 to 600 nm. Fractions were combined based on TLC profiles and evaporated to dryness on 
the rotavap (resulting in 8 fractions, A to H). This process was repeated four times with 0.99 g 
(run 1), 1.35 g (run 2), 4.52 g (run 3), and 3.13 g (run 4) of the extract.  
Table 6.1: Elution steps for gradient of the DCM extract from D. giraldii. 
Time %B %C %D 
00 s 00 95 05 
38 s 00 94 06 
04:21 00 94 06 
04:24 00 93 07 
04:47 00 93 07 
04:57 00 92 08 
05:03 00 92 08 
05:41 00 90 10 
10:23 00 90 10 
13:47 00 79 21 
18:48 00 79 21 
43:47 00 00 100 
44:47 50 00 50 
48:47 50 00 50 
49:47 100 00 00 
53:47 100 00 00 
01:02:14 100 00 00 
 
Speed-Centrifugal-Partition-Chromatography (SCPC) on Dgi-E, -F, -G, and -H: The SCPC system 
(AlphaCrom SCPC-250) was kindly borrowed from AlphaCrom (Dr. Thomas Pfeiffer). 
Components of the system include AlphaCrom SCPC-250 (sample size up to 5 g, rotor volume 
250 mL), diode array detector 335 (190 – 950 nm, flowrate into flow cell up to 1 000 mL/min), 
sample loading loop (10 mL volume), Pump 210 (flow 0.01-100 mL/min, low pulsation), and a 
fraction collector (FC 701). An appropriate liquid phase system was selected based on the 
distribution of compounds in the upper and lower phases monitored by TLC and HPLC-UV-MS. 
Solvent system selected for all four fractions was hexane:EtOAc:MeOH:H2O 1:1:1:1. The upper 
phase (hexane:EtOAC) was used as a stationary phase (SP) while the lower phase (MeOH:H2O) 
was used as the mobile phase (MP). Solvents were mixed in a separating funnel by shaking 
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thoroughly. The flowrate for loading of the solvent systems was set at 20 mL/min with the rotor 
at 500 rpm (or acceleration of 21 G), and the run time flowrate was set at 5 mL/min with 2 000 
rpm (or 332 G). UV was monitored at 254 nm. Once stationary and mobile phases were 
equilibrated into the system, the sample was taken up into 10 mL of 1:1 ratio of the two phases 
(volume depends on size of injection loop) and injected into the rotor (column). Instrument was 
run in DSC mode (descending) while MP was passed through; thereafter the instrument was 
switched to ASC mode (ascending) to push the SP out. Fractions were collected every 2.00 min 
(10 mL/tube) and the pressure was maintained at 54 bar.  
Fraction E was loaded into four parts (100 mg in 1.0 mL, 500 mg in 10 mL, 500 mg in 10 mL, and 
1.5 g in 10 mL). MP was run for 30, 60, 40 and 40 min, respectively while SP was run for 30 min 
each time. Fraction F was loaded one time (680.68 mg in 10 mL) with MP run for 44 min and SP 
for 30 min. Fraction G was also loaded one time (89.15 mg in 10 mL) with MP runtime of 39 min 
and SP runtime of 28 min. Fraction H was loaded in two parts (1.0 g in 10 mL, and 0.6 g in 10 
mL) with MP runtime of 50 and 41 min, respectively, while SP runtime was 30 min each time. 
Fractions were monitored by HPLC-UV-MS and combined based on their similarities to give 
fractions E-a to E-i (9 fractions), F-a to F-i (9 fractions), G-a to G-j (10 fractions) and H-a to H-k 
(11 fractions). All CPC fractions were tested at 10 μg/mL. 
CPC fraction Ed semi-preparative sub-fractionation: 45.9 mg of Ed was dissolved in 230 μL of 
DMSO and separated by semi-preparative HPLC-UV on a C18 SunFire HPLC column (10.0 x 150 
mm; 5 μm; Waters). The mobile phase consisted of H2O (A) and MeCN (B) with a gradient of 20 
to 70% B in 25 min. The flowrate was 4.0 mL/min. Detection was set at UV 210, and 320 nm. 
Aliquots of 50 μL (3 times) and 75 μL (2 times) were injected. Eleven fractions were obtained 
(fractions Ed-1 to Ed-11), by using a combination of peak-based and time-based collection. Sub-
fractions were tested at 10, 1 and 0.1 μg/mL. 1H-NMR spectra of active fractions were recorded 
on an Avance III spectrometer (Bruker) equipped with a 1-mmTXI microprobe. Fraction Ed-8 
was elucidated to be daphneolone.  
Semi-preparative micro-fractionation of Ed-9, -10, and -11: Ed-9, Ed-10 and Ed-11 were further 
separated by semi-preparative HPLC-UV, using the same column and solvent system as above 
just with optimised conditions for each. For Ed-9 (1.89 mg in 200 μL DMSO), two injections of 
100 μL each were separated with 45% B isocratic for 16 min and a 5 min 100% B wash fraction 
was collected at the end. Detection was set at UV 254, 205 and, 320 nm. For Ed-10 (1.09 mg in 
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200 μL DMSO), 2 injections of 100 μL each were separated with a gradient of 38 to 40% B in 35 
min, 40% B isocratic for 1 min followed by 5 min of 100% B. Detection was set at UV 205, 320 
and, 270 nm. For Ed-11 (1.95 mg in 200 μL DMSO), 2 injections of 100 μL each were separated 
with a gradient of 35 to 85% B in 20 min, followed by 5 min of 100% B. Detection was set at UV 
254, and 320 nm. 
A total of 35 micro-fractions were obtained (fractions Ed-9-1 to Ed-9-10; Ed-10-1 to Ed-10-6; 
and Ed-11-1 to Ed-11-9), by using a combination of peak-based and time-based collection. 1H-
NMR spectra and HPLC-UV-MS-ELSD data of all micro-fractions were recorded before sending 
an aliquot of each for testing. Micro-fractions were tested at 10, and 1 μg/mL. 
Semi-preparative isolation of compounds from CPC fraction Ea: 86 mg were dissolved in 430 
μL DMSO (200 mg/mL concentration). Aliquots of 100 μL each were injected and separated by 
semi-preparative HPLC-UV on a C18 SunFire HPLC column (10.0 x 150 mm; 5 μm; Waters). The 
mobile phase consisted of H2O (A) and MeCN (B). A gradient of 10-50% B in 20 min, with a 5 
min 100% B wash was applied. The flowrate was 4.0 mL/min. Detection was set at UV 254, and 
277 nm. Twelve fractions were obtained (fractions Ea-1 to Ea-12), by using a combination of 
peak-based and time-based collection. Fractions Ea-4 and Ea-12 crystallised upon drying under 
nitrogen flow. Crystals from these samples were cleaned up with cold MeOH and elucidated to 
be daphnetin and chrysoeriol, respectively. 
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Figure 6.3: Isolation scheme for Daphne giraldii and resulting compounds, fractions, sub-
fractions and micro-fractions. 
3D sprouting assay: The assay was developed at the ETH Zürich. It is a phenotypic screening of 
novel inducers of lymphatic vessel growth in a 3D sprouting assay. Human dermal 
microvascular lymphatic endothelial cells (LECs) were coated onto gelatin-covered cytodextran 
microcarrier beads (Sigma) and labelled with cell tracker green (CTG, Invitrogen). Fully LEC-
covered beads were embedded into collagen type I hydrogels in black clear-bottom 96-well 
plates. Plates are incubated at 37 °C with / without the addition of test samples for 24 hours 
and afterwards fixed with 1% paraformaldehyde. Extracts from the library were tested at 10 
μg/mL, with 0.1% DMSO as a negative control and 10 μg/mL Iris germanica extract as a positive 
control. Automated imaging and analysis of number of sprouts / bead was used as a readout for 
positive inducers of LEC growth154.  
Compound data: 
Daphnetin (Dgi_Ea_4_XTL): white, amorphous solid; [α]D = +0.92 (c, 0.1, CH3OH). 
1H NMR data, 
see Table A9 in Appendix; ESIMS m/z 178.7 [M+H]+; tR: 10.2 min. 
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Chrysoeriol (Dgi_Ea_12_XTL): yellow, amorphous solid; [α]D = +0.89 (c, 0.1, CH3OH). 
1H NMR 
data, see Table A9 in Appendix; ESIMS m/z 300.8 [M+H]+; tR: 16.8 min. 
Daphneolone (Dgi_Ed_8): yellow, oil; [α]D = +57.05 (c, 0.1, CHCl3). 
1H NMR data, see Table A9 in 
Appendix; ESIMS m/z 270.8 [M+H]+; tR: 18.5 min. 
6.5 CHF project 
Crataegus extract semi-preparative isolation: From an ongoing project, two fractions were 
found active (fractions E-7 and E-8) and further separated by semi-preparative HPLC-UV. 
Fraction E-8 (92 mg) was dissolved in DMSO-THF 1:1 at a concentration of 100 mg/mL, and 
separated by semi-preparative HPLC on a C18 SunFire HPLC column (10.0 x 150 mm; 5 μm; 
Waters). The mobile phase consisted of H2O (A) and MeCN (B). A gradient of 5-100% B in 30 
min, with a 5 min 100% B wash was applied. The flowrate was 4.0 mL/min. Detection was set at 
UV 288 nm. Aliquots of 100 μL each were injected. Nine fractions were obtained (fractions E-
8/1 to E-8/9), by using a combination of peak-based and time-based collection. Fraction E-7 
(141 mg) was separated following the same chromatographic conditions as for fraction E-8, but 
with detection at UV 247 nm resulting in 8 fractions (E-7/1 to E-7/8). 1H-NMR spectra of active 
fractions and the reference compound hyptatic acid were recorded on a 500 MHz Avance III 
spectrometer (Bruker) equipped with a 1-mmTXI microprobe (see Fig. 6.4). 
 
Figure 6.4: Isolation scheme for Crataegus WS 1442 extract and resulting compounds (isolated 
by M. Bauhart) and fractions. 
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Bioassay for Crataegus samples: Testing of the samples was done on edema-preventing 
mechanisms which include interference with calcium signalling induced by thrombin and 
activation of cortactin. A detailed explanation of the process followed with the biological assays 
can be found in the article by Fuchs et al., 2017197. Briefly, the fraction worked on by our group 
was shown to inhibit the influx of calcium induced by thrombin. Changes in cytosolic calcium 
levels were detected by fluorescence microscopy using Fura-2-AM in a static tempered system 
at 37 °C. Thrombin was added at time point t = 1 min after initiation of experiment. 
Experiments were independently performed three times (n = 3) as expressed as a %. 
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Chapter 7 
7. Conclusions and Future Perspectives 
Natural products have contributed approximately 50% of new chemical entity approvals in 2010 
and still possess a large amount of unexplored chemical diversity. It is estimated that from 
approximately 300 000 plant species, only about 6% of higher plants, very few marine sources, 
as well as less than 1% of microbial species have been pharmacologically investigated so far79. 
Their structural and molecular diversity allow natural products to continue to play a 
fundamental role in the discovery of novel bioactive molecules. Following technological 
advances on instruments that are used for characterisation of natural products as well as in 
extraction and screening methods, the field of natural products is growing fast and making 
significant contributions in areas of biochemistry and drug discovery79. On the other hand, 
progress in genetics and molecular biology swiftly improve the target-based drug discovery 
approach; as a result it enhances the pharmaceutical values of natural products. For example 
between 1999 and 2013, 113 drugs were approved by the FDA225; of which 69% were 
discovered through target-based research approaches225. The target-based approach is 
hypothesis driven with the goal to modulate a specific component within a biological system226. 
As part of the target identification process, understanding the molecular mechanisms of a 
biological system is of fundamental importance to increase the confidence in target 
selection226. 
At the Neurobiology Department, University of Basel, the inhibition of pathogenic complex 
formation between CUGn-RNA and MBNL1 was identified to be an important target for the 
treatment of Myotonic Dystrophy type 1. A protein called coronin-1 was found to be essential 
for the survival of pathogenic Mycobacterium tuberculosis (MTB) in the human host138. Thus at 
the Biozentrum, University of Basel, an assay which enables us to measure the effectiveness of 
a molecule in inhibiting the expression of coronin-1 was developed (referred as GFP and RFP 
assay). Promoting Lymphatic Endothelial Cell (LEC) growth plays an essential role in treating 
lymphedema149; accordingly, at the Pharmacogenomics group, ETH Zürich, an assay which 
allows us to test the efficiency of a molecule in promoting lymphatic vessel growth was 
developed. The underlying mechanism through which Crataegus extracts treats Chronic Heart 
Failure (CHF) was found to be via inhibiting thrombin-induced [Ca2+] influx which leads to a 
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reduction in endothelial hyperpermeability186,197. Therefore, to assess various aspects of 
Crataegus extracts that are related with CHF, at the Institute of Pharmaceutical Biology, Goethe 
University, an assay was developed. 
The aforementioned emerging biological targets are very crucial for various research activities 
which intend to discover molecules that have the ability to interact with these respective 
biological targets. Given the fact that natural products are a major source of complex and highly 
structurally diverse chemical compounds, they need to be tested on these emerging biological 
targets, via processing them and analysing their results with modern technologies such as HPLC 
and NMR. In this context, the main aims of this study were: (a) to test the activity of various 
plant and fungal extracts on aforementioned biological targets (assays), and (b) to characterise 
the active extracts and to distinguish the molecules which are possibly responsible for observed 
biological activities on each of these biological targets (assays). With these main objectives, this 
study was divided into four projects; namely: (1) DM1 project which focuses on Myotonic 
Dystrophy type 1 and natural products; (2) TB project which focuses on Tuberculosis and 
natural products; (3) Lymphatic project which focuses on lymphedema and natural products; 
and (4) CHF project which focuses on Chronic Heart Failure and Crataegus extracts. The main 
findings, concluding remarks and future perspectives for each of these projects are given as 
follows: 
[1] After testing and analysing over 2100 plant and fungal extracts, harmine (from 
Peganum harmala) as well as 1,2-dihydrotanshinquinone I and 
methylenetanshinquinone (from Salvia miltiorrhiza) were identified as the most active 
compounds in inhibiting CUGn-RNA and MBNL1 complex formation. Based on the 
identification of active scaffold of harmine, planar-nitrogen-based compounds (such as 
protoberberine alkaloids) were hypothesised to possess higher activity. Thus selected 
alkaloids from a compound library were tested in assays which measure the % of exon 
inclusion/exclusion in the gene coding for INSR and TNNT2. These test results exhibited 
that the most active compounds were 8-oxoberberine (in INSR assay), and coptisine and 
berberine (in TNNT2 assay). The IC50 and toxicity-IC50 test results for berberine and 
harmine showed that they were effective in restoring MBNL1 function at a 
concentration much lower than their respective IC50 and toxicity-IC50 values. Whereas, 
relative to the alkaloids, 1,2-dihydrotanshinquinone I, and methylenetanshinquinone 
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were found to be weaker in both INSR and TNNT2 assays, this might be due to their 
poor solubility. The identified alkaloids (i.e., harmine and berberine) were able to 
ameliorate certain aspects of the DM1 pathology, whereas the compounds from Salvia 
species (i.e., S. miltiorrhiza) exhibit some activities with certain degrees of toxicity, thus 
these compounds need further investigation. Remarkably, the main findings of this 
study exhibit that compounds with planar scaffolds which contained mostly nitrogen are 
more active in inhibiting CUGn-RNA–MBNL1 complex formation and restoring MBNL1 
function. Given the planar nature of the active molecules and the target being RNA, it is 
projected that the observed activities occurred due to bioactive molecules induced 
reversible intercalation into the RNA hairpin loop via electrostatic interactions, thereby 
blocking the binding of MBNL1 and allowing it to carry out its normal function. Overall 
the hit compounds found in this study may have the potential for drug discovery in RNA-
mediated diseases. 
[2] The TB project finds that among various plant and fungal extracts, the ethyl acetate 
extract from Dorstenia contrajerva and methanol extract from Pancratium littorale 
significantly decreased GFP after 72 hours (indicating they were active). Bioactivity 
tracking on active extracts (via HPLC-based activity profiling) led to the identification of 
constituents (class of compounds) that are possibly responsible for observed activities: 
alkaloids (from P. littorale) and furanocoumarins (from D. contrajerva). A compound 
dorstenin was isolated from D. contrajerva EtOAc extract and it was found that the 
molecule is active only at a higher concentration. This implies that dorstenin was not the 
major contributor for activity observed from D. contrajerva EtOAc extract. Moreover, 15 
alkaloids were isolated from P. littorale MeOH extract and it was found that in GFP assay 
three of them were the most active while four of them were more toxic in RFP assay. 
Also through activity correlated structural analysis of these isolated compounds this 
study found that molecules which contain secondary nitrogen and methylenedioxy 
group had higher toxicity, whereas the active molecules contain a hemiacetal ring and 
acetylation of some hydroxy functions. Moreover, through further tests using western 
blotting, this study found that the above three compounds which exhibited activity in 
GFP assay were not active in downregulating coronin-1 at the protein level (i.e., they 
were not active in inhibiting coronin-1 expression). These contrasting results found from 
the two different test methods (i.e., GFP assay and western blotting) open a question 
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that through which mechanism the active molecules can be able to induce GFP 
reduction? Currently this study did not come across a definite answer to this question 
but it might be through direct interaction with GFP via acting as quenching agents. Also 
considering the GFP assay and western blotting contradictory results, this study would 
like to remark that (a) it is crucial to confirm coronin-1 expression on a genetic level 
when treated with the compounds, such as via RT-PCR tests; and (b) it is important to 
re-evaluate the utilisation of GFP assay for coronin-1 inhibition test, this may include the 
need of conducting further investigation on understanding the interaction mechanism 
of compounds with GFP and its responses. 
[3] The extract library screening results showed that DCM, EtOAc, and MeOH extracts 
from Daphne giraldii were potent inducers of LEC sprouting. The HPLC-activity profiling 
of the MeOH extract illustrated that activities were localised in the lipophilic (a-polar) 
regions; therefore, further studies of this project focused on DCM extract which was 
considered to contain lipophilic compounds in higher quantities. Based on criteria such 
as higher yield, less complex, and higher activity, this study selected a CPC sub-fraction 
of DCM extract (named as E-d) for further investigation. The results of time-peak-based 
HPLC-UV semi-preparative-fractionations of sub-fraction E-d (until micro-fractions 
weighed ≤ 100 μg) and a series of assaying showed that the activity is consistently 
localised in a-polar regions. Thus this study excluded polar compounds from the list of 
compounds that are responsible for observed activity. Also due to the lower amount of 
E-d complex micro-fractions as well as presence of a wide array of structurally related 
minor metabolites in them, the identification of pure a-polar compounds that are 
responsible for observed activities remains challenging. However using daphnetoxin 
(which displayed potent sprouting activity) as a reference, this study conducted 
projected analysis on composition of E-d micro-fractions and it was found that trace 
amounts of daphnetoxin present in D. giraldii active micro-fractions could be (at least 
one of) the main contributing factors for observed activities. This projected remark was 
found through correlative analysis of E-d micro-fractions and daphnetoxin minimum 
effective concentration. Furthermore, this study found the presence of fatty acid signals 
in active E-d micro-fractions, this lead to the projection that a specific type of fatty acid 
present in D. giraldii may play a role in the overall observed activity. However to 
certainly identify this and other constituents of E-d micro-fractions, this study 
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recommends the need of working with large amounts of optimally prepared extracts. 
This will allow bioassay-guided refined separations to end up with suitable amounts of 
pure compounds for identification. Overall, the findings of this study showed that even 
if the active constituents of D. giraldii DCM extract were minor in terms of 
concentrations, they were potent in inducing LEC sprouting. This suggests that D. giraldii 
is crucial for future research activities that are focused on lymphedema. 
[4] On CHF project, Crataegus WS 1442 extract was separated into 9 fractions (namely: 
E-1 to E-9) and their activities were tested in the calcium imaging assay. The results 
exhibited that only E-7 and E-8 were active in inhibiting thrombin-induced [Ca2+] influx 
which leads to a reduction in endothelial hyperpermeability. Through further 
fractionations of E-7 and E-8 (via semi-preparative HPLC-UV chromatography), this study 
found that activities are only located in sub-fractions E-8-4, E-8-5 and E-8-6. Further 
analysis on composition of active sub-fractions showed that all of them contain fatty 
acids and triterpenes; particularly E-8-5 consisted of 40% fatty acids (stearic acid and 
palmitic acid) and 50% triterpene (hyptatic acid A). The test results for these compounds 
(in their pure form) displayed that they were inactive in inhibiting thrombin-induced 
calcium influx. Overall the test results showed that constituents which comprise almost 
90% of E-8-5 active sub-fraction were not active in their pure form, therefore it was 
evident that observed activities were instigated by unidentified minor compounds which 
comprise about 10% of E-8-5 constituents. This suggests that the activities of Crataegus 
WS 1442 extracts were induced by: (a) a minor constituent with potent activity; or (b) 
minor constituents with moderate activity which act synergistically. Finally this study 
recommends that to certainly identify the molecule(s) responsible for observed activity 
and to assess their biological interactions, further studies on large amounts of optimally 
prepared Crataegus extracts is needed. This will allow the researcher to end up with 
suitable amounts of fractions after refined separations. 
Overall each of the studies presented in this thesis (the four projects provided above) were one 
of the first to employ natural products in assessing their interactions or abilities to interact with 
four emerging biological targets. Therefore, the results presented in this thesis make a 
significant contribution in fields of pharmacological studies through the use of natural products, 
via providing: (a) new hit compounds; (b) possible constituents of potently active fractions; (c) 
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activity correlated structural analysis and extract characterisation; (d) opportunities for 
understanding interactions among natural products and biochemical assays; as well as (e) in 
identifying challenges and providing possible recommendations. Moreover, besides presenting 
the findings on different conferences, parts of the studies presented in this thesis have been 
published: 
1) From the DM1 project:  
Herrendorff, R., Faleschini, M. T., Stiefvater, A., Erne, B., Wiktorowicz, T., Kern, F., 
Hamburger, M., Potterat, O., Kinter, J., and Sinnreich, M. (2016) Identification of Plant-
derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I. J. Biol. 
Chem. 291, 17165–17177 
2) From the CHF project: 
Fuchs, S., Bischoff, I., Willer, E. A., Bräutigam, J., Bubik, M. F., Erdelmeier, C. A., Koch, E., 
Faleschini, M. T., De Mieri, M., Bauhart, M., Zahler, S., Hensel, A., Hamburger, M., 
Potterat, O., and Fürst, R. (2017) The Dual Edema-Preventing Molecular Mechanism of 
the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions. 
Planta Med. 83, 1–8 
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Appendices 
Appendix A: NMR Tables and Structures of Isolated Compounds 
Table A1: 1H and 13C spectroscopic data for auroside (La-1) from Lamium album, (CD3OD; 500 
MHz for 1H and 13C extracted from 1H-13C 2D inverse detected experiments; δ in ppm) 
 auroside 
 
Position δH mult (J in Hz) δC type 
1 5.76 d (1.7) 93.6 CH 
3 7.40 s 151.7 CH 
4 - 113.3 
5 - 69.6 qC 
6 2.10 dd (13.8, 6) 
2.60 dd (13.8, 6) 
46.4 CH3 
7 3.61 m  76.9 CH 
8  2.30 m 42.0 CH 
9 2.83 dd (10, 1.5) 49.9 CH 
10 0.98 d (7.4) 12.9 
11 - 166.1 qC 
12 3.77 s 50.5 CH3 
1’ 4.60 d (8.0) 99.4 CH 
2’ 3.24 dd (9.0, 8.0) 73.4 CH 
3’ 3.41 t (9.0) 76.0 CH 
4’ 3.33 m 70.4 CH 
5’ 3.37 m 76.6 CH 
6’ 3.70 dd (12.0, 6.0) 
3.93 dd (12.0, 6.0) 
61.3 CH2 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
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Table A2: 1H and 13C spectroscopic data for compounds methyltanshinoate (Sm-N2), cryptotanhinone (Sm-O2), tanshinone I (Sm-L2), 
dehydromiltirone (Sm-F1) and tanshinone IIA (Sm-H-xtl) from Salvia miltiorrhiza, (CDCl3; 500 MHz for 
1H and 13C extracted from 1H-13C 2D 
inverse detected experiments; δ in ppm) 
 methyltanshinoate
 
cryptotanshinone
 
tanshinone I
 
dehydromiltirone
 
tanshinone IIA
 
Position δH mult (J in 
Hz) 
δC type δH mult (J in 
Hz) 
δC type δH mult (J 
in Hz) 
δC type δH mult (J in Hz) δC type δH mult (J in 
Hz) 
δC type 
1 3.23 m  28.9 CH2 3.17 t (7.0) 29.3 CH2 8.70 d (8.0) 118.7 CH 7.84 br dt (10.0) 122.5 CH 3.15 t (7.0) 29.5 CH2 
2 1.81 m 19.2 CH2 1.75 m 19.0 CH2 7.53 br dd 
(8.0, 6.0) 
129.1 CH 6.28 br ddd (9.0, 
7.1, 4.9) 
132.1 CH 1.81 m 19.3 CH2 
3 1.75 m 
2.27 m 
34.1 CH2 1.62 m 37.8 CH2 7.32 d (6.0) 128.8 CH 2.24 br dd (4.5, 
2.0) 
35.9 CH2 1.64 m 37.9 CH2 
4 - 47.3 qC - 34.5 qC - 134.8 qC - 32.4 qC - 34.5 qC 
5 - 149.5 qC - 150.0 qC - 123.2 qC - 146.2 qC - 150.0 qC 
6 7.55 d (8.0) 135.4 CH 7.58 d (8.0) 132.4 CH 7.98 d (8.0) 131.9 CH 7.45 br d (8.0) 128.4 CH 7.60 br d (8.0) 135.4 CH 
7 7.47 d (8.0) 120.4 CH 7.44 d (8.0) 122.3 CH 8.05 d (8.0) 124.8 CH 7.20 d (8.0) 126.9 CH 7.50 br d (8.0) 120.4 CH 
8 - 127.4 qC - 127.4 qC - 129.6 qC - 132.4 qC - 127.4 qC 
9 - 128.3 qC - 126.6 qC - 126.9 qC - 125.5 qC - 126.2 qC 
10 - 144.9 qC  144.3 qC - 133.6 qC - 136.2 qC - 144.0 qC 
11 - 183.1 qC  183.2 qC - 183.4 qC - 182.5 qC - 183.1 qC 
12 - 175.6 qC  175.6 qC - 175.6 qC - 180.0 qC - 175.6 qC 
13 - 121.2 qC  120.0 qC - 121.0 qC - 143.5 qC - 121.1 qC 
14 - 161.8 qC  161.4 qC - 161.7 qC 7.06 s 137.7 CH - 161.7 qC 
15 - 141.8 qC 3.54 m 34.5 CH - 120.9 qC 2.98 br spt (6.9) 24.81 CH - 142.0 qC 
16 7.22 br d 
(1.3) 
141.3 CH 4.30 dd (9.0, 
6.0) 
4.84 t (9.0) 
81.4 CH2 7.27 d (1.5) 141.7 CH 1.13 d (6.9) 19.4 CH3 7.20 br s 120.1 CH 
17 2.25 s 8.7 CH3 1.32 d (7.0) 18.5 CH3 3.02 s 8.8 CH3 1.13 d (6.9) 19.4 CH3 2.24 br d (1.5) 8.6 CH3 
18 1.57 s 27.5 CH3 1.27 br d (1.5) 31.9 CH3 3.16 s 20.7 CH3 1.25 s 26.2 CH3 1.31 s 31.7 CH3 
19 - 176.9 qC 1.27 br d (1.5) 31.9 CH3   1.25 s 26.2 CH3 1.31 s 31.7 CH3 
20 3.66 s 52.3 CH3         
For 13C shifts, data was extrapolated by HSQC and HMBC contours.  
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
  
Structures of (a) methyltanshinoate, (b) cryptotanhinone, (c) tanshinone I, (d) 
dehydromiltirone, and (e) tanshinone IIA with atom numbering
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Table A3: 1H and 13C spectroscopic data for bergapten and dorstenin (compounds Dc-A1 and 
Dc-A2) from Dorstenia contrajerva, (CDCl3; 500 MHz for 
1H and 13C extracted from 1H-13C 2D 
inverse detected experiments; δ in ppm) 
 bergapten 
 
dorstenin 
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
2 - 161.1 qC - 161.5 qC 
3 6.19 d (9.9) 112.3 CH 6.30 d (9.7) 113.1 CH 
4 8.06 d (9.9) 139.6 CH 8.13 d (9.7) 139.1 CH 
4a - 105.5 qC - 107.1 qC 
5 -  149.9 qC - 148.7 qC 
6 - 112.6 qC - 113.8 qC 
7 - 158.4 qC - 158.5 qC 
8 7.05 s 93.4 CH 7.17 s 94.6 CH 
8a - 151.3 qC - 152.7 qC 
2’ 6.94 d (2.5) 146.2 CH 7.60 d (2.3) 145.1 CH 
3’ 7.51 d (2.5) 104.3 CH 7.07 m 104.9 CH 
1’’ 4.19 s 60.7 CH3 4.49 m 70.49 CH2 
2’’   2.11 m 
2.25 m 
34.5 CH2 
3’’   3.00 m 32.7 CH 
4’’   1.36 m 18.1 CH3 
2’’’   - 194.2 qC 
3’’’   5.42 s 100.3 CH 
4’’’   - 207.2 qC 
5’’’   - 88.9 qC 
6’’’   1.35 m 23.1 CH3 
7’’’   1.35 m 23.1 CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
 
(a) 
 
(b) 
 
Structures of (a) bergapten, and (b) dorstenin with atom numbering 
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Table A4: 1H and 13C spectroscopic data for 8-O-demethyl-homolycorine and 8-O-demethyl-6-O-
methyl-lycorenine (compounds Pl-K2 and Pl-K9) from Pancratium littorale, (DMSO-d6; 500 MHz 
for 1H and 13C extracted from 1H-13C 2D inverse detected experiments; δ in ppm) 
 8-O-demethyl-homolycorine 
 
8-O-demethyl-6-O-methyl-lycorenine 
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
1 4,75 dd (5.0, 1.5) 76.3 CH 4.09 dd (5.8, 1.8) 65.9 CH 
2 2.35 ov 
2.61 ov 
30.2 CH2 2.15 ov 
2.55 m 
31.0 CH2 
3 5.45 m 114.2 CH 5.37 m 115.0 CH 
4 - 140.3 qC - 140.6 qC 
4a 2.46 ov 65.8 CH 2.39 br d (9.0) 66.7 CH 
6 - 163.9 qC 5.35 br s 97.3 CH 
6a - 116.0 qC - 126.0 qC 
7 7.32 s 115.0 CH 6.66 s 114.0 CH 
8 - 146.0 qC - 145.4 qC 
9 - 151.2 qC - 146.7 qC 
10 7.01 s 111.2 CH 6.84 s 112.9 CH 
10a - 135.8 qC - 128.4 qC 
10b 2.62 dd (9.2, 1.5) 42.2 CH 2.28 dd (9.0, 1.8) 43.0 CH 
11 2.35 m 
2.42 m 
27.2 CH2 2.28 m 
2.42 m 
27.7 CH2 
12 2.12 dd (9.2, 8.9) 
3.00 ddd (9.5, 8.0, 2.5) 
55.2 CH2 2.13 ov 
3.00 ddd (8.8, 8.8, 3.0) 
55.9 CH2 
MeN (13) 1.89 s 42.7 CH3 1.95 s 43.7 N-CH3 
9-MeO (14) 3.85 s 55.4 CH3 3.73 s 55.5 O-CH3 
6-MeO (15)   3.36 s 54.5 O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
 
(a) 
 
(b) 
 
Structures of (a) 8-O-demethyl-homolycorine, and (b) 8-O-demethyl-6-O-methyl-lycorenine 
with atom numbering 
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Table A5: 1H and 13C spectroscopic data for 8-demethyoxy-10-O-methyl-hostasine and 10-O-
methyl-hostasine (compounds Pl-H11 and Pl-H15) from Pancratium littorale, (DMSO-d6; 500 
MHz for 1H and 13C extracted from 1H-13C 2D inverse detected experiments; δ in ppm) 
 8-demethyoxy-10-O-methyl-
hostasine
 
10-O-methyl-hostasine 
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
1 3.51 br s 76.6 CH 3.53 br s 76.4 CH 
2 4.05 br s 70.9 CH 4.04 br s 71.0 CH 
3 5.53 br s 119.5 CH 5.53 br s 119.5 CH 
4 - 145.5 qC - 139.5 qC 
4a 3.31 br s 65.5 CH 3.28 br s 65.8 CH 
6 - 169.4 qC - 170.1 qC 
6a - 117.8 qC - 110.3 qC 
7 7.24 s 105.7 CH - 151.3 qC 
8 - 150.6 qC - 141.8 qC 
9 - 153.5 qC - 158.3 qC 
10 7.26 s 106.8 CH 7.10 s 103.3 CH 
10a - 145.1 qC - 148.6 qC 
10b - 83.8 qC - 83.0 qC 
11 2.33 m 
2.45 m 
27.7 CH2 2.32 m 
2.44 m 
27.7 CH2 
12 2.20 q (8.8) 
2.92 td (8.8, 3.0) 
55.1 CH2 2.21 q (8.8) 
2.93 td (8.8, 3.1) 
55.2 CH2 
MeN (13) 1.49 s 42.8 N-CH3 1.55 s 42.9 N-CH3 
9-MeO (14) 3.88 s 55.9 O-CH3 3.90 s 56.4 O-CH3 
6-MeO (15) 3.85 s 55.9 O-CH3 3.76 s 60.9 O-CH3 
7-MeO (16) 3.85 s 55.9 O-CH3 3.96 s 62.0 O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
 
(a) 
 
(b) 
 
Structures of (a) 8-demethyoxy-10-O-methyl-hostasine, and (b) 10-O-methyl-hostasine with 
atom numbering 
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Table A6: 1H and 13C spectroscopic data for carinatine, lycorine, pseudolycorine, and 1-O-acetyl-pseudolycorine (compounds Pl-I10, Pl-I14, 
Pl-M1, and Pl-H18) from Pancratium littorale, (DMSO-d6; 500 MHz for 1H and 13C extracted from 1H-13C 2D inverse detected experiments; 
δ in ppm) 
 carinatine
 
lycorine
 
pseudolycorine
 
1-O-acetyl-pseudolycorine
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
1 4.39 m 66.0 CH 4.29 m 69.5 CH 4.28 m 70.8 CH 5.50 br s 71.9 CH 
2 3.65 m 81.2 CH 4.00 m 71.0 CH 4.04 m 72.0 CH 3.97 m 68.5 CH 
3 5.46 m 115.0 CH 5.39 m 118.1 CH 5.41 br s  118.8 CH 5.41 m 117.9 CH 
4 - 143.1 qC - 140.6 qC - 142.4 qC - 142.2 qC 
4a 2.64 br d (10.3) 60.3 CH 2.69 br d (10.5) 60.2 CH 2.66 br d (10.5) 61.4 CH 2.60 br d (10.5) 61.0 CH 
6 3.35 d (14.0) 
4.00 d (14.0) 
55.9 CH2 3.41 d (13.0) 
4.04 d (13.0) 
55.9 CH2 3.37 br d (13.8) 
4.05 br d (13.8) 
56.9 CH2 3.37 d (14.0) 
4.04 d (14.0) 
55.6 CH2 
6a - 127.8 qC - 129.2 qC - 127.3 qC - 126.5 qC 
7 6.64 s 110.9 CH 6.68 s 106.5 CH 6.68 s 111.8 CH 6.66 s 111.3 CH 
8 - 145.5 qC - 146.0 qC - 146.2 qC - 145.0 qC 
9 - 144.5 qC - 145.8 qC - 145.4 qC - 145.9 qC 
10 6.76 s 111.6 CH 6.81 s 104.6 CH 6.78 s 112.5 CH 6.59 s 111.1 CH 
10a - 126.2 qC - 128.9 qC - 129.0 qC - 126.8 qC 
10b 2.35 br d (10.3) 40.2 CH 2.54 m 39.6 CH 2.55 m 40.2 CH 2.75 br d (10.5) 38.4 CH 
11 2.40-2.54 m 27.7 CH2 2.40-2.50 m 27.8 CH2 2.45-2.53 m 28.5 CH2 2.47-2.53 m 27.8 CH2 
12 2.26 q (8.5) 
3.21 td (8.8, 1.6) 
52.8 CH2 2.31 q (8.5) 
3.19 td (8.5, 1.8) 
52.8 CH2 2.25 q (8.5) 
3.26 br t (8.5) 
53.8 CH2 2.28 q (8.5) 
3.23 br d (8.5) 
53.1 CH2 
13 3.72 s 55.7 O-CH3 5.94 br d (5.6) 100.0 CH2 3.77 s 56.4 O-CH3  3.72 s 55.5 O-CH3 
14       - 169.8 qC 
15       1.85 s 20.7 O-CH3  
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Structures of (a) carinatine, (b) lycorine, (c) pseudolycorine, and (d) 1-O-acetyl-pseudolycorine 
with atom numbering
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Table A7: 1H and 13C spectroscopic data for narcissidine, and 3-O-acetyl-narcissidine 
(compounds Pl-K7, and Pl-G17) from Pancratium littorale, (DMSO-d6; 500 MHz for 1H and 13C 
extracted from 1H-13C 2D inverse detected experiments; δ in ppm) 
 narcissidine 
 
3-O-acetyl-narcissidine 
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
 1 4.67 br s 66.0 CH 4.58 br t(2.5) 65.8 CH 
2 3.62 dd(3.5, 2.0) 80.7 CH 3.60 br t (2.3) 80.9 CH 
3 4.50 d (2.0) 66.3 CH 5.51 br s 67.6 CH 
4 - 140.4 qC - 136.7 qC 
4a 3.81 m 60.9 CH 3.77 ov 61.5 CH 
6 3.55 d (13.0) 
4.01 d (13.0) 
53.0 CH2 3.57 br d (13.1) 
3.97 br d (13.1) 
53.7 CH2 
6a - 128.4 qC - 129.5 qC 
7 6.82 s 110.4 CH 6.79 s 111.0 CH 
8 - 147.2 qC - 142.2 qC 
9 - 148.0 qC - 147.1 qC 
10 6.94 s 108.2 CH 6.95 s 109.2 CH 
10a - 129.2 qC - 129.3 qC 
10b 2.63 br d (11.0) 39.8 CH 2.57 br d (11.0) 40.1 CH 
11 5.67 ddd (2.0, 2.0, 1.5) 120.1 CH 5.87 br q (1.8) 125.6 CH 
12 3.49 ddd (14.0, 6.0, 2.0) 
3.89 ddd (14.0, 6.0, 2.0) 
60.7 CH2 3.51 br dd 
3,84 br dd  
60.9 CH2 
8-MeO (13) 3.77 s 56.3 O-CH3 3.73 s 55.5 O-CH3 
9-MeO (14) 3.80 s 56.2 O-CH3 3.77 s 55.5 O-CH3 
2-MeO (15) 3.41 s 57.7 O-CH3 3.40 s 57.2 O-CH3 
16   - 169.9 qC 
17   1.95 s 20.7 CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
 
(a) 
 
(b) 
 
Structures of (a) narcissidine, and (b) 3-O-acetyl-narcissidine with atom numbering 
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Table A8: 1H and 13C spectroscopic data for 10-deoxy-6(α)-hydroxy-hippeastidine, and 6-
hydroxy-hippeastidine (compounds Pl-G16, and Pl-I19) from Pancratium littorale, (DMSO-d6; 
500 MHz for 1H and 13C extracted from 1H-13C 2D inverse detected experiments; δ in ppm)  
 10-deoxy-6(α)-hydroxy-
hippeastidine
 
6-hydroxy-hippeastidine
 
Position δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
1 1.58 td (13.6, 4.4) 
2.45 dt (13.6, 3.5, 3.5) 
25.5 CH2 1.62 ov 
3.15 ov 
25.8 CH2 
2 1.37 m 
2.00 m 
26.7 CH2 1.34 ov 
1.92 ov 
26.7 CH2 
3 3.12 ov 77.0 CH 3.15 ov 76.5 CH 
4 1.10 q (12.0) 
1.85 m 
32.2 CH2 1.92 q (12.0) 
1.14 q (12.0) 
31.8 CH2 
4a 3.11 m 59.4 CH 3.34 m 60.0 CH 
6 4.87 s 87.8 CH 5.02 s 87.9 CH 
6a - 127.6 qC - 129.8 qC 
7 6.74 br s 112.2 CH 6.38 s 103.7 CH 
8 - 147.5 qC - 150.8 qC 
9 - 148.6 qC - 136.1 qC 
10 6.69 br s 106.0 CH - 147.8 qC 
10a - 140.5 qC - 125.6 qC 
10b - 42.2 qC - 46.3 qC 
11 1.40 m 
2.09 m 
33.9 CH2 1.56 m 
2.19 m 
31.6 CH2 
12 2.61 m 
3.16 m 
46.2 CH2 2.70 m 
3.30 m 
46.3 CH2 
8-MeO (13) 3.70 s 55.3 O-CH3 3.73 s 55.3 O-CH3 
9-MeO (14) 3.73 s 55.6 O-CH3 3.65 s 59.9 O-CH3 
3-MeO (15) 3.26 s 54.5 O-CH3 3.25 s 54.7 O-CH3 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
 
(a) 
 
(b) 
 
Structures of (a) 10-deoxy-6(α)-hydroxy-hippeastidine, and (b) 6-hydroxy-hippeastidine with 
atom numbering 
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Table A9: 1H and 13C spectroscopic data for daphnetin, chrysoeriol, and daphneolone 
(compounds Dgi-4-xtl, Dgi-12-xtl, and Dgi-Ed-8) from Daphne giraldii, (DMSO-d6; 500 MHz for 
1H and 13C extracted from 1H-13C 2D inverse detected experiments; δ in ppm) 
 daphnetin
 
chrysoeriol 
 
daphneolone
 
Position δH mult (J in 
Hz) 
δC type δH mult (J in Hz) δC type δH mult (J in Hz) δC type 
1     - 196.3 qC 
2 - 163.4 qC - 163.9 qC 2.91 dd (15.0, 
5.0) 
3.08 dd (15.0, 
8.0) 
45.3 CH2 
3 6.17 d (9.5) 112.2 CH 6.33 s 103.8 
CH 
4.05 spt 66.4 CH 
4 7.82 d (9.5) 146.7 CH - 182.0 qC 1.74 m 38.6 CH2 
5 6.99 d (8.5) 120.2 CH - 157.7 qC 2.63 m 
2.76 m 
31.0 CH2 
6 6.80 d (8.5) 113.7 CH 6.12 d (3.0) 99.2 CH   
7 - 146.7 CH - 164.7 qC   
8 - 133.5 CH 6.48 d (3.0) 94.2 CH   
9 - 145.0 qC - 162.1 qC   
10 - 113.9 qC - 104.0 qC   
3’-MeO 
(11) 
  3.85 s 56.2 O-
CH3 
  
1’   - 123.5 qC - 128.4 qC 
2’    7.28 d (2.0) 113.3 
CH 
7.84 d (8.8) 130.2 CH 
3’    - 147.0 qC 6.86 d (8.5, 2.0) 114.7 CH 
4’   - 147.1 qC - 161.5 qC 
5’   6.85 d (8.0) 112.5 
CH 
6.86 d (8.5, 2.0) 114.7 CH 
6’   7.35 dd (8.0, 2.5) 118.9 
CH 
7.84 d (8.8) 130.2 CH 
1’’     - 141.7 qC 
2’’      7.20 m 127.8 CH 
3’’      7.26 m 127.3 CH 
4’’     7.15 m 125.0 CH 
5’’     7.26 m 127.3 CH 
6’’     7.20 m 127.8 CH 
For 13C shifts, data was extrapolated by HSQC and HMBC contours. 
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Structures of (a) daphnetin, (b) chrysoeriol, and (c) daphneolone with atom numbering 
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Myotonic dystrophy type I (DM1) is a disabling neuromuscu-
lar disease with no causal treatment available. This disease is
caused by expanded CTG trinucleotide repeats in the 3UTR of
the dystrophia myotonica protein kinase gene. On the RNA
level, expanded (CUG)n repeats form hairpin structures that
sequester splicing factors such as muscleblind-like 1 (MBNL1).
Lackof availableMBNL1 leads tomisregulated alternative splic-
ing of many target pre-mRNAs, leading to the multisystemic
symptoms in DM1. Many studies aiming to identify small mol-
ecules that target the (CUG)n-MBNL1 complex focused on syn-
thetic molecules. In an effort to identify new small molecules
that liberate sequesteredMBNL1 from(CUG)nRNA,we focused
specifically on small molecules of natural origin. Natural prod-
ucts remain an important source for drugs and play a significant
role in providing novel leads and pharmacophores formedicinal
chemistry. In a new DM1 mechanism-based biochemical assay,
we screened a collection of isolated natural compounds and a
library of over 2100 extracts from plants and fungal strains.
HPLC-based activity profiling in combination with spectro-
scopicmethods were used to identify the active principles in the
extracts. The bioactivity of the identified compounds was inves-
tigated in a human cellmodel and in amousemodel ofDM1.We
identified several alkaloids, including the -carboline harmine
and the isoquinoline berberine, that ameliorated certain aspects
of theDM1pathology in thesemodels. Alkaloids as a compound
class may have potential for drug discovery in other RNA-medi-
ated diseases.
Myotonic dystrophy type I (DM1)4 is the most common
muscular dystrophy in the adult population, with a relatively
high prevalence of about 1:8000 (1). This autosomal domi-
nantly inherited disease affects multiple organs, most promi-
nently the skeletal muscle, with wasting, weakness, and an
inability to relax (myotonia) (1). Currently, there is no effective
treatment for this disabling disease. The pathomechanism of
DM1 is linked to a CTGn expansion in the 3 UTR of the dys-
trophia myotonica protein kinase (DMPK) gene (2, 3), leading
to a toxic gain-of-functionRNA (4, 5). ThemutantDMPK tran-
script is entrappedwithin nuclei of affected cells, where it forms
aggregates (foci) with splicing factors such as muscleblind-like
1 (MBNL1) (6, 7). Bound to mutant DMPK (CUG)n RNA,
MBNL1 is no longer available for correct splicing of its target
pre-mRNAs (8, 9). Thus, the splicing of a multitude of
pre-mRNAs is misregulated, including the skeletal muscle
chloride channel (CLCN1), the insulin receptor (INSR), sarco-
plasmic/endoplasmic reticulumCa2ATPase 1 (SERCA1), and
cardiac troponin T type 2 (TNNT2) pre-mRNA (10–16). Inter-
estingly, the missplicing of some pre-mRNAs can be linked
directly to a certain disease symptom, e.g.myotonia in the case
of the CLCN1 pre-mRNA. MBNL1 sequestration by (CUG)n
RNAcauses inclusion of alternative exon 7a, leading to a shift in
the open reading frame and to premature termination of trans-
lation (12, 13). As a result, functional CLCN1 protein is
decreased, which leads to the myotonia characteristic of DM1
(17).
To date, most therapeutic strategies toward DM1 focused
either on the development of agents degrading the toxic RNA
or blocking its pathogenic interaction with proteins; these
strategies are reviewed in Ref. 18. Antisense oligonucleotides
targeting the DMPK-(CUG)n transcripts (5, 19) and viral over-
expression ofMBNL1 (20) have been shown to reverse the toxic
RNA effect in vitro and in vivo. Compared with the antisense
oligonucleotide and gene therapy approaches, an advantage of a
suitable small molecule is its potential to penetrate all tissues
affected in DM1 patients and its potential oral bioavailability. A
variety of small molecules have been described that inhibit
the (CUG)n-MBNL1 complex and improve DM1-associated
molecular defects in vitro and in some cases also in vivo. Several
approacheswere successful in identifying smallmolecules, such
as screening of known nucleic acid binders (21), rational design
of small molecules based on the structure of (CUG)n RNA (22),
rational design of oligomers of (CUG)n RNA binders by modu-
lar assembly (23, 24), combinatorial chemistry (25, 26), and
high-throughput screening (27, 28).
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Most of the described (CUG)n RNA-targeting molecules are
synthetic. Only a few small molecules of natural origin have
been described, such as neomycin B (21) and lomofungin (27).
To our knowledge, our study is the first to focus on small mol-
ecules of natural origin and represents the first screening of
natural extracts in DM1 drug discovery. As RNA is still a rela-
tively unexploited drug target, natural products present a rich
source of new and diverse RNA binders (29). Interestingly,
many known RNA-binding drugs are of natural origin, such as
antibiotics that target the bacterial ribosomal RNA (30). Hence,
it is of interest to investigate natural products in drug discovery
for RNA-mediated diseases such as DM1.
We describe here the screening of isolated natural com-
pounds and extracts from plants and fungal strains in a novel
CUG78-MBNL1 complex inhibition assay. We identified sev-
eral alkaloids as CUG78-MBNL1 complex inhibitors. Testing
their bioactivity in a humanmyoblastmodel of DM1 (31) and in
the human skeletal -actin long repeat (HSALR) mouse model
of DM1 (4) showed that the alkaloids ameliorate certain aspects
of the DM1 pathology.
Results
CUG78-MBNL1 Complex Inhibitors of Natural Origin—A
collection of 70 isolated natural compounds and a library con-
taining 2128 extracts from plants and fungi were screened with
a novel in vitro CUG78-MBNL1 complex inhibition assay (Fig.
1a). Biotinylated CUG78 RNA was immobilized on Neutr-
Avidin-coated plates that were then co-incubated with
MBNL1-HIS and compounds or extracts. The plates were
washed to remove unbound components, and MBNL1-HIS in
complex with immobilized CUG78 RNA was detected via an
anti-HIS and a secondary HRP-conjugated antibody. The
library of isolated natural compounds was screened at 100 M
concentration and led to the identification of the isoquinoline
alkaloid berberine (Fig. 1b) as a complex formation inhibitor
with an IC50 of 86.3 5.8 M (Fig. 1c). Another alkaloid, isain-
digotone, showedweak inhibitory activity at 100Mconcentra-
tion. From the extract library we identified 21 extracts that
inhibited CUG78-MBNL1 complex formation by 40–82% at a
concentration of 100 g/ml compared with solvent-only con-
trols. Seven extracts were chosen for fractionation. To identify
the active principles in these extracts, we used an approach
referred to as HPLC-based activity profiling. It combines the
separation of complex mixtures with spectroscopic data
recorded online and with biological information obtained in
parallel from time-based microfractionation and a subsequent
bioassay (32). In addition, offlinemicroprobeNMRanalysiswas
used to fully establish the structure of active compounds. The
alkaloid harmine (Fig. 1b) was identified as an active constitu-
ent in amethanolic extract from the roots of Peganumharmala
(Nitrariaceae) (Fig. 2a). Besides, two closely related diterpene-
quinones, methylenetanshinquinone and 1,2-dihydrotanshin-
quinone,were detected in the active fractions of an ethyl acetate
extract from roots of Salvia miltiorrhiza (Lamiaceae) (Fig. 2b).
A commercial sample of harmine had an IC50 of 132.4 9.3M
(Fig. 1c), whereas the two diterpenequinones, also commer-
cially obtained, showed weak inhibitory activity at 100 M con-
centration. The inhibitory activity of the remaining extracts
could be assigned to tannins. These extracts lost their complex
inhibitory effect after filtration through a polyamide cartridge
to remove polyphenolic tannins.
The alkaloids berberine and harminewere chosen for further
study.We tested a small set of structural analogues of berberine
and identified coralyne (Fig. 1b), a planar berberine derivative,
as a stronger CUG78-MBNL1 complex inhibitor with an IC50 of
17.8  0.2 M (Fig. 1, b and c). As reference compounds,
Hoechst 33258 and neomycin B, two known nucleic acid bind-
FIGURE 1. Screening for small molecules of natural origin that disrupt the CUG78-MBNL1 complex in vitro. a, the CUG78-MBNL1 inhibition assay detects
the amount of MBNL1 bound to CUG78-RNA. b, structure of the identified alkaloids berberine, coralyne, and harmine. c, CUG78-MBNL1 complex inhibition
curves. OD, optical density; TMB, 3,3,5,5-tetramethylbenzidine.
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ers, were tested and had IC50 values of 195.5 3.0M and 5.3
0.6 M, respectively.
Identified Alkaloids Improve Splicing in Human DM1
Myoblasts—The alkaloids identified in our in vitro screening
assay were tested for their ability to ameliorate splicing in a
human DM1myoblast cell line containing a CTG1300 repeat in
the 3 UTR of the DMPK gene (31). The WT control cell line
contained a normal repeat length in the same locus. Differenti-
ated DM1myoblasts were treated with the identified alkaloids,
and alternative splicing was analyzed by a quantitative PCR
(qPCR) method using two primer pairs. This method allowed
real-time quantitation of the inclusion/exclusion of an investi-
gated alternatively spliced exon.
Berberine improved the splicing of the TNNT2 pre-mRNA
exon 5. In 80Mberberine-treatedDM1myoblasts, the splicing
was close to that of the WT control myoblasts. TNNT2
pre-mRNA splicing was rescued by 62.1%  3.2% (p  0.001,
Student’s t test, 20 M), 75.1% 2.8% (p 0.0006, 40 M), and
86.2% 0.8% (p 0.0003, 80M) through berberine treatment
(Fig. 3a). However, berberine treatment had a negative effect on
INSR pre-mRNA exon 11 splicing (Fig. 3a) in DM1 myoblasts.
In contrast to berberine, harmine improved both the splicing of
the TNNT2 pre-mRNA exon 5 by 53.3% 3.5% (p 0.003, 20
M), 76.8% 1.6% (p 0.0005, 40M), and 66.1% 1.2% (p
0.0009, 80 M), and, furthermore, the splicing of the INSR
pre-mRNA exon 11 by 6.3%  0.3% (p  0.003, 40 M) and
55.4%  3.3% (p  0.0003, 80 M) (Fig. 3, a and b). The alter-
native splicing results obtained with the qPCR method for
berberine and harmine were confirmed with classical RT-
PCR and visualization of two alternatively spliced isoforms
of the INSR and TNNT2 pre-mRNA on 3% agarose gels (Fig.
3, c and d). The synthetic berberine derivative coralyne and
the two diterpenequinones, identified together with harmine
during the extract screening, showed no effect on splicing in
the DM1 cell model.
To investigate the selectivity of berberine and harmine, we
tested their effect on alternative splicing of two genes known to
be alternatively spliced but independent of MBNL1, i.e. ATE1
and FHL1 (Fig. 3, e and f) (33).We analyzed exon 7 inclusion in
theATE1 pre-mRNA, which was close to 33% for theWT cell
line and close to 40% in the DM1 cell line. Exon 5 inclusion in
the FHL1 pre-mRNA was close to 0.1–0.2% for both the WT
and the DM1 cell line. The levels of alternative exon inclu-
sion in berberine- and harmine-treated (both at 20 M and
80 M) myoblasts were in the range of the levels of vehicle-
treated WT and DM1 control myoblasts. The qPCR analysis
of the harmine effect on TNNT2 pre-mRNA alternative
splicing in WT myoblasts showed an enhancement of
MBNL1-dependent splicing analogous to harmine-treated
DM1 myoblasts. This effect, however, was only observed
with the qPCR method and not visible by the classical RT-
PCR method (Fig. 3, b and d).
The cellular toxicity of berberine and harmine was deter-
mined in a viability assay with C2C12 mouse myoblasts. Con-
centrations (toxicity IC50) were determined at which half of the
myoblasts remained viable after 2 days of compound incuba-
tion. Berberine yielded a toxicity IC50 of 212.1  18.3 M and
harmine one of 123.3 4.6 M. Mitomycin C was measured as
reference compound with a toxicity IC50 of 20.4  1.6 M.
Although the IC50 and toxicity IC50 values were relatively close
for both alkaloids, both compounds showed an effect on alter-
native splicing in the myoblast model at concentrations signif-
icantly lower than the IC50 and toxicity IC50 values, e.g. at 20M
(Fig. 3).
Harmine Reduces Focus Formation in Human DM1
Myoblasts—To examine whether the alkaloids berberine and
harmine reduce the sequestration of MBNL1 by (CUG)n RNA,
focus formation was investigated in the two human myoblast
cell lines. Immunofluorescence staining in both the WT (nor-
FIGURE 2. a, HPLC-based activity profiling of the P. harmalamethanol extract.
Shown on the y axis are the online HPLC-UV trace at 254 nm (black) and the
A450 signal from the CUG78-MBNL1 inhibition assay (red). The x axis shows the
time inminutes. 29 fractions were collected, 1 min each. The inhibitory activ-
ity of the fraction atminutes 8–9was assigned to the alkaloid harmine. Based
on online MS and UV spectroscopic data, the other major peak eluting at 6.6
minwas assigned toharmol. Theactivity in theearly-eluting fraction, 2–3min,
did not correspond to any UV peak and was not further investigated. OD,
optical density; mAU, milli absorbance units. b, HPLC-based activity profiling
of the ethyl acetate extract of S. miltiorrhiza. The inhibitory activity of the
fraction at minutes 26–27 was assigned to two diterpenequinone isomers,
1,2-dihydrotanshinquinone and methylenetanshinquinone.
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FIGURE 3. Representative qPCR splicing data for WT and DM1 control myoblasts and treated human myoblasts. The percentage of alternative exon
inclusion is shown.a, berberine improves the splicingof the TNNT2pre-mRNAbut has a detrimental effect on the INSRpre-mRNA splicing.b, harmine improves
the splicingof both the TNNT2 andof the INSRpre-mRNA.Harmine also promotesMBNL1-dependent splicing in treatedWTmyoblasts, as shown for the TNNT2
pre-mRNA. c and d, RT-PCR analysis of INSR and TNNT2 pre-mRNA alternative splicing. Visualized on 3% agarose are two alternative splicing isoforms for both
pre-mRNAs in untreated WT and DM1 control myoblasts and DM1 myoblasts treated with (c) berberine and (d) harmine. The harmine effect on MBNL1-de-
pendent splicing in treated WT myoblasts was not visible with this method, as shown for the TNNT2 pre-mRNA. e and f, berberine and harmine do not affect
alternative splicing of MBNL1-independently regulated ATE1 and FHL1 pre-mRNAs in treated DM1myoblasts compared with untreated WT and DM1 control
myoblasts. **, p 0.01; ***, p 0.001; ****, p 0.0001.
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mal CUG repeat length) and the DM1 (CUG1300) cell line
showed that MBNL1 was mainly localized to the nuclei. In the
DM1 cells, punctate staining of MBNL1 within the nucleus
could be co-localized in foci with (CUG)n RNA, visualized by
fluorescence in situ hybridization. Treatment with 80 M
harmine significantly reduced (p 0.00005, Student’s t test) the
quantity of foci in DM1myoblasts (Fig. 4a) to 0.9 0.2 foci per
nucleus compared with DMSO-treated DM1 myoblasts with
4.7  0.3 foci per nucleus (Fig. 4, a and b). Harmine-treated
myoblasts lost their punctate nuclear MBNL1 staining,
indicative of MBNL1 release from the toxic (CUG)n RNA,
although the nuclear MBNL1 staining pattern of WT myo-
blasts was not regained. We analyzed by Western immuno-
blotting whether treatment with harmine reduced the levels
FIGURE 4.Analysis of foci with FISH and immunofluorescence. a, harmine reduces the amount of foci at 80M concentration, whereas berberine does not
reduce foci. For each condition, (CUG)n RNA staining (red), MBNL1 staining (green), and a merge of both with nuclear DAPI staining (blue) is shown. Vehicle-
treated controlWT andDM1myoblasts and compound-treated (80M)myoblasts are shown. b, quantification of the number of foci in humanDM1myoblasts
either treated with vehicle or alkaloids at 80 M. ****, p 0.0001.
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of MBNL1 in cell lysates of treated DM1 myoblasts to
account for the reduced nuclear staining and found that
harmine in fact increased the total levels of MBNL1 in
treated DM1 myoblasts compared with vehicle-treated con-
trol DM1 myoblasts (Fig. 5, a and b). An increase in MBNL1
levels was also observed in harmine-treated WT myoblasts
(Fig. 5, c and d). 80 M berberine treatment of DM1 myo-
blasts led to a statistically insignificant increase (p  0.099)
in the number of foci to 5.8 0.9 foci per nucleus in the DM1
myoblast cell line (Fig. 4, a and b).
Identified Alkaloids Ameliorate Splicing of CLCN1 Pre-
mRNA in HSALR Mice—Next, we treated HSALR mice, a DM1
model containing a CTG250 repeat expressed under a human
skeletal actin promoter (4), with the identified alkaloids. The
compounds were tested for their ability to restore splicing of
CLCN1 (12, 13) and SERCA1 (15) pre-mRNA in quadriceps
muscle. MBNL1 promotes the exclusion of the alternatively
spliced exon 7a of the CLCN1 pre-mRNA and promotes the
inclusion of exon 22 of the SERCA1 pre-mRNA (12, 13, 15).
Vehicle-treated WT mice at the age of 10–12 weeks showed a
CLCN1 pre-mRNA exon 7a inclusion of 5.0% 0.5%, whereas,
in vehicle-treated HSALR mice, the inclusion level was elevated
to 40.9%  2.5%. The level of SERCA1 pre-mRNA exon 22
inclusion in WT mice was at 83.9%  2.9%. In HSALR mice,
exon 22 inclusion was decreased to 24.8%  2.7%. We first
tested berberine, which, at a dose of 20 mg/kg, led to reduced
activity and decreased body temperature, which urged us to
lower the dose. Treatment with 5 mg/kg and 10 mg/kg of ber-
berine did not result in any significant splicing improvement.
We then tested two close derivatives of berberine, dihydrober-
berine (DHB) and palmatine, with higher reported LD50 values.
DHB improved the splicing of the CLCN1 pre-mRNA at a dose
of 10 mg/kg by 32.5%  2.9% (p  0.0008, Student’s t test),
whereas 5 mg/kg showed no statistically significant effect (Fig.
6a). The CLCN1 splicing improvement with 10 mg/kg DHB
was confirmed by classical RT-PCR and analysis of splicing iso-
forms on a 3% agarose gel (Fig. 6d). Palmatine treatment
improved CLCN1 pre-mRNA splicing at a dose of 40 mg/kg by
34.8% 2.1% (p 0.0009) and at a dose of 25mg/kg by 25.3%
0.7% (p 0.0017), whereas 10mg/kg did not show a significant
effect (Fig. 6b). Harmine treatment at a dose of 40 mg/kg
decreased CLCN1 pre-mRNA exon 7a inclusion by 31.2% 
1.7% (p 0.0003) and did not significantly improve splicing at
a dose of 20 mg/kg (Fig. 6c). Side effects observed during
harmine treatment were transient tremors. DHB, palmatine,
and harmine had no significant effect on SERCA1 pre-mRNA
splicing (Fig. 6).
CLCN1 Protein Levels in Quadriceps Muscle of WT, HSALR,
andTreatedHSALRMice—Weexamined byWestern immuno-
blotting analysis whether the high-dose alkaloid treatments,
FIGURE 5. a, Western blot showing MBNL1 protein levels of DM1 myoblasts treated with 40 and 80 M harmine, of vehicle-treated DM1 myoblasts, and of
vehicle-treatedWTmyoblasts (left to right).b, quantificationofMBNL1band intensities normalized to laminB. Themeans of three replicates for each condition,
including the standard deviation, are shown. c, Western blot showingMBNL1 protein levels ofWTmyoblasts treatedwith vehicle or 40 and 80Mharmine (left
to right). d, quantification ofMBNL1 band intensities normalized to lamin B. Themeans of three replicates for each condition, including the standard deviation,
are shown. *, p 0.05; **, p 0.01.
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which had ameliorated CLCN1 pre-mRNA splicing, also
increased the protein levels of the full-length CLCN1 channel
in vivo. CLCN1 protein levels in quadriceps muscle of four
vehicle-treated HSALR mice were decreased by 29.1% 
12.4% (p 0.023, Student’s t test, n 4, three immunoblots)
compared with four vehicle-treatedWTmice (Fig. 7). Treat-
ment of HSALR mice with 10 mg/kg DHB raised CLCN1
protein levels by 27.1% 16.1% (p 0.095, n 4) compared
with levels of vehicle-treated HSALR mice (Fig. 7). Although
the CLCN1 protein levels of DHB-treated HSALR mice were
close to WT levels, the effect did not reach statistical signif-
icance. Both palmatine and harmine high-dose treatments of
40 mg/kg did not increase the CLCN1 protein levels in
HSALR mice (Fig. 7).
Analysis of Internalized Nuclei in GastrocnemiusMuscle Sec-
tions of Vehicle-treated WT, HSALR, and Harmine-treated
HSALRMice—Despite the very short treatment duration of only
14–16 h (two injections at a 12-h interval), we wished to exam-
ine whether the most promising small molecule, harmine, also
improved the histology in gastrocnemius muscle of harmine-
treated mice (Fig. 8). Different histological parameters were
analyzed, most importantly the percentage of fibers with inter-
FIGURE 6. Representative qPCR splicing data for vehicle-treatedWT andHSALRmice and compound-treatedHSALRmice (quadricepsmuscle). Shown
is the percentage of exon 7a (CLCN1) and exon 22 (SERCA1) pre-mRNA inclusion. The alkaloids improve the splicing of CLCN1, whereas the splicing of SERCA1
is unchanged. a, DHB treatment. b, palmatine treatment. c, harmine treatment. d, alternative splicing of the CLCN1 pre-mRNA analyzed by RT-PCR and
visualized on 3% agarose gel. Shown are two alternative splicing isoforms in vehicle-treated control mice and DHB-treated HSALR mice. **, p 0.01; ***, p
0.001.
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nalized nuclei, where no difference was detected between vehi-
cle-treated and harmine-treated HSALR mice after this short
treatment duration.
Discussion
We report the discovery of several plant-derived alkaloids as
novel bioactive small molecules with therapeutic potential for
DM1. Through inhibition of the (CUG)n-MBNL1 complex, the
alkaloids ameliorate certain aspects of the DM1 pathology. Our
screening of natural products identified the alkaloids berberine
and harmine, which were chosen for further study. Interest-
ingly, both have been described previously to bind to specific
RNA structures, such as double-stranded RNA, tRNA, and
poly(A) RNA (34–37). The berberine derivative coralyne has
been described as a complete intercalator for double-stranded
RNA and berberine as a partial intercalator (36). We therefore
hypothesize that the binding of these three aromatic alkaloids
to the double-stranded (CUG)n RNAmay involve intercalation
because of planarity. Aromatic alkaloids such as berberine,
coralyne, and harmine might be of particular interest for RNA
drug discovery, as they can interact with RNA via stacking
(intercalation), hydrogen bonding, or electrostatic interaction
(38). To our knowledge, in the context of DM1, no alkaloids
have been described so far. An in vitro screening study by Chen
et al. (28) yielded six hits of which four were alkaloids or alka-
loid derivatives of the opioid- and ergot alkaloid-type, but none
of these alkaloids could be confirmed in a secondary assay .
Berberine and harmine showed partially positive effects on
splicing and focus formation in a human DM1 cell line.
Harmine showed positive effects inmost of the studiedmodels.
It inhibited CUG78-MBNL1 complex formation in vitro and
ameliorated the pre-mRNA splicing of both the INSR exon 11
FIGURE7.a,Westernblot showingCLCN1protein levels of (i) vehicle-treatedWTmice, (ii) vehicle-treatedHSALRmice, and (iii–v) compound-treatedHSALRmice.
b, quantificationof CLCN1band intensities normalized to laminB. Themeansof four replicates for each condition, including the standarddeviation, are shown.
*, p 0.05.
FIGURE8. Shown is the analysis of internalizednuclei byH&E stainingof 8-m
mouse gastrocnemius muscle cross-sections of 10-week-old (a) vehicle-
treated WT mice, (b) vehicle-treated HSALR mice, and (c) HSALR mice after
treatment by two injections of 40 mg/kg harmine at a 12-h interval. d, quan-
titative analysis of the percentage of muscle fibers with internalized nuclei.
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andTNNT2 exon 5 in the humanDM1myoblast cell line,where
it also reduced the formation of foci without decreasing
MBNL1 protein levels. Interestingly, harmine enhanced
MBNL1-dependent alternative splicing to a comparable rela-
tive extent in both DM1 and WT myoblasts, indicating that
harmine does not act primarily via (CUG)n-MBNL1 complex
disruption but, rather, via another mechanism leading to
increased MBNL1 protein levels. We could not detect a signif-
icant difference of TNNT2 pre-mRNA splicing in myotubes
upon harmine treatment, although a trend toward MBNL1-
mediated alternative splicing was visible (data not shown).
Harmine also improved the splicing of CLCN1 pre-mRNA in
the HSALR DM1mousemodel at a high dose of 40mg/kg. Even
though 40mg/kg harmine treatment amelioratedCLCN1 splic-
ing in HSALR mice, it did not affect the histology of these mice.
This was, however, expected because of the short treatment
duration of only 14–16 h. Berberine did not perform as well as
harmine in the studied models. Although it was a stronger
CUG78-MBNL1 complex inhibitor than harmine, it only
improved the splicing of the TNNT2 pre-mRNA in the DM1
myoblast cell line, whereas the splicing of the INSR pre-mRNA
was worsened in treated DM1 myoblasts. This undesirable
splicing effect of berberine might be due to insufficient selec-
tivity of berberine for the (CUG)n RNA over the MBNL1 bind-
ing motifs in pre-mRNAs and, therefore, interference with
MBNL1-mediated splicing. MBNL1-targeted pre-mRNAs as
the toxic DMPK-(CUG)n transcripts have similar MBNL1
binding motifs (39). Interestingly, the berberine derivative
coralyne was an even stronger CUG78-MBNL1 complex inhib-
itor than berberine but showed no effect on splicing in theDM1
cell model. Coralyne is a nonspecific intercalator for double-
stranded RNA (36). Its insufficient selectivity for the (CUG)n
RNAover other double-stranded RNAsmight be the reason for
lacking specific bioactivity. Like coralyne, the two identified
diterpenequinones, methylenetanshinquinone and 1,2-dihy-
drotanshinquinone, lacked bioactivity. As the two planar diter-
penequinones were poorly water-soluble, they precipitated at
higher concentrations in the screening assay and precipitated
from solution in cell culture at concentrations of 20 and 40 M.
Among all identified compounds during our screening of nat-
ural products, planarity and aromaticity turned out to be com-
mon features, and the partly double-stranded (CUG)n RNA tar-
get selects for planar molecules with intercalating properties.
The evaluation of the alkaloids berberine, dihydroberberine,
palmatine, and harmine in the HSALR mouse model showed
promising results. Most interestingly, two alkaloids of the ber-
berine type, DHB and palmatine, and the alkaloid harmine sig-
nificantly improved the splicing of the CLCN1 pre-mRNA in
this mouse model. The alkaloid DHB was the most active alka-
loid, as it improved CLCN1 exon 7a splicing at a dose of 10
mg/kg. However, these alkaloids are not suited for therapeutic
application themselves. Their relatively low potency and toxic-
ity are issues that require medicinal chemistry optimization.
Berberine has been described as an inhibitor of complex I in the
mitochondrial respiratory chain (40). Hence, decreased meta-
bolic activity might account for the side effects we observed
upon treatmentwith berberine and its derivatives at high doses,
i.e. reduced activity and decreased body temperature. The
effect of berberine on thermoregulation in mice has been
described previously by Jiang et al. (41). In harmine-treated
mice we observed tremors after administration. Harmine has
been described as a tremorogenic substance (42). Berberine, its
derivatives DHB and palmatine, as well as harmine exert CNS
effects given that they are monoamine oxidase inhibitors (43,
44). These side effects need to be addressed bymedicinal chem-
istry modifications. However, the fact that these alkaloids pen-
etrate the blood-brain barrier stirs hope for a future small-mol-
ecule therapy that also ameliorates the DM1-associated CNS
pathology. Moreover, the identified molecules help to further
understand the characteristics of small molecules that interact
with toxic (CUG)n RNA and provide new chemical scaffolds for
medicinal chemistry studies. Particularly harmine, with its low
molecular weight of 212.25 Da, offers an appealing starting
point for chemical modifications. Harmine furthermore repre-
sents an interestingmolecule, as its biological effect is likely not
mediated only by liberation of MBNL1 from toxic (CUG)n
RNA, which was initially assumed based on results from the in
vitroCUG78-MBNL1 inhibition screening assay, but mainly via
another, yet unidentified mechanism leading to an increase in
MBNL1 protein levels in treated myoblasts. This effect will be
investigated inmore detail in follow-up studies. Our study thus
contributes to further progress in small-molecule drug discov-
ery for this disabling neuromuscular disease.
Experimental Procedures
Statistical Analysis—Unless otherwise stated, results are
expressed as mean  S.D. of n  3 independent experiments.
Comparisons between two conditions were performed using
Student’s t test with a 0.05 confidence level accepted for statis-
tical significance (*, p  0.05; **, p  0.01; ***, p  0.001; ****,
p 0.0001).
Compounds and Extracts—The compounds and extracts
screened in this study were part of natural product libraries
established at the Division of Pharmaceutical Biology of the
University of Basel. One library contained 70 pure natural com-
pounds as 10 mM solutions in DMSO, and a second library
consisted of 2128 extracts from plants and fungi archived as 10
mg/ml solutions in DMSO (32). Harmine hydrochloride was
purchased from TCI Europe (H0002). Berberine chloride
(B3251), palmatine chloride hydrate (361615), and coralyne
sulfoacetate (S424536) were obtained from Sigma-Aldrich.
Dihydroberberine (80429) was purchased from PhytoLab
GmbH. Methylenetanshinquinone (QP-393) and 1,2-dihydro-
tanshinquinone (QP-1166) were obtained from Quality Phyto-
chemicals LLC (East Brunswick, NJ). The reference substances
neomycin B (N1876), Hoechst 33258 (B2883), and mitomycin
C (M4287) were ordered from Sigma-Aldrich.
MBNL1 Preparation—MBNL1 cDNA (an isoform with
amino acids 1–382) was kindly provided by Maurice Swanson
(9) (University of Florida). The pGEX-6P-MBNL1-N-His
(amino acids 1–253) construct used in this study was cloned
according to Yuan et al. (9), and protein expression and purifi-
cation were performed similar to the procedure published by
Yuan et al. (9).MBNL1-HISwas stored in a buffer containing 10
mM Tris (pH 7.4), 50 mM NaCl, and 1 mM DTT. Protein con-
centration was determined with a NanoDrop spectrophotom-
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eter and a BCA assay (Sigma). The purity of MBNL1-HIS was
evaluated by means of SDS-PAGE followed by Coomassie
staining. MBNL1-HIS aliquots were snap-frozen in liquid
nitrogen and stored at70 °C.
CUG78 RNA Preparation—Genomic DNA was isolated
from a patient blood sample (with informed consent) with
the Puregene Blood Core Kit B (Qiagen) according to
the protocol of the manufacturer. A CTG78-containing
genomic DMPK fragment was PCR-amplified with HOT Start
DNA polymerase (Solis BioDyne) and the following primers:
DMPK forward, 5CAGCTCCAGTCCTGTGATCC3; DMPK
reverse, 5CTGGCCGAAAGAAAGAAATG3. The amplicon
was agarose gel-purified with the QIAquick gel extraction kit
(Qiagen). The purified DNA fragment was cloned by TA
cloning with the pCR II-TOPO plasmid vector in Dh5 bac-
terial cells. The plasmid was purified with the QIAprep spin
miniprep kit (Qiagen) and used as a template for PCR ampli-
fication with the following primers: T7 CUG forward,
5TAATACGACTCACTATAGGCAGCTCCAGTCCTGTG-
ATCC3; and T7 CUG reverse, 5TAATACGACTCAC-
TATAGGCTGGCCGAAAGAAAGAAATG3. The amplified
DNAwas purifiedwith theQIAquick PCRpurification kit (Qia-
gen). 200 ng of DNA was used as a template for in vitro RNA
transcription with the MEGAscript T7 transcription kit
(Ambion). CUG78 RNAwas biotin-labeled by addition of 1.875
mM biotin-14-CTP (37.5 nmol). RNA quality and purity was
tested by visualization of RNA on 8 M urea/Tris borate-EDTA
5% polyacrylamide gels.
CUG78-MBNL1 Inhibition Assay—Wash steps were per-
formed at room temperature with 150 l of wash buffer/well
(25 mM Tris (pH 7.4), 80 mM NaCl, 1 mM MgCl2, 0.5 mM DTT,
0.05% Tween 20, 1.5 mg/ml BSA, and diethylpyrocarbonate-
treated water) and incubation steps with 50 l of incubation
buffer/well (wash buffer  25 units/ml RNasin (Promega)) at
30 °C on a BIOSAN plate shaker at 300 rpm. Reacti-Bind Neu-
trAvidin-coated 96-well plates (Pierce) were prewashed once.
Wash buffer was removed, and incubation buffer containing 25
ng of biotinylated CUG78 RNA was added/well. After incuba-
tion for 1 h, the plates were washed twice. Wash buffer was
removed, and 45 l of incubation buffer containing 300 ng of
MBNL1-HIS was added, followed by addition of 5 l of 10
concentrated compound or 5 l of DMSO/water for controls.
After washing wells twice, mouse anti-HIS antibody (1:2000,
GEHealthcare, 27-4710-01) was incubated for 1 h. Twowashes
preceded 1-h incubation with goat anti-mouse-HRP antibody
(1:8000, Jackson ImmunoResearch Laboratories, 115-035-174).
After two final wash steps, 70 l of 3,3,5,5-tetramethylbenzi-
dine substrate (Thermo Scientific) was added/well at room
temperature. The colorimetric reactionwas performed at 30 °C
and 700 rpm for 3–5 min and stopped with 70 l of 0.15 M
H2SO4/well. The optical density was read at 450-nm wave-
length with aMolecular Devices plate reader. Inhibition curves
were fitted with Prism software.
HPLC-based Activity Profiling of Extracts—HPLC-based
activity profilingwas performed on aWaters 2695Alliance sep-
aration module equipped with a Waters 996 photodiode array
detector and a C18 SunFire column (3.0  150 mm, 3.5 m).
Themobile phase consisted of 0.1% formic acid in H2O (A) and
MeCN (B). A gradient of 5–100% B in 30 min was applied. The
flow rate was 0.4ml/min. 900g of extract was injected in three
portions, and time-based microfractions were collected into a
deep-well 96-well microtiter plate (29 fractions of 60 s each)
with a Gilson FC204. The microtiter plate was dried in a Gene-
vac EZ-2 evaporating system at 35 °C overnight. The dried frac-
tions were taken up in 16 l of DMSO, and 2 l was used in the
CUG78-MBNL1 inhibition assay.
Myoblast Splicing Assay—Two human fibroblast cell lines
with a doxycycline-inducible MyoD construct for differentia-
tion into myoblasts were kindly provided by Denis Furling
(Université Pierre etMarie Curie-Paris, Paris, France) (31). The
WT control cell line was derived from a 19-year-old healthy
individual with a normal CTG repeat length in the DMPK
locus, whereas the DM1 cell line was derived from an 11-year-
old individual with a CTG1300 repeat length in the same locus.
Fibroblasts were grown in growth medium (GM; 1 DMEM
with 1 GlutaMax, 10% FBS (Gibco), 30 mM HEPES, and 50
g/ml gentamycin (Sigma)) at 37 °C under 5% CO2. 50,000
cells/well were seeded in 6-well plates and grown for 3 days.
Cells were washed with 1 DMEM, and then differentiation
medium (GMwith 5 g/ml doxycycline) was added. After 24 h
in differentiation medium, the cells were washed with 1
DMEMand treated for 24 hwith either compound orDMSO in
differentiation medium. The cells were washed with 1 PBS,
and total RNA was extracted with TRI reagent (Sigma)
according to the protocol of the manufacturer. 500 ng of
RNA was used for reverse transcription with the SuperScript
III first-strand synthesis system for RT-RCR (Invitrogen),
according to the protocol of the manufacturer with random
hexamer primers. Pre-mRNA targets were chosen based on
prior studies of small molecules in cellular and in vivo mod-
els of DM1 (21). 1 l of cDNA was used for qPCR with 40
amplification cycles of 15 s at 95 °C, 15 s at 61 °C, and 20 s at
72 °C. qPCR was performed with two primer pairs, one
primer pair only amplifying splicing variants that contain an
investigated alternative exon and the other primer pair
amplifying all possible splicing variants (pan): INSR, 5GAC-
CTGGTCTCCACCATTCG3 (forward), 5CACCAGTGC-
CTGAAGAGGTT3 (reverse exon), and 5ACGAAAAC-
CACGTTGTGCAG3 (reverse pan); TNNT2, 5CAGCTG-
CTGTTCTGAGGGAG3 (forward), 5CTGCTCGTCTTC-
GTCCTCTC3 (reverse exon), and 5CCTCGTACTCTTC-
CACCACC3 (reverse pan). -ACTIN was used as a control
gene with the following primers: forward, 5CCAACCGC-
GAGAAGATGA3; reverse, 5CCAGAGGCGTACAGGG-
ATAG3. MBNL1-independent splicing of ATE1 and FHL1
(33) was analyzed using the following primers: ATE1,
5GGGTTTCCAGGCTCAAGGTC3 (forward), 5TGAACT-
GCGAACTTGGTGGA3 (reverse exon), and 5TGTGTGAT-
GCATTCTCTGGTAA3 (reverse pan); FHL1, 5ATGC-
CGATTGCTTTGTGTGT3 (forward), 5CTGGGTGGC-
TCACTCTTGAC3 (reverse exon), and 5TCTTGCATC-
CAGCACACTTCT3 (reverse pan). Amplification was done
withHOTFIREPol EvaGreen qPCRmixture (Solis BioDyne) on
an Applied Biosystems StepOnePlus real-time PCR machine.
The amount of the splicing variant, including the investigated
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alternative exon, was quantified relative to the amount of the
pan-amplicon, which gave a percentage of exon inclusion.
For classical RT-PCR, 1 l of cDNA was used for PCR with 40
amplification cycles of 15 s at 95 °C, 15 s at 61 °C, and 20 s at 72 °C.
The following primer pairs were used: INSR, 5CCAAAGAC-
AGACTCTCAGAT3 (forward) and 5AACATCGCCAA-
GGGACCTGC3 (reverse); TNNT2, 5ATAGAAGAGGTG-
GTGGAAGAGTAC3 (forward) and 5GTCTCAGCCTC-
TGCTTCAGCATCC3 (reverse). Amplificationwas donewith
HOT Start DNA polymerase (Solis BioDyne) on an Applied
Biosystems PCR machine. The PCR products were run on 3%
agarose gels stained with RedSafe (iNtRON). Gels were imaged
with a Gel Doc XR (Bio-Rad).
Myoblast Viability Assay—C2C12 mouse myoblasts were
plated in 96-well plates inGM (4000 cells/well, 100l/well) and
grown overnight. Compounds/DMSOwere then added in GM.
After incubation for 48 h, the CellTiter-Blue reagent (Pro-
mega) was added according to the protocol of the manufac-
turer. Fluorescence was measured with an Infinite F500 plate
reader (Tecan) with an excitation/emission wavelength of 535/
590 nm. Signal concentration curves were fitted with Prism
software to determine toxicity IC50 values.
FISHand Immunofluorescence—15,000 fibroblasts/well were
grown for 24 h in GM on 0.3% gelatin-coated coverslips (24-
well dishes). Cells were washed with 1 DMEM and differen-
tiated in DM for 24 h. Washing with 1 DMEM preceded the
compound/vehicle incubation in DM for 24 h. Coverslip wash-
ing, permeabilization of myoblasts, FISH and immunostaining
withMBNL1 antibody (A2764, a kind gift fromCharles Thorn-
ton, University of Rochester) was performed according to the
procedure of Warf et al. (21). Wash buffer I contained 1 PBS
and 0.05% Triton X-100. Coverslips were blocked in buffer
(wash buffer I and 3% BSA, 15 min, room temperature) before
MBNL1 antibody incubation. 1:750 diluted goat anti-rabbit
DyLight 488 antibody (Jackson ImmunoResearch Laboratories,
111-485-144) was added in wash buffer I (1 h, room tempera-
ture). Myoblasts were stained with 1:20,000 DAPI in wash
buffer I (5 min, room temperature). Coverslips were mounted
on glass slides with FluorSave reagent (Calbiochem). Cells were
imaged using a Leica DMRE fluorescence microscope. For
quantification, the amount of foci was counted for 3 50 ran-
domly chosen nuclei from three experiments.
Treatment of Mice—HSALR transgenic mice in line 20b were
kindly provided by C. Thornton. FVB/N (WT) control mice
were obtained from the animal facility of the Department of
Biomedicine, University Hospital Basel, Switzerland. Age- and
gender-matched groups of a minimum of three mice (10–12
weeks old, male) of WT or HSALR mice were treated by two
intraperitoneal injections of compound/vehicle (12-h interval).
Harmine hydrochloride was administered in saline and berber-
ine chloride, dihydroberberine, and palmatine chloride hydrate
in 5% DMSO/PBS. Mice were sacrificed 2–4 h after the second
injection. Dissected quadriceps muscle was powdered after
freezing in liquid nitrogen. Animal studies were conducted in
accordance with the Animal Research Authorities (Canton
Basel-Stadt, Switzerland, permit no. 2632).
Mouse Skeletal Muscle Splicing Assay—Powdered quadri-
ceps muscle tissue was taken up in TRI reagent (Sigma) and
was grinded with a Polytron (Kinematica) for 30 s at 4 °C.
Insoluble material was removed by centrifugation at 12,000
rpm (10 min, 4 °C). From the supernatant, RNA was
extracted with TRI reagent (Sigma) according to the proto-
col of the manufacturer. The qPCR amplification protocol
was analogous to the myoblast qPCR protocol with the
following primer pairs: CLCN1, 5GGGCGTGGGATGC-
TACTTTG3 (forward exon), 5CTGACATCCTGACAG-
TGGGC3 (forward pan), and 5AGGACACGGAACAC-
AAAGGC3 (reverse); SERCA1, 5GCCCTGGACTTTACC-
CAGTG3 (forward), 5ACGGTTCAAAGACATGGAGGA3
(reverse exon), and 5CCTCCAGATAGTTCCGAGCA3
(reverse pan). Pre-mRNA targets were chosen based on prior
studies of small molecules in cellular and in vivo models of
DM1 (21). Classical RT-PCR was performed analogously to
the myoblast splicing assay with the following primers:
CLCN1, 5GGAATACCTCACACTCAAGGCC3 (forward)
and 5CACGGAACACAAAGGCACTGAATGT3 (reverse);
SERCA1, 5GCTCATGGTCCTCAAGATCTCAC3 (forward)
and 5GGGTCAGTGCCTCAGCTTTG3 (reverse).
Western Blotting Detection of CLCN1 Protein from Mouse
Skeletal Muscle—Proteins were extracted from powdered
mouse quadriceps muscle according to Dimauro et al. (45) to
obtain the nuclear/membrane fraction. Instead of NET, radio-
immunoprecipitation assay buffer (50mMTris HCL (pH 8.0),
150mMNaCl, 1%Nonidet P-40, 0.5% sodium deoxycholate, 1%
TritonX-100, 0.1%SDS, and 10%glycerol)was used, containing
protease and phosphatase inhibitor tablets (Roche). Protein
concentrations were determined with a BCA assay (Sigma).
10-g samples were separated by Tris/glycine SDS-PAGE on
8% gels and analyzed by Western blotting using Protran BA85
nitrocellulose membranes (GE Healthcare), rabbit polyclonal
antibody against the N terminus of full-length CLCN1 (1:1000,
a kind gift from Thomas Cooper, Baylor College of Medicine)
(13), and HRP-tagged goat anti-rabbit secondary antibody
(1:10000, Jackson ImmunoResearch Laboratories, 111-035-
003). To detect lamin B (loading control), goat polyclonal anti-
lamin B antibody (1:1000, Santa Cruz Biotechnology, sc-6216)
andHRP-tagged swine anti-goat antibody (1:10,000, Life Tech-
nologies, ACI3404) were used. All antibodies were incubated in
1 TBS, 3% BSA, 0.1% Tween 20, and 0.08% SDS. Membranes
were incubated for 5min with LumiGLO (KPL) chemilumines-
cent substrate and exposed to Super RX films (Fuji).
Western Blotting Detection of MBNL1 Protein from Myo-
blasts—Human fibroblasts were cultured, differentiated into
myoblasts, and treated in 6-well plates as described above for
the myoblast splicing assay. Myoblasts were washed with 1
PBS, harvested in 1 PBS, and centrifuged for 10 min at 4 °C
and 15,000 rpm, and then the pellet was resuspended in 100 l
of radioimmune precipitation assay buffer containing prote-
ase and phosphatase inhibitor tablets (Roche). After 2-h incu-
bation on a wheel at 4 °C, the samples were centrifuged for 10
min at 4 °C and 12,000 rpm. Protein concentrations in super-
natantswere determinedwith a BCAassay (Sigma). 10-g sam-
ples were separated by Tris/glycine SDS-PAGE on 12% gels.
Western blotting was performed as described above using
1:5000 diluted A2764 anti-MBNL1 antibody and anti-rabbit
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secondary antibody (1:10,000, Jackson ImmunoResearch Labo-
ratories, 111-035-003).
Histological Analysis of Internalized Nuclei—8-m cryostat
cross-sections from gastrocnemius mouse muscle were stained
withH&E and analyzed for the percentage ofmuscle fibers with
internalized nuclei.
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ABSTRACT
The hawthorn (Crataegus spp.) extract WS 1442 is used
against mild forms of chronic heart failure. This disease is as-
sociated with endothelial barrier dysfunction and edema for-
mation. We have recently shown that WS 1442 protects
against this dysfunction by a dual mechanism: it both pro-
motes endothelial barrier integrity by activation of a barrier-
enhancing pathway (cortactin activation) and inhibits endo-
thelial hyperpermeability by blocking a barrier disruptive
pathway (calcium signaling). In this study, we aimed to identi-
fy the bioactive compounds responsible for these actions by
using a bioactivity-guided fractionation approach. From the
four fractions generated from WS 1442 by successive elution
with water, 95% ethanol, methanol, and 70% acetone, only
the water fraction was inactive, whereas the other three trig-
gered a reduction of endothelial hyperpermeability. Analyses
of intracellular calcium levels and cortactin phosphorylation
were used as readouts to estimate the bioactivity of subfrac-
tions and isolated compounds. Interestingly, only the etha-
nolic fraction interfered with the calcium signaling, whereas
only the methanolic fraction led to an activation of cortactin.
Thus, the dual mode of action of WS 1442 could be clearly as-
signed to two distinct fractions. Although the identification of
the calcium-active substance(s) was not successful, we could
exclude an involvement of phenolic compounds. Cortactin ac-
tivation, however, could be clearly attributed to oligomeric
procyanidins with a distinct degree of polymerization. Taken
together, our study provides the first approach to identify
the active constituents of WS 1442 that address different cel-
lular pathways leading to the inhibition of endothelial barrier
dysfunction.
The Dual Edema-Preventing Molecular Mechanism of the Crataegus
Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions
* These authors contributed equally to this work.
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ABBREVIATIONS
CHF chronic heart failure
ECs endothelial cells
HMEC human microvascular endothelial cell
HUVEC human umbilical vein endothelial cell
OPC oligomeric procyanidin
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CHF is a progressive and severe cardiovascular pathology. Extracts
of different hawthorn (Crataegus) species are used as an adjuvant
treatment of CHF. The most widely studied Crataegus extract WS
1442 is approved for the treatment of mild forms of CHF accord-
ing to the New York Heart Association functional class II [1]. The
efficacy of WS 1442 was proven in various clinical trials [2, 3] and
is based on its positive inotropic, antiarrhythmic, vasodilating, and
cardioprotective actions [4–6]. One of the various symptoms of
CHF is the formation of peripheral edema. This symptom is not
only based on the altered hydrostatic pressure due to an increased
cardiac preload, but is also caused by the inflammation-associ-
ated occurrence of endothelial barrier dysfunction. Interestingly,
treatment with WS 1442 has been reported to improve ankle ede-
ma in CHF [7,8]. Recently, our group provided evidence that WS
1442 protects against edema formation by directly affecting the
endothelium. In vitro experiments revealed that WS 1442 inhibits
thrombin-induced endothelial barrier dysfunction in human ECs.
WS 1442 also showed a barrier-protecting activity in vivo in a mu-
rine model of endothelial hyperpermeability. Analysis of the ef-
fects of WS 1442 on key regulators of the endothelial barrier func-
tion gave detailed insights into the dual action of the extract
(▶ Fig. 1): WS 1442 blocks barrier disruptive pathways on the
one hand, and activates barrier-stabilizing mechanisms on the
other hand. The thrombin-evoked rise of intracellular calcium lev-
els ([Ca2+]i), and the activation of protein kinase C (PKC) and RhoA
were markedly reduced byWS 1442. Apart from the abrogation of
the stimuli-induced impairment of barrier function, the extract
per se activated a barrier-stabilizing cascade by increasing endo-
thelial cAMP levels leading to the activation of the Epac1/Rap1
signaling pathway. By stimulating the cAMP cascade, WS 1442 in-
creased the activity of Rac1, resulting in the cortactin-mediated
induction of a cortical F-actin ring that finally stabilized endothe-
lial barrier integrity [9]. Interestingly, WS 1442 alone increased
basal [Ca2+]i without affecting endothelial permeability, but re-
duced the rise of [Ca2+]i induced by barrier-disruptive stimuli [10].
OPCs and flavonoids have been described as the pharmacolog-
ically most important secondary metabolites in the extract [11].
However, individual compounds responsible for the protection
against barrier dysfunction have not been identified up to now.
Therefore, we aimed to shed light on the bioactive group(s) of
compounds responsible for the positive effects of WS 1442 on
barrier integrity of thrombin-induced endothelial cells in vitro. To
identify the bioactive principle(s), an iterative bioactivity-guided702fractionation procedure was used. For the assessment of bioactiv-
ity, measurements of thrombin-induced endothelial hyperperme-
ability, cytosolic calcium levels, and activation of cortactin in hu-
man endothelial cells were used as readout parameters.Results and Discussion
WS 1442 was separated into four different fractions (A–D). Frac-
tion A contained non-phenolic and aliphatic compounds, while
small phenolic compounds and flavonoids were present in frac-
tion B. OPCs were identified in fraction C, and fraction D consisted
of polymeric procyanidins (▶ Fig. 2A). Since we have previously
shown that WS 1442 significantly reduces the thrombin-evoked
macromolecular permeability [9], we were interested in identify-
ing the fraction responsible for this effect. Thus, ECs were treated
with each fraction and, subsequently, the thrombin-induced mac-
romolecular permeability was analyzed as an indicator for vascular
leakage and, thus, edema formation [12]. The flux of fluores-
cence-labeled dextran through a thrombin-activated monolayer
of HMECs was monitored after 30min. Pretreatment (30min) of
HMECs with fractions B, C, or D evoked a significant decrease of
the macromolecular permeability (▶ Fig. 2B), whereas the de-
crease triggered by fraction A was slight and statistically not sig-
nificant. Thus, procyanidins, small phenolic compounds, and fla-
vonoids might be responsible for the barrier-protecting action of
WS 1442. In fact, both classes of secondary plant metabolites
have already been reported to act against endothelial barrier dys-
function [13,14]. Taken together, our results suggest that the
barrier-protecting effect of WS 1442 is based not only on one
group of secondary metabolites.
WS 1442 has been previously shown to protect against endo-
thelial barrier dysfunction via cortactin activation (phosphory-
lation at tyrosine 421) and by blocking the thrombin-induced rise
of [Ca2+]i levels. Therefore, these two systems were used as a read-
out parameter to estimate the bioactivity of each fraction. Immu-
nofluorescence stainings of phosphorylated cortactin revealed
that only fraction C induced a rim of activated cortactin at the
border of endothelial cells (▶ Fig. 3A). In contrast, only fraction B
was able to prevent the thrombin-induced peak of [Ca2+]i
(▶ Fig. 3B). These results indicate that the dual modes of action
of WS 1442 can be clearly assigned to two distinct fractions. While
fraction B, i.e., small phenolic compounds and flavonoids, seems
to be responsible for the inhibition of barrier disruptive signaling,
the activating effects of the extract on the barrier-stabilizing path-
way might be attributed exclusively to oligomeric procyanidins
(▶ Fig. 3C). Interestingly, although polymeric procyanidins (frac-
tion D) were able to act against endothelial hyperpermeability,
this fraction did not cause any alteration in the two signaling path-
ways. This might point towards other, as yet unidentified, targets
that are addressed by fraction D.
To track the constituents responsible for the activity, fraction B
was submitted to a process referred to as HPLC-based profiling
[15]. This approach combines physicochemical data recorded on-
line with biological information obtained in parallel from time-
based HPLC microfractionation. An aliquot of fraction B was sepa-
rated by semipreparative HPLC, and the resulting nine subfrac-Fuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709
WS 1442
inhibition of a
barrier-disruptive
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PKC
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hyperpermeability ↓
▶ Fig. 1 WS 1442 prevents endothelial hyperpermeability via a dual
mechanism. The hawthorn extract inhibits the barrier disruptive
pathway by reduction of the thrombin-evoked intracellular calcium
rise, PKC, and RhoA activity on the one hand. On the other hand, the
barrier protective signaling was activated by increasing cAMP levels,
the activation of the Rap1/Rac1signaling, and cortactin rearrange-
ment at the borders of the endothelial cells.
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▶ Fig. 2 Influence of fractions of WS 1442 on the thrombin-
induced endothelial hyperpermeability. A Fractionation scheme of
WS 1442. B HMECs were left untreated or pretreated with WS 1442
fractions A–D (A: 57 µg/mL, B: 17 µg/mL, C: 12 µg/mL, D: 8 µg/mL)
for 30min. To measure the flux of FITC-labeled dextran (1mg/mL)
across the endothelial monolayer, a Transwell two-compartment
system was used. FITC-dextran was added at time point t = 0min
and, subsequently, thrombin (1 U/mL) was applied to the upper
compartment. After 30min, samples were taken from the lower
compartment. Data are expressed as the mean ± SD. *P ≤ 0.05
(one-way ANOVA followed by Dunnettʼs post hoc test) vs. thrombin
(black bar). # P ≤ 0.05 (one-way ANOVA followed by Dunnettʼs post
hoc test) vs. control (white bar), n = 3; n. s. = not significantly dif-
ferent compared to thrombin.
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evoked increase of [Ca2+]i. The activity was recovered in a subfrac-
tion eluted with 100% acetonitrile (▶ Fig. 4A). Importantly, phe-
nolic compounds, in particular flavonoids, eluted earlier and could
thus be excluded as active principles (▶ Fig. 4A). The separation
of fraction B by two successive steps of preparative HPLC afforded
a lipophilic active fraction containing terpenic constituents (data
not shown). The low amounts of material, however, precluded ad-
ditional separation steps and identification of the active com-
pounds. Therefore, the further characterization of active sub-
stances was performed starting from the whole extract WS 1442,
since it was available in larger amounts. The extract was parti-
tioned between ethyl acetate (EtOAc) and water. Fractionation of
the EtOAc-soluble portion (E) by column chromatography on silica
gel afforded two fractions, E-7 and E-8 (▶ Fig. 4B,C), which were
able to block the [Ca2+]i peak and trigger the typical (nontoxic) in-
crease of [Ca2+]i. Unfortunately, no active fractions could be ob-
tained after the further separation of E-7 (data not shown). How-
ever, purification of fraction E-8 by semipreparative HPLC on an
RP-18 column resulted in three active subfractions (E-8/4, E-8/5,
and E-8/6; ▶ Fig. 4B,D), which were characterized by NMR,
GC‑MS, and HPLC‑MS analysis. These subfractions each consisted
of a mixture of triterpenes and fatty acids. According to GC‑MS
analysis, the major fatty acids in all fractions were palmitic acid
and stearic acid (Fig. 1S, Supporting Information). As to the triter-
penes, hyptatic acid A could be identified as the main triterpene in
fraction E-8/5, with a content of approx. 50% according to the
1H‑NMR spectrum (Fig. 2S, Supporting Information). Triterpenes
detected in fractions E-8/4 and E-8/6 (Fig. 3S, Supporting Infor-
mation) could not be identified. Pure hyptatic acid A, stearic acid,Fuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709and palmitic acid were tested for their influence on the thrombin-
evoked rise of [Ca2+]i, but none of the compounds was found to be
active (Fig. 4S, Supporting Information). These constituents rep-
resent, according to NMR and GC‑MS analysis, approx. 90% of
the active fraction E-8/5. The low amounts of active fractions pre-
cluded further separation. Some other triterpenes that had been
isolated during the fractionation of WS 1442, such as pomolic
acid, corosolic acid, oleanolic acid, and ursolic acid, were also in-
active (data not shown). Taken together, we could exclude that
the action of WS 1442 on [Ca2+]i is based on small phenolic com-
pounds and flavonoids. However, the exact nature of the active
compounds remains unresolved. Synergetic effects of extract
constituents cannot be excluded.
Immunofluorescence stainings of ECs treated with six subfrac-
tions of fraction C revealed that only the subfractions C-3 and C-5703
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▶ Fig. 3 Influence of the WS 1442 fractions on cortactin activation
and thrombin-induced [Ca2+]i. A HUVECs were pretreated for
30min with WS 1442 fractions A–D (A: 57 µg/mL, B: 17 µg/mL,
C: 12 µg/mL, D: 8 µg/mL) prior to treatment with thrombin (1 U/mL,
30min). Control cells were treated with DMSO as the vehicle con-
trol. The increase of cortactin phosphorylation was determined with
an antibody against Tyr421-phosphorylated cortactin. Images were
taken by confocal microscopy with a 40-fold magnification. One
representative image out of three independently performed ex-
periments (n = 3) is shown. Scale bar represents 20 µm. B Conflu-
ent HUVECs were pretreated for 30min with fractions A–D
(A: 57 µg/mL, B: 17 µg/mL, C: 12 µg/mL, D: 8 µg/mL). Changes of
[Ca2+]i were detected by fluorescence microscopy using Fura-2-AM
(2 µM) in a static tempered system (37°C). Thrombin (1 U/mL) was
added at time point t = 0min. Basal [Ca2+]i was set as 100% and the
[Ca2+]i increase is shown; n = 3. C Scheme of WS 1442 fractions
A–D. Active fractions B and C are highlighted.
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tain more information on the bioactive compounds, C-3 and C-5
were further fractionated into six and four subfractions, respec-
tively, and again analyzed for cortactin activation. Unfortunately,
the bioactivity could not be narrowed down, but was found to be
broadly distributed. The five subfractions C-3/2 to C-3/6
(▶ Fig. 5C) and the three subfractions C-5/1, C-5/3, and C-5/4
(▶ Fig. 5D) were active. To circumvent this issue, we decided to
use OPCs with different degrees of polymerization (DP2 to DP10)
that had been previously isolated from hawthorn leaves with flow-
ers [16]. Four out of nine OPC clusters (DP5–DP6 and DP8–DP9)
were found to induce the phosphorylation of cortactin (▶ Fig. 6).
Numerous studies previously demonstrated that OPC containing
extracts reduce edema formation in animal models [17,18]. How-
ever, none of them elucidates the specific phytochemical com-
pound that positively regulates endothelial barrier functions. Our
study presents an unique approach identifying certain OPC clus-
ters to be highly bioactive compounds in WS 1442 that stabilize
the endothelial barrier integrity. We want to point out that our
conclusions based on these in vitro findings cannot simply be ap-
plied to the in vivo or human situation. It is not very likely that
OPCs consisting of more than three monomers are readily ab-
sorbed. In contrast, plasma levels of dimeric and trimeric procya-
nidins (e.g., procyanidin dimers B1 or B2 or the trimer C2) have
been reported in animal or human plasma after oral administra-
tion of different OPC-containing products [19–21]. There is a lack
of data on the absorption of OPCs with higher degrees of
polymerization. However, we want to emphasize that it is also
not clear whether DP5/6 and DP8/9 exert their pharmacological
in vitro effects as whole molecules or, e.g., as metabolites result-
ing from the enzymatic environment. Therefore, there is an un-
certainty about the precise molecules that exert the in vitro action
and also about the question as to whether these compounds can
enter the cell.
Taken together, we could demonstrate that the dual mecha-
nism by which WS 1442 exerts its barrier-protecting function can
be clearly assigned to certain groups of secondary metabolites.
Bioactivity-guided fractionation of WS 1442 revealed that the ex-
tractʼs influence on [Ca2+]i was not due to phenolic compounds, in
particular flavonoids. The calcium active subfractions mostly con-
tained triterpenes and fatty acids. However, none of the pure
compounds tested from these groups showed any activity. Thus,
one may speculate that a mixture of these compounds, or other
(minor) substances, is responsible for the influence of [Ca2+]i. In
contrast, distinct OPC clusters were found to be responsible for
the cortactin activating property of WS 1442. In conclusion, our
study supports the principle of phytotherapy, namely that a
multi-compound mixture is able to address different cellular sig-
naling pathways that jointly lead to a beneficial therapeutic effect.Materials and Methods
Compounds
The Crataegus special extract WS 1442 (lot no. 289 N001) was
kindly provided by Dr. Willmar Schwabe GmbH & Co. KG (Karls-
ruhe, Germany). A voucher specimen is deposited under the lotFuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709
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D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
itä
t B
as
el
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.number at the company. WS 1442 is a dry extract from hawthorn
leaves with flowers with a drug extract ratio of 4–6.6 :1 using
ethanol (45% w/w) as the extraction solvent. WS 1442 is adjusted
to a content of 17.3–20.1% of OPCs. WS 1442, fractions, and OPC
clusters were solubilized in DMSO (≥ 99.9%; Sigma-Aldrich) and
stored at − 20 °C. Substances were diluted (concentrations as de-
scribed in the respective passages) without exceeding a final
DMSO concentration of 0.1%. Hyptatic acid A was kindly provided
by Prof. Yongxian Cheng (Kunming Institute of Botany, Chinese
Academy of Sciences). The purity was > 95% according to NMR
analysis. Stearic acid (purity > 98.5%) and palmitic acid (purity
> 99%) were purchased from Sigma-Aldrich and were dissolved in
DMSO. Accustain, bovine serum albumin, fluorescein isothiocya-
nate (FITC)-dextran (40 kDa), thrombin, and Triton X-100 were
obtained from Sigma-Aldrich. Fura-2-AM ester was purchased
from Biotrend.
Cell culture
Primary HUVECs were purchased from PELOBiotech. The human
microvascular endothelial cell line CDC/EU.HMEC‑1 [22] was
kindly provided by the Centers for Disease Control and Prevention
(CDC). HMECs were exclusively used in the permeability assay. ECs
were cultured in EC growth medium (ECGM, PELOBiotech), which
was supplemented with 10% heat-inactivated FBS (Biochrom),
100 U/mL penicillin (PAN-Biotech), 100 µg/mL streptomycin
(PAN-Biotech), and 0.25 µg/mL amphotericin B (PAN-Biotech)
under constant humidity at 37 °C in an atmosphere containing
95% air and 5% CO2.Fuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709Macromolecular permeability assay
Macromolecular endothelial permeability was investigated using
HMECs in a two-compartment system (Transwell plate with in-
serts; Corning Life Sciences). The assay was performed as previ-
ously reported [9]. Briefly, cells were seeded ontoTranswell inserts
(pore size 0.4 µm, 12mm diameter, polyester membrane) until
confluency. FITC-dextran (40 kDa; 1mg/mL) was applied to the
upper compartment of the Transwell chamber at t = 0min and
cells were treated as indicated. After 30min, the samples were
taken out of the lower compartment to determine fluorescence
intensity with a SpectraFluor Plus plate reader (Tecan).
Cytosolic calcium imaging
Changes in cytosolic calcium levels were determined by ratiomet-
rical analysis with the fluorescent dye Fura-2-AM as previously re-
ported [10]. In brief, HUVECs were grown on 8-well µ-slides (ibidi
GmbH) to reach a monolayer. Cells were incubated in HEPES buf-
fer (138mM NaCl, 10mM HEPES, 10mM glucose, 5mM KCl,
2mM CaCl2, and 1mM MgCl2, pH adjusted to 7.4) with Fura-2-
AM (2 µM) for 30min, washed and treated as indicated. Measure-
ments were performed at 37 °C and fluorescence intensity was
obtained by a Zeiss Axiovert 200 inverted microscope with a
Polychrome V monochromator and an IMAGO‑QE camera (TILL
Photonics) or with a Leica DMI6000 B microscope and a
DFC365FX camera (Leica Microsystems GmbH). Images were tak-
en every 5 seconds and data analysis was performed using
TILLvisION software (version 4.0.1.2, TILL Photonics) or LAS X soft-
ware (version 1.0.12269.0, Leica Microsystems GmbH). Each data
point of the different graphs was calculated from a randomly cho-705
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▶ Fig. 5 Bioactivity-guided subfractionation of fraction C. A Scheme of subfractionation and activity distribution (active subfractions in grey).
B A confluent HUVEC monolayer was either left untreated or was treated for 15min with WS 1442 fraction C (12 µg/mL) or with one of the differ-
ent subfractions (C-1 to C-6) (5 µg/mL). Immunocytochemistry and confocal microscopy of Tyr421-phosphorylated cortactin was subsequently
performed. C-3 and C-5 are the most potent subfractions, both leading to a strong phosphorylation of cortactin. C, D Confluent HUVECs were
either left untreated or were treated with 5 µg/mL for 15min with one of the different WS 1442 subfractions of fraction C-3 (C-3/1 to C-3/6) or with
one of the different subfractions of fraction C-5 (C-5/1 to C-5/4). Images were obtained by confocal microscopy (magnification: 40-fold) after im-
munocytochemical staining of Tyr421-phosphorylated cortactin. One representative image out of three independently performed experiments
(n = 3) is shown. Scale bar represents 20 µm.
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l.sen rectangle containing ≥ 30 adjacent cells and thereby mean
values were expressed.
Immunocytochemistry and confocal laser scanning
microscopy
HUVECs were cultured until confluency on 8-well µ-slides (ibidi
GmbH). After treatment as indicated, cells were washed, fixed
with Accustain, and permeabilized using Triton X-100 (0.2%). The
following antibodies were used: rabbit anti-phospho-cortactinY421
(New England Biolabs GmbH) as the primary antibody and Alexa
Fluor 488 goat anti-rabbit (Life Technology GmbH) as the second-
ary antibody. Stained cells were finally embedded in FluorSave
mounting medium (Merck Millipore). Images were obtained with
a Zeiss LSM 510 Meta confocal laser-scanning microscope.
Fractionation of the Crataegus extract WS 1442
140 g of WS 1442 (lot no. 289 N001) were fractionated using
Sephadex LH-20 column (11.5 cm × 150 cm; Pharmacia) chroma-
tography by sequential elution with the following eluents: demin-
eralized water, ethanol 95% (v/v), methanol 100%, and acetone-
water 70% (v/v) (organic solvents were of analytical grade from706Merck). The complete volume of each individual eluent was col-
lected in a single fraction to give fractions A (yield 80.1 g), B (yield
23.0 g), C (yield 20.7 g), and D (yield 13.8 g), respectively.
HPLC-based activity profiling of fraction B
To localize the activity in fraction B, semipreparative HPLC was
performed on an Agilent 1100 instrument equipped with a PDA
detector. An aliquot (50mg) of fraction B was separated in four
portions on a SunFire C18 column (5 µm, 150 × 10mm i. d.;
Waters) equipped with a precolumn (10 × 10mm i.d.). The mo-
bile phase consisted of water with 0.1% HCOOH (A) and MeCN
(B). A gradient of 5 to 100% B in 30min was used, followed by
100% MeCN for 10min. The flow rate was 4mL/min. Nine frac-
tions were collected between 1.5 and 40.0min. Activity was re-
covered in the last fraction (4.4mg, tR 30–40min).
Fractionation of the extract WS 1442 to identify
active compounds in fraction B
The extract WS 1442 (48 g) was partitioned between H2O
(900mL) and EtOAc (3 × 900mL). The organic layers were com-
bined and dried under reduced pressure. The EtOAc-soluble frac-Fuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709
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▶ Fig. 6 The bioactivity distribution could be narrowed down to the
highly active OPC clusters DP5, DP6, DP8, and DP9. Increasing cor-
tactin phosphorylation at the cell border of HUVECs was analyzed
by immunocytochemistry. Confluent HUVECs were either left un-
treated or treated for 15min with OPC clusters with rising degrees
of polymerization (DP2-DP10) (5 µg/mL). Images were obtained by
confocal microscopy (magnification: 40-fold) after immunocyto-
chemical staining of Tyr421-phosphorylated cortactin. One repre-
sentative image out of three independently performed experiments
(n = 3) is shown. The scale bar represents 20 µm.
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l.tion (8.34 g, fraction E) was separated by silica gel CC (75 × 6 cm
i.d. column) with CHCl3-MeOH mixtures of increasing polarity
(97 :3 to 9 :1). The resulting fractions were analyzed by TLC and
combined to nine fractions according to the similarity of the chro-
matograms. Fraction E-8 (92mg) was dissolved in DMSO‑THF 1 :1
at a concentration of 100mg/mL, and separated by semiprepara-
tive HPLC on a C18 SunFire HPLC column (10.0 × 150mm; 5 µm;
Waters). The mobile phase consisted of H2O (A) and MeCN (B). A
gradient of 5–100% B in 30min, with a 5min 100% B wash, was
applied. The flow rate was 4.0mL/min. Detection was set at UV
288 nm. Aliquots of 100 µL each were injected. Nine fractions
were obtained (fractions E-8/1 to E-8/9) by using a combination
of peak-based and time-based collection. Activity was found in
fractions E-8/4 (tR 19.2–19.4min, 0.7mg), E-8/5 (tR 21.1–
22.1min, 1.9mg), and E-8/6 (tR 25.7–25.9min, 2.0mg). Fraction
E-7 (141mg) was separated following the same chromatographic
conditions as for fraction E-8, but with detection at UV 247 nm.
Eight fractions were collected, but no activity could be recovered
in any of them. 1H‑NMR spectra of active fractions and the refer-
ence compound hyptatic acid A were recorded on an Avance III
spectrometer (Bruker) equipped with a 1-mm TXI microprobe.
Subfractionation of fraction C
12 g of fraction C were further fractionated by using the prepara-
tive HPLC system (VWR International); column: 350 × 50mm
packed with YMC RP-18 ODS‑AQ 15 µm (Phenomenex). Elution
with methanol 30% (v/v) afforded six fractions (C-1 to C-6),
namely C-1 (0.8 g), C-2 (0.7 g), C-3 (2.7 g), C-4 (3.6 g), C-5Fuchs S et al. The Dual Edema-Preventing… Planta Med 2017; 83: 701–709(1.8 g), and C-6 (2.3 g). Fractions C-3 (2.0 g) and C-5 (1.36 g) were
further separated over a Sephadex LH-20 column (70 × 4.25 cm;
Pharmacia). Methanol 100% was used as the eluent. The flow rate
was 1mL/min, and fractions of 15min were collected and
combined to fractions C-3/1 (90mg), C-3/2 (240mg), C-3/3
(260mg), C-3/4 (310mg), C-3/5 (350mg), C-3/6 (670mg), C-5/
1 (260mg), C-5/2 (360mg), C-5/3 (380mg), and C-5/4 (380mg).
Isolation of oligomeric oligomeric procyanidin
clusters
Hawthorn leaf and flower (Crataegi folium cum flore) dried plant
material according to the specification of the European Pharma-
copoeia [European Pharmacopoeia Version 8.0 (2015) Hawthorn
leaf and flower, version 01/2010 :1432] were obtained from
Caesar-Loretz GmbH (Ch. No. 52467097). Reference samples
(Voucher No. IPBP240) are stored at the Institute of Pharmaceuti-
cal Biology and Phytochemistry (University of Münster, Germany).
An acetone-water (7 : 3) extract and the water-soluble part of this
extract were prepared from hawthorn leaf and flower plant mate-
rial as recently described in detail [23]. Of the lyophilized acetone-
water extract, 1.3 g dissolved in 10mL MeOH-water (1 : 9 v/v)
were fractionated by medium-pressure liquid chromatography
(MPLC) on RP-18, 18–32 µm, 100 Å, 460 × 26mm (Büchi Labor-
technik GmbH) at a flow rate of 9mL/min (pump BESTA E100;
BESTA Technik GmbH). A step gradient of MeOH 30% (460mL),
MeOH 50% (480mL), and MeOH 100% (510mL) was used. Frac-
tionation: pre-run 200mL, discarded (no OPCs detectable by
TLC); fractions 1–15 (590mL), discarded (no OPCs detectable by
TLC); fractions 16–24 (238mL), OPCs detectable by TLC (named
as “F1”; 0.09 g); fractions 25–51 (632mL), OPCs detectable by
TLC (named as “F2”; 0.14 g); fractions 52–62 (234mL), OPCs
detectable by TLC (named as “F3”; 0.06 g); fractions 63–84
(780mL), discarded (no OPCs detectable by TLC). For further frac-
tionation, the MPLC fraction “F2” was used, which had been ob-
tained in a yield of 10.8% (w/w) related to the acetone-water ex-
tract [16].
Preparative HPLC for isolation of oligomeric
procyanidins from F2
136mg of MPLC fraction F2, dissolved in acetonitrile-water (1 : 1),
were fractionated by HPLC into distinct OPC clusters (total OPC
yield 41.6mg). Yield of cluster DP2 was 6mg, DP3 7mg, DP4
6.5mg, DP5 5.6mg, DP6 5.4mg, DP7 4mg, DP8 3mg, DP9
2.5mg, and DP10 1.6mg. HPLC was performed using two Waters
515HPLCpumps,Watersdual λabsorbancedetector,Waterspump
control module, softwareMillenium32 (Waters), and degasser uni-
flows degasys DG-2410 (Optilab). Stationary phase: Uptisphere
120 Å, bonding OH, 6 µm, 250 × 21.2mm ID (Interchim). Mobile
phase A: acetonitrile; mobile phase B: MeOH-water (95 :5 v/v); elu-
tion gradient [min (%A)]: initial (100), 0–30 (100→ 60), 30–40 (60,
isocratic), 40–45 (60→ 50), 45–50 (50→ 0), 50–55 (0, isocratic),
55–60 (0→ 100), 60–70 (100, isocratic). The flow rate was 10mL/
min and detection λwas 280 nm [16].707
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procyanidins by MS
The molecular weight of OPCs was determined by ESI‑MS in the
negative ion mode (Bruker Daltonics micrOTOF; Bruker). MS spec-
troscopy was performed exemplarily on OPC clusters DP2, DP4,
and DP7: OPC cluster DP2, found m/z 577.1349 (M – H)−, calcu-
lated m/z 577.1352; OPC cluster DP4, found m/z 1153.2601 (M –
H)−, calculated m/z 1153.2608; OPC cluster DP7, found m/z
1008.2137 (M – H)−, calculated m/z 1008.2224 [16].
Purity control of oligomeric procyanidin clusters
(HPLC on diol and RP-18 phase)
Purity control of OPC clusters by HPLC was performed using
Waters Alliance with Waters 996 PAD and Waters 2475 multi-λ
fluorescence detector and the software Empower 2 (Waters).
Stationary phase 1: Uptisphere 120 Å, bonding OH, 6 µm,
250 × 4.6mm ID (Interchim); detection PAD 200–400 nm, FLD
λexc 280 nm, λem 316 nm; column temperature 40 °C; injection
volume 10 µL; test sample dissolved in acetonitrile-water (1 :1);
flow rate 0.8mL/min. Mobile phase A: acetonitrile-acetic acid
(98 :2 v/v); mobile phase B: MeOH-water-acetic acid (95 :3 :2 v/v/
v); elution gradient [min (% A)]: initial (100), 0–38 (100→ 60),
38–45 (isocratic), 45–50 (60→ 0), 60–65 (isocratic), 65–70
(0→ 100). Stationary phase 2: Phenomenex 100 Å, Luna 5 µm,
250 × 3.0mm ID (Phenomenex); detection PAD 200–400 nm; col-
umn temperature 40 °C; injection volume 10 µL. Flow gradient:
0min 0.9mL/min, 50min 0.9mL/min, 55min 1.0mL/min,
60min 1.0mL/min, 65min 0.9mL/min. Mobile phase A: water +
TFA 0.1% (1 :1 v/v); mobile phase B: acetonitrile; elution gradient:
0min 95% A, 50min 50% A, 55min 0% A, 60min 0% A, 65min
95% A. 13C‑NMR spectroscopy was performed by using 100mg
of the polymer fraction in MeOH-d4 (VWR International GmbH)
over 60 h using a Varian UNITY Plus 600 (Varian, Inc.) [16].
Statistical analysis
All experimentswere independently performed three times (n = 3).
In the case that nothing else is mentioned, bar graph data are ex-
pressed as means ± SD. Statistical analysis was performed with the
software Prism (version 5.04; GraphPad Software). One-way analy-
sis of variance (ANOVA) followed by Dunnettʼs post-hoc test was
used. P values ≤ 0.05 were considered statistically significant.
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